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PRE-MEETING SATELLITES
The International Study Group Investigating Bonanza A
Drugs as Reinforcers (ISGIDAR)
Chaired by Elise Weerts
9 th Annual Meeting Center for Substance Abuse Bonanza B and
Treatment (CSAT) Southern Pacific B/F
Chaired by Cathy Crowley
The 14th Annual NIDA International Forum on Ponderosa B and
Building International Research on Drug Abuse: Pavilion C/E
Progress through Collaboration
Chaired by Steven Gust
Treating Addiction during Pregnancy: Exploring Multinational Bonanza A
Perspectives to Build a Treatment Approach Consensus 8:00 - 10:00 PM
Chaired by Hendree Jones
CPDD REGISTRATION
Ponderosa A
Saturday, June 20 1:30 PM - 5:00 PM
(Pool Area) 7:00 PM - 7:30 PM 
Sunday, June 21 8:00 AM - 12:00 PM
1:30 PM - 5:00 PM
Monday, June 22 8:00 AM - 12:00 PM
1:30 PM - 5:00 PM
Tuesday, June 23 8:00 AM - 1:00 PM
Wednesday, June 24 8:00 AM - 12:00 PM
1:30 PM - 5:00 PM
Thursday, June 25 8:00 AM - 1:00 PM
OPENING RECEPTION 7:00 - 9:00 PM
(Cash Bar) Pool Area
Saturday, June 20, 2009
CSAT Travel Awards Breakfast Poolside Terrace
(By Invitation Only) 7:00 - 8:00 AM
Plenary Session Rose Ballroom A
8:30 - 11:00 AM
8:30 Welcome, CPDD President
Sharon L. Walsh
8:45 Report from the National Institute on Drug Abuse
Nora Volkow, NIDA
9:15 Presentation of the CPDD/NIDA Media Award to Nancy Campbell 
Introduction by Marc J. Kaufman
9:25 Presentation of the Joseph Cochin Young Investigator Award to Laura Bohn 
Introduction by Linda Dykstra
9:30 Presentation of the Mentorship Award to George Bigelow 
Introduction by Stephen Higgins
9:35 Presentation of the Nathan B. Eddy Award to Robert L. Balster 
Introduction by Louis Harris
9:40 Nathan B. Eddy Award Lecture
Robert L. Balster
EARLY CAREER INVESTIGATOR 
AWARDS LUNCHEON Poolside Terrace
(By Invitation Only) 11:30 AM - 1:00 PM
Presidential Symposium Rose Ballroom A
1:00 - 3:00 PM
OPIOID RECEPTORS FROM THE CUTTING EDGE TO THE CLINIC:
KNOCKOUTS, CROSSTALK AND BEHAVIOR
Chair: Sharon L. Walsh
1:00 Our shifting view of the nature of the opioid receptors
Christopher Evans, University of California, Los Angeles, Los Angeles, CA
1:20 Cellular mechanisms of opioid receptor regulation
Mark Van Zastrow, University of California, San Francisco, CA
1:40 Novel mouse model of human OPRM1 polymorphism (A118G)
Julie Blendy, University of Pennsylvania, Philadelphia, PA
2:00 Involvement of the endogenous opioid system in nicotine reward
Rafael Maldonado, Universitat Pompeu Fabra, Barcelona, Spain
2:20 Discussant
Nora Volkow, Director of NIDA
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium I Ponderosa B
3:15 - 5:15 PM
HOW DOES STRESS CONTRIBUTE TO ADDICTION
VULNERABILITY? STUDIES FROM ADOLESCENT 
AND ADULT SAMPLES
Chairs: Rajita Sinha and Kathleen T. Brady
3:15 Racial differences in stress, emotional regulation and DSM-IV substance abuse and dependence
in young, low-income women
Helen Wu, University of Texas Medical School-Houston, Galveston, TX
3:40 Hypothalamic-pituitary-adrenal axis and substance use among adolescents: The TRAILS study
Anja Huizink, Erasmus Medical Center, Rotterdam, CB Rotterdam, Netherlands
4:05 Stress response and risk for substance use in prenatally cocaine-exposed and non-exposed
adolescents
Tara Chaplin, Linda Mayes, Yale University School of Medicine, New Haven, CT
4:30 Altered nucleus accumbens activity in individuals with high childhood trauma is predictive of
addictive behaviors
Rajita Sinha, Zhiru Jia, Yale Stress Center, Yale University School of Medicine, New
Haven, CT
4:55 Discussant
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC
Symposium II Bonanza
3:15 - 5:15 PM
VIRTUAL MODELING: A NEW FRONTIER FOR INVESTIGATING
DRUG-RECEPTOR INTERACTIONS
Chair: Christopher K. Surratt
3:15 Uptake inhibitor interactions in the primary and “staging area” substrate pockets of the plasma
membrane monoamine transporters
Christopher K. Surratt, Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA
3:40 Ligand-receptor docking of epibatidine analogs to a nicotinic acetylcholine receptor model
S. Wayne Mascarella, Research Triangle Institute, Research Triangle Park, NC
4:05 Understanding sigma receptor ligand interactions
Christopher McCurdy, University of Mississippi School of Pharmacy, University, MS
4:30 A structural model of salvinorin A recognition at the kappa opioid receptor
David M. Ferguson, University of Minnesota, Minneapolis, MN
4:55 Discussant
F. Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Oral Communications 1 Rose Ballroom A
3:15 - 5:15 PM
A FULL HOUSE OF NOVEL TREATMENTS
Chairs: Susan C. Sonne and Kevin Gray
3:15 Extended-release naltrexone for treatment of alcohol dependence in primary care
J. D. Lee, E. Grossman, D. DiRocco, J. Rotrosen, D. Stevens, M. Gourevitch, Medicine, NYU
School of Medicine, New York, NY
3:30 The use of acamprosate vs placebo in alcoholics with comorbid anxiety or depression
S. C. Sonne1, J. S. Potter2, R. N. Rosenthal3, C. Tyson1, 1Medical University of South Carolina,
Charleston, SC, 2McLean Hospital, Belmont, MA, 3Columbia University, New York, NY
3:45 A randomized placebo-controlled trial of sertraline and sertraline plus gabapentin in depressed,
recently abstinent cocaine-dependent patients
M. J. Mancino, Z. Feldman, M. Chopra, C. S. Cargile, A. Oliveto, Psychiatry, University of
Arkansas for Medical Sciences, Little Rock, AR
4:00 Atomoxetine in marijuana-dependent adults with ADHD
A. McRae-Clark1, R. E. Carter2, T. K. Killeen1, M. J. Carpenter1, K. T. Brady1, 1Psychiatry,
Medical University of South Carolina, Charleston, SC, 2Biometry, Medical University of
South Carolina, Charleston, SC
4:15 Bupropion SR and contingency management in adolescent smokers: Main findings
K. M. Gray1, M. J. Carpenter1, N. L. Baker1, E. M. Klintworth1, A. S. Leinbach1,
H. P. Upadhyaya1,2, 1Medical University of South Carolina, Charleston, SC, 2Eli Lilly and
Company, Indianapolis, IN
4:30 Dextroamphetamine as a treatment for methamphetamine dependence
G. P. Galloway, L. Fiske, J. D. Siegrist, M. J. Baggott, K. Flower, R. Buscemi, D. Polcin,
J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute,
San Francisco, CA
4:45 Long-acting vs. oral naltrexone for preventing heroin addiction relapse
E. Krupitsky1, E. Zvartau1, E. Verbitskaya1, V. Egorova1, D. Masalov1, M. Tsoi1, A. Burakov1,
N. Bushara1, T. Romanova1, T. Slavina1, A. Tyurina1, V. Palatkin1, G. E. Woody2, 1Addictions,
Pavlov State Medical University, St. Petersburg, Russia, 2Psychiatry, University of
Pennsylvania, Philadelphia, PA
Oral Communications 2 Rose Ballroom B
3:15 - 5:15 PM
AGING AND DEATH: THE DECK IS STACKED
Chairs: Stefan Kertesz and Howard Chilcoat
3:15 Prescription drug use among baby boomers: Insights from clinician interviews
C. L. Striley, K. S. Leung, V. Satyanarayana, A. Ben Abdallah, L. B. Cottler, Psychiatry,
Washington University School of Medicine, St. Louis, MO
3:30 Trajectories of illicit drug use among adults in the general population (the CARDIA study)
S. Kertesz1,2, M. Pletcher3, B. Jones4, J. Tucker2, Y. Khodneva2, 1Birmingham VAMC,
Birmingham, AL, 2University of Alabama, Birmingham, AL, 3University of California, San
Francisco, CA, 4Carnegie-Mellon University, Pittsburgh, PA
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3:45 Testing pathways between alcohol and opioid dependence
H. Chilcoat1,3, N. Dasgupta2,1, S. S. Martins3, 1Worldwide Epidemiology, GlaxoSmithKline,
Research Triangle Park, NC, 2Epidemiology, University of North Carolina, Chapel Hill, NC,
3Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
4:00 Late injection drug use initiators: Epidemiological trends and risk factors
A. Kral1,2, L. Wenger1, L. Carpenter1, P. Bourgois3, M. Iguchi5,4, R. Bluthenthal4,6, 1RTI
International, San Francisco, CA, 2University of California, San Francisco, CA, 3University of
Pennsylvania, Philadelphia, PA, 4RAND, Santa Monica, CA, 5University of California, Los
Angeles, CA, 6California State University, Dominguez Hills, Los Angeles, CA
4:15 Persistence of cocaine use once it starts: Initial findings from epidemiological research
E. Meyer, J. Anthony, Epidemiology, Michigan State University, East Lansing, MI
4:30 Age effects on heroin and prescription opioid abuse among enrollees into methadone
maintenance treatment
C. Cleland1, A. Rosenblum1, C. Fong1, M. Parrino2, S. Magura3,1, 1National Development and
Research Institutes, Inc., New York, NY, 2American Association for the Treatment of Opioid
Dependence, New York, NY, 3Western Michigan University, Kalamazoo, MI
4:45 Medical examiner methadone-related drug deaths: Single vs polydrug abuse
M. J. Wunsch1, P. A. Nuzzo1, G. Behonick2, S. L. Walsh1, 1Behavioral Sciences, Center on
Drug and Alcohol Research, University of Kentucky, Lexington, KY, 2Forensic Toxicology,
University of Massachusetts, Worcester, MA
5:00 Age and its relationship with cause of death among opiate users
T. Clausen1, H. Waal1, M. Gossop2,1, 1Norwegian Centre for Addiction Research, University of
Oslo, Oslo, Norway, 2National Addiction Centre, Maudsley Hospital/Institute of Psychiatry,
Kings College, London, United Kingdom
Primm-Singleton Travel Awardees Meeting Genoa
6:30 - 8:00 PM
ASPET MIXER Poolside Terrace
6:30 - 8:00 PM
AMERICAN SOCIETY FOR PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS (ASPET)
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Workshop I Ponderosa B
8:00 - 10:00 PM
INTERVENTIONS FOR PARENTS WITH SUBSTANCE USE
DISORDERS: NEW FINDINGS FROM CLINICAL RESEARCH
Chair: Nancy Suchman
Fathers too! A parent-intervention for drug-abusing men
Thomas McMahon, Yale Child Study Center, Yale University School of Medicine, West
Haven, CT
Project SUPPORT: A parenting intervention for mothers in drug treatment
Mary-Louise Kerwin, Rowan University and Treatment Research Institute, Glassboro, NJ
Learning sobriety together for substance-abusing women: Effects on children’s adjustment
Michelle Kelley, Old Dominion University, Norfolk, VA
Attachment-based program for substance-using mothers of infants and toddlers: Treatment
approach, outcomes and integrity in a randomized clinical trial
Nancy Suchman, Yale University School of Medicine, West Haven, CT
Discussant
Karol Kaltenbach, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
Workshop II Bonanza
8:00 - 10:00 PM
FIT TO BE TIED: ABUSE POTENTIAL OF ANTIEPILEPTICS?
Chairs: Edward M. Sellers and Jack Henningfield
Evidence for abuse of anti-epileptics
Edward M. Sellers, Kendle Early Phase (Toronto), Toronto, ON, Canada
Medical need and “euphoria-related” adverse events of anti-epileptics
Deborah Leiderman, CNS Drug Consulting LLC, McLean, VA
Selecting the best measures of abuse liability in human abuse liability studies: Application to
anti-epileptics
Kerri A. Schoedel, Kendle Early Phase (Toronto), Toronto, ON, Canada
The puzzling case of levetiracetam
Douglas Feltner, Pfizer Global Research and Development, Novi, MI
Case study: Lacosamide
Pamela Doty, Schwarz Biosciences, Inc., Research Triangle Park, NC
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Workshop III Rose Ballroom A
8:00 - 10:00 PM
WHAT’S NEW AT NIDA AND NIH: A PEEK INTO THE BLACK BOX
Chair: Gerald McLaughlin
Workshop IV Rose Ballroom B
8:00 - 10:00 PM
LEADERSHIP IN THE MAKING: IMPACT AND INSIGHTS FROM
LEADERSHIP DEVELOPMENT PROGRAMS FOR LEADERS OF
ADDICTION SERVICES
Chairs: Anne-Helene Skinstad and Pamela Waters
Leadership training: A foundation for the development of a network of African-American
addiction service leaders
Paula Horvatich, Virginia Commonwealth University, Richmond, VA
A retrospective study of the impact of the Southern Coast ATTC’s leadership development
program
Pamela Waters, Southern Coast ATTC, Tallahassee, FL
The change leader academy: Developing change leaders for NIATx
Eldon Edmundson, Oregon Health and Science University, Portland, OR
The change leader academy: Developing change leaders for NIATx
Dennis McCarty, Oregon Health and Science University, Portland, OR
Leadership development for women and men. Any different?
Anne-Helene Skinstad, The University of Iowa, Iowa City, IA
Leaders and tradition: Native American mentors’ experience in the Mountain West ATTC
leadership institute: Implications for developing culturally competent leaders in the substance
abuse treatment workforce
Nancy Roget, University of Nevada, Reno, Reno, NV
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium III Ponderosa B
8:45 - 9:45 AM
UNCONTROLLED INTERSECTION:
PROBLEM GAMBLING AND DRUG ABUSE
Chairs: Ken Winters and Linda B. Cottler
8:45 Overview of the association of drug abuse and pathological gambling
Ken Winters, University of Minnesota-Fairview, Minneapolis, MN
9:05 Is level of gambling related to reductions in crack cocaine use among community-recruited
female drug users?
Linda B. Cottler, Washington University, St. Louis, MO
9:25 The Alberta leisure, lifestyle, lifecycle cohort: The first waves
Nady El-guebay, Foothills Addiction Center, University of Calgary, Calgary, AB, Canada
Symposium IV Bonanza
8:45 - 9:45 AM
DRUG WITHDRAWAL, REINFORCING EFFECTS,
AND VULNERABILITY TO RELAPSE:
NEW METHODS AND INSIGHTS
Chair: Lance McMahon
8:45 Withdrawal-associated increases in the relative reinforcing effects of heroin
S. Stevens Negus, Pharmacology and Toxicology, Virginia Commonwealth University,
Richmond, VA
9:05 Role of withdrawal in relapse to marijuana use
Margaret Haney, New York State Psychiatric Institute, College of Physicians and Surgeons of
Columbia University, New York, NY
9:25 New methods and insights: Characterizing tobacco withdrawal and relapse vulnerability
David Gilbert, Psychology, Southern Illinois University Carbondale, Carbondale, IL
Oral Communications 3 Rose Ballroom A
8:45 - 9:45 AM
PREDICTION OF ADDICTION
Chairs: Theodore Cicero and William W. Stoops
8:45 Geographic and contextual factors of prescription opioid abuse: Results from ASI-MV® Connect
T. C. Green1, J. S. Brownstein2, S. F. Butler2, 1Yale School of Public Health, Medford, MA,
2Inflexxion, Inc., Newton, MA
9:00 Secondhand exposure to smoked opium
M. S. Gold1, D. M. Martin2, N. A. Graham3, B. A. Goldberger4, 1Psychiatry, University of
Florida College of Medicine, Gainesville, FL, 2Drug Detection Solutions, LLC, Lansdale, PA,
3Psychiatry, University of Florida College of Medicine, Gainesville, FL, 4Pathology,
Immunology and Laboratory Medicine, University of Florida College of Medicine,
Gainesville, FL
9:15 Abuse Deterrent Adjusted Measurement Model: ADAMM™
R. A. Black, S. H. Budman, T. A. Cassidy, S. F. Butler, Inflexxion, Inc., Newton, MA
Monday, June 22, 2009
7
9:30 Relative abuse potential of intravenous oxycodone, hydrocodone and morphine in non-
dependent opioid abusers
W. W. Stoops1,2, K. W. Hatton3, M. R. Lofwall1,2,4, P. A. Nuzzo1, S. L. Walsh1,2,4, 1Behavioral
Science, University of Kentucky, Lexington, KY, 2Center for Drug and Alcohol Research,
University of Kentucky, Lexington, KY, 3Anesthesiology, University of Kentucky,
Lexington, KY, 4Psychiatry, University of Kentucky, Lexington, KY
Oral Communications 4 Rose Ballroom B
8:45 - 9:45 AM
PROGRAMS AND POLICIES
Chairs: Steven Ondersma and Dennis McCarty
8:45 Evidence-based practices in substance abuse treatment: Staff familiarity, opinions, and training
J. May1, A. Breland1, D. Farrell-Moore1, F. Taxman3, J. R. Koch2, D. Svikis2, 1Richmond
Behavioral Health Authority, Richmond, VA, 2Virginia Commonwealth University,
Richmond, VA, 3George Mason University, Fairfax, VA
9:00 Using coaches to develop EBP skills for providers treating patients with co-occurring mental
health and substance use disorders
S. Larkins, T. E. Freese, S. Cousins, R. Rawson, Integrated Substance Abuse Programs,
University of California, Los Angeles, Los Angeles, CA
9:15 Educating addiction providers to use the NIATx Process Improvement Model to enhance client
services
A. Pulvermacher1, T. Zastowny2, E. Edmundson3, L. Madden4,5, J. H. Ford1, D. H. Gustafson1,
D. McCarty3, 1University of Wisconsin - Madison, Madison, WI, 2University of Rochester,
Rochester, NY, 3Oregon Health and Science University, Portland, OR, 4APT Foundation, New
Haven, CT, 5Yale University, New Haven, CT
9:30 Implementation of medication-assisted treatment in Maine and Missouri: The Advancing
Recovery program
D. McCarty1, D. Brucker2, M. Hile3, T. Morris4, L. Frazier2, A. Abraham5, T. Molfenter7,
L. Schmidt6, P. Roman5, 1Oregon Health and Science University, Portland, OR, 2Maine Office
of Substance Abuse, Augusta, ME, 3Missouri Institute of Mental Health, St Louis, MO,
4Division of Alcohol and Drug Abuse, Missouri Dept of Mental Health, Springfield, MO,
5Institute for Behavioral Research, University of Georgia, Athens, GA, 6Institute for Health
Policy Studies, University of California, San Francisco, CA, 7NIATx, University of Wisconsin,
Madison, WI
Symposium V Ponderosa B
10:00 AM - 12:00 PM
SPECIAL SYMPOSIUM HONORING THE MEMORY OF 
BILLY MARTIN, PHD
HOT TOPICS IN CANNABINOID RESEARCH:
FROM CHEMISTRY TO THE CLINIC
Chair: Mary Abood
10:00 Introduction
Louis Harris, Virginia Commonwealth University, Richmond, VA
10:20 Pieces of a cannabinoid puzzle: CB1-selective agonists with antagonist structures
Jenny Wiley, Virginia Commonwealth University, Richmond, VA
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10:40 Ligand-assisted protein structure: Studies on the endocannabinoid proteins
Alexandros Makriyannis, Northeastern University, Boston, MA
11:00 The enzymatic regulation of endocannabinoid signaling
Benjamin Cravatt, The Scripps Research Institute, La Jolla, CA
11:20 Treating addictive disorders by modulation of endogenous systems
Charles O’Brien, Center for Studies of Addiction, University of Pennsylvania,
Philadelphia, PA
11:40 Discussants
Mary Abood1, Louis Harris2, 1Temple University School of Medicine, Philadelphia, PA,
2Virginia Commonwealth University, Richmond, VA
Oral Communications 5 Rose Ballroom B
10:00 AM - 12:00 PM
RISKY BUSINESS: HIV/AIDS AND BEHAVIOR
Chairs: Christian Hopfer and Stuart King
10:00 HIV transmission risk behaviors among opioid-dependent HIV-infected individuals entering
integrated buprenorphine and HIV care
A. A. Chaudhry1, M. Botsko3, L. Weiss3, J. Egan3, J. Mitty5, B. Estrada4, G. Lucas1,
T. Woodson1, T. Flanigan5, D. Fiellin2, 1Medicine, Johns Hopkins University, Baltimore, MD,
2Medicine, Yale University, New Haven, CT, 3New York Academy of Medicine, New York, NY,
4Impact Consultants, Tuscon, AZ, 5Medicine, Brown University, Providence, RI
10:15 Development of injection HIV risk behaviors in adolescents followed into young adulthood
C. Hopfer1, H. Gelhorn1, T. Crowley1, M. Stallings2, S. Young2, J. Hewitt2, 1University of
Colorado, Aurora, CO, 2Institute for Behavior Genetics, University of Colorado Boulder,
Boulder, CO
10:30 Relationship influence and HIV risk behavior among re-entering women offenders
M. Staton-Tindall1, L. Frisman2, H. Lin2, C. Leukefeld1, C. Oser1, J. Havens1, M. Prendergast3,
H. Surratt4, J. Clarke5, 1University of Kentucky, Lexington, KY, 2Connecticut Department of
Mental Hospital and Addiction Services, Hartford, CT, 3University of California, Los
Angeles, CA, 4University of Delaware, Wilmington, DE, 5Brown University, Providence, RI
10:45 The impact of gender and other baseline characteristics on AIDS risk perception ratings
S. King1, B. Brown2,1, R. Schwartz1, K. O’Grady3, E. C. Katz4,1, 1Friends Research Inst.,
Baltimore, MD, 2Univ. of North Carolina, Wilmington, NC, 3Univ. of Maryland, College
Park, MD, 4Psychology, Towson University, Towson, MD
11:00 Gender differences in HIV risk behaviors among drug abusers
A. Brooks1, C. Meade2, J. Potter2, Y. Lokhnygina3, D. Calsyn4, S. Greenfield3, 1University of
Arizona, Tucson, AZ, 2McLean Hospital, Belmont, MA, 3Duke University, Durham, NC,
4University of Washington, Seattle, WA
11:15 Interventions to reduce HIV risk and drug use among heterosexual methamphetamine users:
Preliminary results from a pilot study
K. F. Corsi1, W. K. Lehman1, R. E. Booth1, S. Shoptaw2, 1Psychiatry, University of Colorado
Denver, Denver, CO, 2Family Medicine and Psychiatry, David Geffen School of Medicine at
University of California, Los Angeles, CA
11:30 Predictors of alcohol- and/or drug-related consensual and unwanted sexual encounters
D. Tzall, E. C. Katz, Psychology, Towson University, Towson, MD
Monday, June 22, 2009
9
11:45 Contingency management reduces substance use and increases healthy behaviors among
homeless, out-of-treatment MSM
C. J. Reback1,2, J. A. Peck1,2, R. Dierst-Davies1, M. Nuño3, J. B. Kamien1, L. Amass1, 1Friends
Research Institute, Los Angeles, CA, 2Integrated Substance Abuse Programs, University of
California, Los Angeles, CA, 3Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA
Oral Communications 6 Bonanza
10:00 AM - 12:00 PM
SPINNING THE WHEELS OF CRIMINAL JUSTICE
Chairs: Carl G. Leukefeld and Jennifer R. Havens
10:00 Criminalization of addiction and mental illness: Do not pass go, go directly to jail
R. Crecelius1,2, A. Ben Abdallah1, C. W. Striley1, C. O’Leary1, L. B. Cottler1, 1Epidemiology
and Prevention Research Group, Washington University School of Medicine, St. Louis, MO,
2Division of Corrections, City of St. Louis, St. Louis, MO
10:15 Substance use, posttraumatic stress disorder and violent crime
E. L. Barrett, K. Mills, M. Teesson, National Drug and Alcohol Research Centre (NDARC),
University of New South Wales, Sydney, NSW, Australia
10:30 Evaluation of criminal justice diversion: California’s Proposition 36
D. Urada, E. Evans, J. Yang, J. Fan, B. Conner, M. D. Anglin, R. Rawson, B. Rutkowski,
J. Hunter, A. Hawken, C. Teruya, R. Gonzales, M. Campos, M. L. Brecht, Integrated Substance
Abuse Programs, University of California, Los Angeles, CA
10:45 A randomized controlled trial on naltrexone implants and methadone maintenance among
heroin-dependent inmates: Results 6 months after prison release
P. P. Lobmaier1,2, N. Kunøe2, M. Gossop3, H. Waal2, 1Addiction Medicine, Aker University
Hospital Trust, Oslo, Norway, 2Norwegian Centre for Addiction Research, University of Oslo,
Oslo, Norway, 3National Addiction Centre, Institute of Psychiatry, King’s College, London,
United Kingdom
11:00 Modified TC for persons with co-occurring disorders: Meta-analysis
S. Sacks, K. McKendrick, Center for the Integration of Research and Practice, National
Development and Research Institutes, Inc, New York, NY
11:15 Factors associated with hepatitis C seropositivity among incarcerated women re-entering the
community
J. R. Havens1, M. Tindall1, C. Oser1, J. Mooney1, H. Knudsen1, J. Duvall1, J. Inciardi2,
H. Surratt2, J. Clarke3, L. Frisman4, C. Leukefeld1, 1CDAR, University of Kentucky,
Lexington, KY, 2University of Delaware, Newark, DE, 3Brown University, Providence, RI,
4University of Connecticut, Hartford, CT
11:30 Thirty-day outcomes: A randomized trial of women’s relationships and HIV
C. Leukefeld1, J. Havens1, C. Oser1, M. Tindall1, H. Knudsen1, H. Palmer1, H. Surratt2,
J. Clarke3, L. Frisman4, 1University of Kentucky, Lexington, KY, 2University of Delaware,
Coral Gables, FL, 3Brown University, Providence, RI, 4University of Connecticut,
Hartford, CT
11:45 The impact of parole officer-offender relationships on recidivism and substance use: Results
from a randomized trial
A. G. Rhodes1, F. S. Taxman1, P. D. Friedmann2, 1Administration of Justice, George Mason
University, Manassas, VA, 2Alpert Medical School, Brown University, Providence, RI
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Oral Communications 7 Rose Ballroom A
10:00 AM - 12:00 PM
A ROYAL FLUSH OF PRESCRIPTION OPIOID EPIDEMIOLOGY
Chairs: Stephen F. Butler and Kathryn A. Saulsgiver
10:00 Relative rates of prescription opioid abuse: Comparison of public health databases
S. F. Butler, J. S. Brownstein, Inflexxion, Inc, Newton, MA
10:15 The risk of developing a dependence syndrome in recent onset users of analgesic compounds
O. A. Adelaja1, N. S. Miller2, J. C. Anthony1, 1Epidemiology, Michigan State University, East
Lansing, MI, 2Medicine, Michigan State University, East Lansing, MI
10:30 Prevalence of pain among prescription-opioid abusers
K. A. Saulsgiver, K. Dunn, S. Sigmon, S. Higgins, Psychiatry, University of Vermont,
Burlington, VT
10:45 Partying on Rx: Changes in prescription drug use and mental distress in a natural history study
of club drug users
S. P. Kurtz, D. J. O’Connell, H. L. Surratt, J. A. Inciardi, J. C. Weaver, N. W. Bakken, Center
for Drug and Alcohol Studies, University of Delaware, Coral Gables, FL
11:00 Prescription opioid use among convicted drinking drivers
B. Brands1,2,3, R. F. Zalcman2, R. E. Mann2,3, G. Stoduto2, R. K. Thomas2, 1Office of Research
and Surveillance, Health Canada, Ottawa, ON, Canada, 2Centre for Addiction and Mental
Health, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada
11:15 Gender differences in prescription opioid dependence: A pilot study
S. E. Back, K. T. Brady, Z. B. Stroud, Psychiatry, Medical University of South Carolina,
Charleston, SC
11:30 Motives for non-medical prescription opioid use among RADARS® System College Survey
respondents–indication of a substance abuse disorder?
A. Montoya1, L. M. Zolot1, J. E. Bailey1, R. C. Dart1,2, 1Rocky Mountain Poison and Drug
Center, Denver Health, Denver, CO, 2University of Colorado, School of Medicine, Aurora, CO
11:45 Randomized, double-blind trial evaluating buprenorphine taper for prescription opioid abuse
S. C. Sigmon1,2, K. Dunn2, K. Saulsgiver1, S. Heil1,2, S. Higgins1,2, 1Psychiatry, University of
Vermont, Burlington, VT, 2Psychology, University of Vermont, Burlington, VT
POSTER SESSION I (Lunch) Pavilion
12:00 - 2:00 PM
Odd-numbered posters manned first hour;
Even-numbered, second hour
Set-up time begins Sunday no earlier than 12:00 PM
Must be removed by Monday no later than 2:30 PM
ADOLESCENCE
1 Waking at night to smoke in adolescent and adult smokers
M. E. Mooney, A. J. Oliver, D. K. Hatsukami, Psychiatry, University of Minnesota,
Minneapolis, MN
2 Sustained attention is related to treatment outcomes for adolescent cigarette smokers
C. Collins, K. Leraas, S. Fields, S. Imhoff, B. Reynolds, Nationwide Childrens Hospital,
Columbus, OH
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3 Characteristics of adolescent marijuana smokers: Endorsing the need, and willing to participate
in a MJ quit program
A. Sheer1, C. Collins1, D. Gorelick1, J. Schroeder1, E. Moolchan2, 1NIDA/NIH, Baltimore, MD,
2Alkermes, Inc., Cambridge, MA
4 Delivering prevention for alcohol and cannabis over the Internet
N. C. Newton1, M. Teesson1, G. Andrews2, L. E. Vogl1, 1National Drug and Alcohol Research
Centre, University of New South Wales, Sydney, NSW, Australia, 2Clinical Research Unit for
Anxiety and Depression, University of New South Wales, Sydney, NSW, Australia
5 Disinhibition and reward sensitivity in relation to alcohol consumption by university
undergraduates
M. Lyvers, C. Czerczyk, A. Follent, P. Lodge, H. Duff, Psychology, Bond University, Gold
Coast, QLD, Australia
6 Crack cocaine use among Montreal street youth
C. Paquette1, É. Roy1,2, G. Petit1,3, 1Toxicomanie, Université de Sherbrooke, Longueuil, QC,
Canada, 2Direction de santé publique de Montréal, Montréal, QC, Canada, 3Direction de santé
publique et de l’évaluation de l’Estrie, Sherbrooke, QC, Canada
7 Predictors of alcohol initiation among Hispanic adolescents in Puerto Rico
T. D. Matos1, R. R. Robles1, J. C. Reyes-Pulliza2,1, J. L. Negron-Ayala1, J. M. Calderon1,
M. A. Cruz1, 1IRESA, Universidad Central del Caribe, Bayamon, PR, 2Epidemiology, School
of Public Health, San Juan, PR
8 Youth drug abuse treatment and prevention needs in Jalisco, Mexico
O. Campollo1,3, P. Sheikhattari2, C. Alvarez-González1, J. Toro1, H. Sánchez3, F. A. Wagner2,
1Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara,
Mexico, 2Center for Health Disparities Solutions, Morgan State University, Baltimore, MD,
3Clínica para Dejar de Fumar, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
9 Associated factors of non-use of drugs among children and youth in street circumstances in
Brazil
Y. G. Moura, E. Opaleye, Z. Sanchez, C. Carlini, A. Noto, Psychobiology, UNIFESP, São
Paulo, Brazil
10 Recreational use of benzydamine: A national cross-sectional survey among children and youth
in street circumstances in Brazil
E. S. Opaleye, Z. Sanchez, Y. Moura, A. Noto, Psychobiology, UNIFESP, Sao Paulo, Brazil
11 Incidence of drug use among school adolescents in Bogotá, Colombia
C. Lopez-Quintero, Y. Neumark, School of Public Health, Hebrew University of Jerusalem,
Jerusalem, Israel
12 Inhalant drug use among Israeli youth
Y. Neumark1, R. Bar-Hamburger2, 1School of Public Health, Hebrew University of Jerusalem,
Jerusalem, Israel, 2Anti-Drug Authority of Israel, Jerusalem, Israel
13 Drug market activity influence on adolescent school conduct
R. J. Evans, L. J. Floyd, E. Hill, W. Latimer, Mental Health, Johns Hopkins University
Bloomberg School of Public Health, Baltimore, MD
14 Neighborhood disadvantage and substance use among adolescents
S. Salomonsen-Sautel1, S. K. Mikulich-Gilbertson1, P. D. Riggs1, C. Thurstone2, 1University of
Colorado Denver, Aurora, CO, 2Denver Health, Denver, CO
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15 Troubled parents, motivated adolescents: Predicting motivation to change substance use among
runaways
N. Slesnick, S. Bartle-Haring, H. Budde, A. Letcher, D. Bantchevska, R. Garren, Human
Development and Family Science, The Ohio State University, Columbus, OH
16 Outreach family intervention for young out-of-treatment drug users
R. Santis1, C. G. Hidalgo2, A. Jaramillo2, V. Hayden1, A. Lasagna2, E. Anselmo1,
M. T. Espinoza1, T. Rodriguez1, D. de la Paz1, J. Salas1, C. Quiroga1, P. González1, P. P. Farías1,
1Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile, 2School of Psychology,
Pontificia Universidad Católica de Chile, Santiago, Chile
17 How does religiosity prevent substance use among adolescents?
Z. V. Sanchez, E. Opaleye, Y. Moura, T. Chaves, A. Noto, S. Nappo, Psychobiology, UNIFESP,
Sao Paulo, Brazil
18 Findings from a randomized clinical trial examining Assertive Continuing Care with two types of
outpatient treatment for adolescents
S. H. Godley, L. Passetti, R. Funk, M. Godley, B. Garner, B. Hunter, Chestnut Health Systems,
Normal, IL
19 Results from a one-session HIV risk reduction intervention in adolescents with substance use
disorder
C. Thurstone1, P. D. Riggs2, S. K. Mikulich-Gilbertson2, S. Salomonse-Sautel2, C. Klein2,
1Denver Health and Hosptital Authority, Denver, CO, 2University of Colorado Denver,
Aurora, CO
FOOD AND OBESITY
20 Neuroimaging of brain activation in response to food cues in obese children
E. Charboneau1,2, A. Bauernfeind1, E. Castellanos1, M. S. Dietrich3, G. Plemmons4, S. Park5,
P. R. Martin1,2, R. L. Cowan1,2, 1Psychiatric Neuroimaging Program, Vanderbilt School of
Medicine, Nashville, TN, 2Vanderbilt Addiction Center, Vanderbilt School of Medicine,
Nashville, TN, 3Biostatistics, Vanderbilt University, Nashville, TN, 4Childhood Weight
Management Clinic, Vanderbilt Children’s Hospital, Nashville, TN, 5Psychology, Vanderbilt
University, Nashville, TN
21 Addiction to food: The relationship between delay discounting, obesity, and the binge eating
scale
B. A. Jones, W. Bickel, R. Yi, R. Landes, D. West, Psychiatry, UAMS, Little Rock, AR
22 Validation of a questionnaire for sugar addiction
M. C. Rosa2,1, C. M. Gomes4, S. B. Slavutzky3, F. H. Kessler1, E. F. Ferreira2, F. Pechansky1,
1Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 2Social and
Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil, 3Social and
Preventive Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil,
4Psychology, Federal University of Minas Gerais, Belo Horizonte, Brazil
23 Are injection-related risk behaviors and food insecurity associated?
C. Strike1,4, A. Sarnocinska Hart1, S. Anstice5, C. Wender2, B. Lester3, N. Scrivo3, J. Luce1,
M. Millson4, 1Health Systems Research and Consulting, Centre for Addiction and Mental
Health, Toronto, ON, Canada, 2My Sisters’ Place, London, ON, Canada, 3AIDS Committee of
London, London, ON, Canada, 4Dalla Lana School of Public Health, University of Toronto,
Toronto, ON, Canada, 5School of Social Work, University of Toronto, Toronto, ON, Canada
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24 The use of appetite suppressant among health sciences undergraduate students in Southern
Brazil
C. Zubaran1, I. Tres2, E. C. de Toni2, R. Pereira2, K. N. Persch2, K. Foresti2, 1School of
Medicine, University of Western Sydney, Sydney, NSW, Australia, 2University of Caxias do
Sul, Caxias do Sul, Brazil
25 Lack of abuse potential of tesofensine in recreational stimulant users
E. Sellers1, D. Meier2, B. Chakraborty1, P. Manniche2, K. A. Schoedel1, 1Clinical
Pharmacology, Kendle Early Phase, Toronto, ON, Canada, 2NeuroSearch A/S, Ballerup,
Denmark
26 Addiction to food: Potential use of 18-methoxycoronaridine to treat obesity
O. Taraschenko, I. Maisonneuve, S. Glick, Albany Medical College, Albany, NY
27 Sugar dependence in low- vs. high-saccharin-consuming rats
V. Yakovenko, C. D. Chapman, N. K. Dess, Occidental College, Los Angeles, CA
28 Food restriction differentially modifies the behavioral effects of the dopamine receptor agonist
quinpirole in rats
M. Baladi, C. P. France, Pharmacology, University of Texas Health Science Center, San
Antonio, TX
METHYLPHENIDATE
29 Role of the dopamine receptor subtypes in the expression of the discriminative stimulus effect
induced by U-50,488H or methamphetamine
K. Yoshizawa1,2, M. Miyatake1, T. Mori1, K. Fukuda2, N. Kuzumaki1, M. Narita1, T. Suzuki1,
1Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan,
2Pharmaceutical Service, Chiba-Hokusoh Hospital Nippon Medical School, Chiba, Japan
30 Distinct mechanism of methamphetamine- and methylphenidate-induced dopamine-related
neurotoxicity
T. Suzuki, D. Ikegami, M. Asato, M. Narita, M. Saeki, N. Kuzumaki, M. Narita, Toxicology,
Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan
31 Early methylphenidate exposure enhances cocaine self-administration but not cocaine-induced
conditioned place preference in young adult rats
S. A. Baella, C. M. Farley, M. S. Herbert, L. R. Horn, R. H. Campbell, C. A. Crawford,
Psychology, California State University, San Bernardino, San Bernardino, CA
32 Effects of oral vs. intraperitoneal methylphenidate on locomotor activity and conditioned place
preference in rats
T. E. Wooters, M. Walton, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
CLUB DRUGS
33 The acute subjective effects of combined benzylpiperazine and trifluoromethylphenylpiperazine
on healthy males
B. R. Russell1, H. Lee1, R. Wan1, W. Koak1, K. Kim1, S. Govan1, R. R. Kydd2, 1School of
Pharmacy, The University of Auckland, Auckland, New Zealand, 2Psychological Medicine, The
University of Auckland, Auckland, New Zealand
34 The acute effects of combined benzylpiperazine and trifluoromethylphenylpiperazine on human
P300 event-related potentials
H. Lee1, R. R. Kydd2, B. R. Russell1, 1School of Pharmacy, The University of Auckland,
Auckland, New Zealand, 2Psychological Medicine, The University of Auckland, Auckland,
New Zealand
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35 Acute effects of benzylpiperazine on cognition and executive functioning using functional
magnetic resonance imaging using the Stroop paradigm-results from the pilot study
L. E. Curley1, N. Mcnair1, R. R. Kydd2, I. J. Kirk3, B. R. Russell1, 1School of Pharmacy, The
University of Auckland, Auckland, New Zealand, 2Psychological Medicine, The University of
Auckland, Auckland, New Zealand, 3Psychology, The University of Auckland, Auckland, New
Zealand
36 Is moderate substance use associated with altered executive functioning in a population-based
sample of young adults?
C. G. Schütz1, F. Indlekofer2, M. Piechatzek2, M. Daamen3, C. Glasmacher2, R. Lieb4,
H. Pfister4, O. Tucha5, K. W. Lange6, H. U. Wittchen7,4, 1Institute of Mental Health, University
of British Columbia, Vancouver, BC, Canada, 2Psychiatry, Ludwig-Maximilians-University,
Munich, Germany, 3Max-Planck-Insitute for Psychiatry, Munich, Germany, 4Radiology,
University of Bonn, Bonn, Germany, 5School of Psychology, University Plymouth, Plymouth,
United Kingdom, 6Experminetal Psychology, University of Regensburg, Regensburg,
Germany, 7Psychiatry, University of Dresden, Dresden, Germany
37 Effects of methamphetamine and MDMA on speech
G. F. Marrone1,3, J. S. Pardo2,3, R. M. Krauss2, C. L. Hart1,2, 1College of Physicians and
Surgeons of Columbia University, NY State Psychiatric Institute, New York, NY, 2Columbia
University, New York, NY, 3Barnard College, New York, NY
38 Effects of 3,4-methylenedioxymethamphetamine on arginine vasopressin in healthy volunteers
M. J. Baggott1,2, J. Mendelson1, K. J. Garrison1, G. P. Galloway1, 1Addiction Pharmacology,
California Pacific Medical Center Research Institute, San Francisco, CA, 2Hellen Wills
Neuroscience Institute, University of California Berkeley, Berkeley, CA
39 Thermoregulatory and behavioral effects of MDMA in Flinders Sensitive Line rats
E. J. Jaehne, I. Majumder, A. Salem, R. J. Irvine, Discipline of Pharmacology, School of
Medical Sciences, University of Adelaide, Adelaide, SA, Australia
40 MDMA reduces serotonin transporter cell surface expression via a p38MAP- kinase-
independent mechanism
B. M. Kivell, P. Bosch, B. Lake, D. Day, S. Schenk, J. H. Miller, Victoria University of
Wellington, Wellington, New Zealand
METHAMPHETAMINE/AMPHETAMINE - ANIMALS
41 Repeated methamphetamine alters prefrontal cortex neurotransmission
K. D. Lominac1,2, K. K. Szumlinski1,2, 1Psychology, University of California, Santa Barbara,
Santa Barbara, CA, 2Neuroscience Research Institute, University of California, Santa Barbara,
Santa Barbara, CA
42 Effects of (-)-trans-PAT, a novel 5-HT2C agonist and 5-HT2A/2B antagonist/inverse agonist, on
amphetamine-induced locomotor activity in rats
D. Morgan1, J. P. DuPree1, Z. Sun2, R. G. Booth2, 1Psychiatry, University of Florida College of
Medicine, Gainesville, FL, 2Medicinal Chemistry, University of Florida College of Pharmacy,
Gainesville, FL
43 Chronic antagonism of 5-HT2C receptors enhance drug-seeking behavior in rats trained to self-
administer methamphetamine
S. M. Graves1,2, T. C. Napier1,2, 1Pharmacology, Rush University Medical Center, Chicago, IL,
2Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL
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44 Lobeline potentiates the methamphetamine-induced decrease in extracellular DOPAC in the
nucleus accumbens shell
N. M. Neugebauer1,2, M. T. Bardo2, L. P. Dwoskin3, 1Psychiatry, Yale University School of
Medicine, New Haven, CT, 2Psychology, University of Kentucky, Lexington, KY, 3College of
Pharmacy, University of Kentucky, Lexington, KY
45 Identification of “agonist” and “antagonist” allosteric modulators of amphetamine-induced
dopamine release
R. B. Rothman1, S. Ananthan2, C. M. Dersch1, J. S. Partilla1, 1Clinical Psychopharmacology
Section, IRP, NIDA, NIH, Baltimore, MD, 2Organic Chemistry Department, Southern
Research Institute, Birmingham, AL
46 Behavioral-stimulant and neurochemical effects of monoamine releasers with varying selectivity
for dopamine and serotonin in squirrel monkeys
H. L. Kimmel1,2, D. F. Manvich2, M. Zhou2, M. E. Pontell2, B. E. Blough3, L. L. Howell1,2,4,
1Pharmacology, Emory University School of Medicine, Atlanta, GA, 2Yerkes National Primate
Research Center, Emory University, Atlanta, GA, 3Center for Organic and Medicinal
Chemistry, RTI International, Research Triangle Park, NC, 4Psychiatry and Behavioral
Sciences, Emory University School of Medicine, Atlanta, GA
47 Sigma antagonists, AC927 and CM156, protect against methamphetamine-induced serotonin
depletion while attenuating hyperthermia
M. J. Seminerio1, N. Kaushal1, J. Shaikh1, M. Medina1, A. Coop2, C. McCurdy3,
R. Matsumoto1, 1West Virginia University, Morgantown, WV, 2University of Maryland,
Baltimore, MD, 3University of Mississippi, Oxford, MS
48 Response to novelty predicts both responding for a visual stimulus and self-administration of a
low dose of methamphetamine in rats
A. M. Gancarz, M. A. San George, L. Ashrafioun, A. C. Thompson, J. B. Richards,
Psychology and Research Institute on Addictions, University at Buffalo, Buffalo, NY
49 Methamphetamine impairs sexually conditioned approach in male Japanese quail
B. L. Bolin, C. K. Akins, Psychology, University of Kentucky, Lexington, KY
50 Valproic acid attenuates acute amphetamine-induced locomotion in mice
N. Enman, J. S. Miller, E. M. Unterwald, Pharmacology and Center for Substance Abuse
Research, Temple University School of Medicine, Philadelphia, PA
51 Reinstatement of amphetamine self-administration by MDMA and its isomers in rhesus monkeys
J. C. McClung1, L. L. Howell1,2, 1Yerkes National Primate Research Center, Emory University,
Atlanta, GA, 2Psychiatry and Behavioral Sciences, Emory University School of Medicine,
Atlanta, GA
OPIOIDS: ANIMALS
52 Strain- and heroin-induced effects on endogenous opioid and GABA A receptor mRNA levels in
the caudate putamen of C57BL/6J and 129P3/J mice
S. D. Schlussman, O. Levran, Y. Zhang, A. Ho, M. J. Kreek, The Laboratory of the Biology of
Addictive Diseases, The Rockefeller University, New York, NY
53 Partial ablation of mu-opioid receptor-rich striosomes results in behavioral deficits on a motor
skill learning task
C. Lawhorn1,2, D. M. Smith3, L. L. Brown2,3, 1Laboratory of the Biology of Addictive Diseases,
Rockefeller University, New York, NY, 2Dominick P. Purpura Department of Neuroscience,
Albert Einstein College of Medicine, Bronx, NY, 3Saul R. Korey Department of Neurology,
Albert Einstein College of Medicine, Bronx, NY
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54 Suppression of dopamine-related side effects of morphine by atypical antipsychotic drugs
including a dopamine system stabilizer
K. Torigoe1, M. Narita1, D. Takei1, M. Shiokawa1,2, Y. Matsushima1, S. Takagi1, M. Narita1,
T. Suzuki1, T. Amano1,3, N. Kuzumaki1, T. Suzuki1, 1Toxicology, Hoshi Univ. Sch. Pharm.
Pharmaceut. Sci., Tokyo, Japan, 2Pharmacy, St. Luke’s International Hospital, Tokyo, Japan,
3Molecular and Pharmacological Neuroscience, Division of Integrated Medical Science,
Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
55 Therapeutic implications of delta opioid receptor expression in the VTA of EtOH-drinking or
morphine-injected Lewis rats
J. M. Mitchell1,2, H. L. Fields1,2, A. R. Coker1, J. R. Driscoll1, E. B. Margolis1, 1Ernest Gallo
Clinic and Research Center, Emeryville, CA, 2University of California, San Francisco, CA
56 Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus
monkeys: Comparison with heroin and antagonism by naltrexone and naloxonazine
C. Achat-Mendes, G. R. Valdez, D. M. Platt, J. K. Rowlett, R. D. Spealman, Harvard Medical
School, Southborough, MA
GENETICS
57 Ethnic diversity of OPRM1 gene promoter DNA methylation and its association with subjects in
methadone treatment
D. A. Nielsen2,1, S. Hamon3, V. Yuferov1, C. Jackson1, A. Ho1, J. Ott3, M. J. Kreek1, 1The
Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY,
2Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine,
Houston, TX, 3The Laboratory of Statistical Genetics, The Rockefeller University, New
York, NY
58 Difference in allelic frequency in two ethnic groups and analysis of possible association of the
830 bp indel polymorphism in the OPRK1 promoter with cocaine and/or alcohol dependence
V. Yuferov1, S. Hamon2, O. Levran1, A. Ho1, J. Ott2, M. J. Kreek1, 1The Laboratory of the
Biology of Addictive Diseases, The Rockefeller University, New York, NY, 2Laboratory of
Statistical Genetics, The Rockefeller University, New York, NY
59 CM156, a novel antagonist of σ receptors, attenuates cocaine-induced conditioned place
preference: Behavioral evaluations and molecular analysis
Y. Xu1, M. Elliott1, J. Shaikh1, C. R. McCurdy2, R. R. Matsumoto1,2, 1Basic Pharmaceutical
Sciences, West Virginia University, Morgantown, WV, 2School of Pharmacy, The University of
Mississippi, University, MS
60 Alpha-2A adrenoceptors play a role in behavioral flexibility in mice, but are not required for
improvements caused by atomoxetine
A. S. James1, C. A. Jairl1, E. Seu1, J. Jentsch1,2, 1Psychology, University of California, Los
Angeles, CA, 2Psychiatry and Biobehavioral Science, University of California, Los
Angeles, CA
61 The special case of the mu opioid receptor and the evolution of the opioid receptor family
C. W. Stevens, Pharmacology and Physiology, Oklahoma State University Center for Health
Sciences, Tulsa, OK
DRUG INTERACTIONS/POLYDRUG ABUSE
62 Changes in cigarette use among cocaine abusers in a pharmacologic treatment trial
L. R. Rothenberg2, D. J. Brooks2, D. Feldman2, A. Bisaga1,2, J. Mariani1,2, F. R. Levin1,2,
1Psychiatry, Columbia University, New York, NY, 2Substance Abuse, New York State
Psychiatric Institute, New York, NY
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63 Effects of acute oral caffeine pretreatment on response to intravenous nicotine and cocaine in
stimulant users
M. W. Johnson, E. C. Strain, R. R. Griffiths, Behavioral Pharmacology Research Unit, Johns
Hopkins University School of Medicine, Baltimore, MD
64 The relationship between nicotine use and opioid-dependence treatment during the early phase
of primary care buprenorphine stabilization
B. R. Bryan1, E. W. Gunderson1,2, S. K. Vosburg1, G. Perez1, L. Archibald1, F. R. Levin1,
1Division on Substance Abuse, Columbia University New York State Psychiatric Institute, New
York, NY, 2Psychiatry and Neurobehavioral Sciences Department of Medicine, University of
Virginia, Charlottesville, VA
65 Mu-opioid receptors on red blood cells of cocaine users
D. Gorelick1, A. Zeiger2, P. Matthews2, J. Slock1, K. Preston1, J. Frost3, 1NIDA IRP,
Baltimore, MD, 2Thomas Jefferson University, Philadelphia, PA, 3Johns Hopkins University,
Baltimore, MD
66 Effects of verapamil and diltiazem in methadone-maintained humans under a naloxone novel-
response discrimination procedure
A. Oliveto1, M. J. Mancino1, C. Cargile1, W. B. Gentry2, 1Psychiatry, University of Arkansas
Medical School, Little Rock, AR, 2Anesthesiology, Pharmacology and Toxicology, University
of Arkansas Medical School, Little Rock, AR
67 Coping styles of sustance abusers seeking organ transplantation
H. Newville1,2, D. L. Haller2,3, M. C. Acosta2,3, 1Psychology, Ferkauf Graduate School of
Psychology, Yeshiva University, Bronx, NY, New York, NY, 2Psychiatry, St. Luke’s-Roosevelt,
New York, NY, 3Psychiatry, Columbia University, New York, NY
68 Acceptability of an MI-based telephone intervention for substance-abusing transplant patients
M. C. Acosta1,2, D. L. Haller1,2, 1Psychiatry, St. Luke’s-Roosevelt, New York, NY, 2Psychiatry,
Columbia University, New York, NY
69 Longitudinal patterns and correlates of smoking in formerly polysubstance-dependent
individuals
A. B. Laudet, Center for the Study of Addictions and Recovery, NDRI, New York, NY
70 Cocaine dependence and concurrent marijuana use: A comparison of clinical characteristics
J. A. Lindsay1, J. M. Schmitz1, A. L. Stotts1, C. Green1, D. Herin2, 1Psychiatry and Behavioral
Sciences, University of Texas Health Science Center at Houston, Houston, TX, 2Psychiatry,
University of Minnesota, Minneapolis, MN
71 The effect of teacher-rated attention-concentration problems in grades 1 through 6 on latent
class growth trajectories of hallucinogens, ecstacy/MDMA, ketamine, sedatives,
amphetamines/stimulants, analgesics, tranquilizers, inhalants, cocaine, and heroin for females
aged 19-20
V. J. Tsamis1,2, N. Ialongo1, G. Rebok1, S. Kellam1, 1Mental Health, Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, 2Psychology, Stevenson University, Stevenson, MD
72 The relationship between increased exercise and reduced substance use
M. J. Dennis1, M. L. Dennis2, 1Heartland Community College, Normal, IL, 2GAIN
Coordinating Center, Chestnut Health Systems, Normal, IL
73 Assignment of involuntary payees in a voluntary money management intervention
M. I. Rosen1,2, K. Ablondi1,2, A. C. Black1,2, B. J. Rounsaville1,2, R. A. Rosenheck2,1,
1Psychiatry, Yale University School of Medicine, New Haven, CT, 2Psychiatry, VA Connecticut
Healthcare System, West Haven, CT
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74 Predictors of job-seeking behaviors
A. A. Forcehimes1, J. M. Houck1, M. P. Bogenschutz1, D. Svikis2, K. Foley3, 1CASAA,
University of New Mexico, Albuquerque, NM, 2Virginia Commonweath University,
Richmond, VA, 3Na’Nizhoozhi Center Inc., Gallup, NM
75 Longitudinal changes in attachment, social support, parenting attitudes, and psychological
functioning among women drug abusers
E. Hall, M. Prendergast, U. Warda, N. Messina, E. Nelson, L. Gregorio, C. Gonzalez,
University of California, Los Angeles, CA
76 Congruence of self-reported drug use with urine toxicology screening in a substance abuse
treatment population
R. C. Desmond1, B. Brands2,3, B. Rush1,3, 1Centre for Addiction and Mental Health,
Toronto, ON, Canada, 2Health Canada, Ottawa, ON, Canada, 3University of Toronto,
Toronto, ON, Canada
GENDER/SEX DIFFERENCES
77 Sources of income for chronic drug users
C. B. McCoy, M. Comerford, Epidemiology and Public Health, University of Miami,
Miami, FL
78 Comparing group process in the single-gender Women’s Recovery Group versus mixed-gender
Group Drug Counseling
S. F. Greenfield1,2, L. E. Kuper1, A. M. Cummings1, R. Gallop3, 1McLean Hospital,
Belmont, MA, 2Psychiatry, Harvard Medical School, Boston, MA, 3West Chester University,
West Chester, PA
79 Gender differences in physical/sexual abuse in outpatients with SUDs: Correlates with medical
and psychiatric symptoms
L. Islam1, A. Sepulveda1, A. Alvanzo2, L. Keyser-Marcus1, T. Rieckman3, M. Stitzer2,
D. Svikis1, 1Psychology, Virginia Commonwealth University, Richmond, VA, 2Psychiatry &
Medicine, Johns Hopkins, Baltimore, MD, 3Public Health, Oregon Health and Science
University, Portland, OR
80 Characteristics of clients with co-occurring disorders in addiction treatment: A comparison by
gender
L. Mangrum, Addiction Research Institute, University of Texas Health Science Center
Houston, Austin, TX
81 Gender differences in suicidal ideation and opioid-use disorder among non-medical opioid users
with lifetime major depression
S. J. Kuramoto1, H. D. Chilcoat1,2, J. Ko1, S. S. Martins1, 1Mental Health, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, 2GlaxoSmithKline WorldWide
Epidemiology, GlaxoSmithKline, Research Triangle Park, NC
82 Gender differences in situational activities associated with heroin and cocaine use among
methadone-maintained outpatients
A. Mitola, D. Epstein, J. Willner-Reid, K. L. Preston, National Institute on Drug Abuse,
Intramural Research Program, Baltimore, MD
83 Gender differences at presentation for treatment-seeking opiate dependence
L. Haynes1, A. Walquist1, R. Carter1, S. Back1, M. Hillhouse2, 1Medical University of South
Carolina, Charleston, SC, 2University of California, Los Angeles, CA
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84 Examination of social contextual variables as risk factors in the relationship between gender
and crack/cocaine
E. K. Reynolds1, C. E. Kopetz1, S. B. Daughters2, C. W. Lejuez1, 1Psychology, University of
Maryland, College Park, MD, 2School of Public Health, University of Maryland, College
Park, MD
85 An investigation of the gender-specific relationship between childhood trauma and low distress
tolerance among low-income minority substance users
T. Geiger, S. B. Daughters, M. A. Bornovalova, C. W. Lejuez, University of Maryland, College
Park, MD
86 Males, females, recent-onset drug dependence, and psychological distress: Epidemiological
evidence from the United States, 2006
M. Radovanovic1,2, J. C. Anthony1, 1Epidemiology, Michigan State University, East
Lansing, MI, 2Psychiatric Office Rudnik, Ljubljana, Slovenia
87 Gender differences in patterns of alcohol dependence symptoms: Evidence from a latent
empirical approach
J. Ko1, S. Martins1, S. Kuramoto1, H. Chilcoat2, 1Mental Health, Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, 2GlaxoSmithKline WorldWide Epidemiology,
GlaxoSmithKline, Research Triangle Park, NC
88 Gender differences in past month marijuana use between individual and team sport participants
among 10th graders: United States, 2006
O. J. Santiago1, C. F. Rios-Bedoya2, D. L. Feltz1, F. A. Fiestas3, 1Kinesiology, Michigan State
University, East Lansing, MI, 2Family Medicine, Michigan State University, East Lansing, MI,
3Epidemiology, Michigan State University, East Lansing, MI
89 Gender differences in tobacco use and smoking risk factors among Spanish adolescents
O. Garcia-Rodriguez1, R. Suárez Vázquez2, L. Ciller Valverde2, 1University of Barcelona,
Barcelona, Spain, 2Health Promotion Studies Center (CEPS), Barcelona, Spain
90 Male-female differences in tobacco dependence experiences: Epidemiological evidence from the
United States, 2006
M. M. Catacora, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
91 Sex differences in response to intravenous nicotine in smokers
M. Sofuoglu1, M. Mooney2, 1Yale University, West Haven, CT, 2Psychiatry, University of
Minnesota, Minneapolis, MN
92 Basal and cocaine-induced sex differences in the DARPP-32 pathway
L. Zhou2,3, W. Sun1,3, A. Nazarian1,3, S. Jenab1,3, V. Quinones-Jenab1,3, 1Psychology, Hunter
College of City University of New York, New York, NY, 2Biology, Hunter College of City
University of New York, New York, NY, 3Graduate Center of City University of New York,
New York, NY
93 Sex differences in approach-avoidance behavior in the runway model of cocaine self-
administration
Z. Su, K. A. Kersetter, D. Guzman, T. Kippin, A. Ettenberg, Psychology, University of
California-Santa Barbara, Santa Barbara, CA
94 The effects of allopregnanolone on cocaine self-administration under a progressive-ratio
schedule in female rats
N. Holtz, J. Anker, M. Carroll, University of Minnesota, Minneapolis, MN
95 Antinociceptive and motoric effects of i.c.v. THC in male vs. female rats
A. A. Wakley, R. M. Craft, Psychology, Washington State University, Pullman, WA
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PAIN
96 Pain-elicited and -suppressed behaviors in CB1 knockout mice and their wild-type littermates:
Effects of morphine
L. L. Miller, M. J. Picker, K. T. Schmidt, L. A. Dykstra, Psychology, University of North
Carolina, Chapel Hill, NC
97 Estrous cycle effects on physiological responses to pain in formalin- and carrageenan-induced
inflammation
N. J. Amador1,2, K. Y. Shivers1,2, D. Hunter1,2, S. Jenab1,2, V. Quinones-Jenab1,2, 1BioPsychology,
CUNY Graduate School and University Center, New York, NY, 2Psychology, Hunter College,
New York, NY
98 Estrogen’s antihyperalgesic effects in paw tissue of ovariectomized rats during carrageenan-
induced inflammation
K. Y. Shivers1,2, L. C. Abrams1,2, T. Mathew1,2, D. Hunter1,2, G. Barr1,2, S. Jenab1,2, V. Quinones-
Jenab1,2, 1Psychology, The Graduate School and University Center, City University of New
York, New York, NY, 2Biopsychology and Behavioral Neuroscience Subprogram, Hunter
College City University of New York, New York, NY
99 Estrogen increases behavioral responses to carrageenan-induced inflammation in
ovariectomized mice
L. Abrams1,2, K. Y. Shivers1,2, N. J. Amador1,2, T. Mathew1,2, D. Hunter1,2, G. Barr1,2, S. Jenab1,2,
V. Quiñones-Jenab1,2, 1Psychology, Hunter College, City University of New York, New
York, NY, 2Psychology, The Graduate Center, City University of New York, New York, NY
100 Mu/delta opioid agonist interactions in an assay of capsaicin-induced thermal allodynia in
rhesus monkeys
S. S. Negus1, J. E. Folk2, K. C. Rice2, 1Pharmacology and Toxicology, Virginia Commonwealth
University, Richmond, VA, 2Chemical Biology Research Branch, NIDA/NIAAA,
Rockville, MD
101 A bivalent ligand (MDAN-21) containing µ-agonist and δ-antagonist pharmacophores is devoid
of significant physical dependence capacity in rats
M. D. Aceto1, P. S. Portoghese2, E. Akgun2, L. S. Harris1, 1Pharmacology and Toxicology,
Virginia Commonwealth University, Richmond, VA, 2Medicinal Chemistry, University of
Minnesota, Minneapolis, MN
102 Phase II study of the safety and tolerability of niacin combined with oxycodone HCl 5mg vs.
oxycodone HCl 5mg alone in healthy adult subjects
D. Freeland1, R. Spivey2, R. Colucci3, 1Bee Caves Family Practice, Austin, TX, 2Acura
Pharmaceuticals, Inc., Palatine, IL, 3Colucci and Assoc., LLC, Newtown, CT
103 ACUROX® (Oxycodone HCl/Niacin) tablets for the treatment of acute, moderate to severe pain
following bunionectomy surgery in adult patients
S. Daniels1, R. Spivey2, R. Colucci3, 1Premier Research Group Ltd, Austin, TX, 2Acura
Pharmaceuticals, Inc., Palatine, IL, 3Colucci and Assoc., LLC, Newtown, CT
104 Evaluation of plasma naltrexone concentrations resulting from use of ALO-01 (morphine sulfate
extended-release with sequestered naltrexone hydrochloride) capsules for chronic pain
F. Johnson1, D. Manning1, C. Wang1, J. Stauffer1,2, 1Alpharma Pharmaceuticals LLC,
Piscataway, NJ, 2Johns Hopkins University School of Medicine, Baltimore, MD
105 Post surgery patient-controlled analgesia in smokers and non-smokers
C. Diederichs1, T. Roehrs1,2, M. Hyde1, M. Greenwald2, T. Roth1,2, 1Sleep Disorders and
Research Center, Henry Ford Health System, Detroit, MI, 2Psychiatry and Behavioral
Neuroscience, School of Medicine, Wayne State University, Detroit, MI
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106 Pain assessment in patients on opioid maintenance therapy
N. A. Authier1,2,3, C. Auclair1, C. Dubray2, A. Eschalier3, P. Y. Courty1, 1Pôle de Psychiatrie -
CMP B, CHU G Monpied, Clermont Ferrand, France, 2Clinical Pharmacology, INSERM CIC
501, Clermont Ferrand, France, 3Pharmacology and Toxicology, UMR INSERM 766, Clermont
Ferrand, France
107 Prevalence of severe pain among methadone maintenance patients
D. Perlman1,2, C. L. Masson3, C. McKnight1, N. Pepper3, L. Coffin1, A. Morganstern3,
A. Jordan1, R. Seewald1, D. C. Des Jarlais1,2, R. Portenoy1, 1Beth Israel Medical Center, New
York, NY, 2NDRI, Inc., New York, NY, 3University of California, San Francisco, San
Francisco, CA
108 Provider confidence recognizing opioid analgesic abuse in HIV care settings
P. Lum1, S. Little2, D. Hersh2, R. Thawley1, J. Egan3, J. Mitty4, D. Fiellin5, 1University of
California, San Francisco, CA, 2San Francisco Department of Public Health, San
Francisco, CA, 3New York Academy of Medicine, New York, NY, 4Brown University,
Providence, RI, 5Yale University, New Haven, CT
109 An integrated intervention for chronic pain and substance use reduces opioid medication misuse
B. J. Morasco, A. Patterson, P. Benson, M. Dogra, M. P. Resnick, S. K. Dobscha, Portland VA
Medical Center, Portland, OR
POLICY
110 Medicaid reimbursement for screening and brief intervention of substance abuse
H. E. Fussell, T. Rieckmann, M. Gilpin, J. Kohon, Oregon Health and Science University,
Portland, OR
111 Alcohol, press and public policies in Brazil: Content analysis of newspaper and magazine
stories in 2006 compared to 2003 and 2000
A. R. Noto, J. D. Silveira, F. C. Mastroianni, Psicobiologia, UNIFESP, São Paulo, Brazil
112 Adolescent tobacco initiation, use and ongoing nicotine addiction: Perspectives on a reduced
nicotine content policy
S. J. Lo1, C. Collins1, J. Henningfield2, E. Moolchan3, 1NIDA/NIH, Baltimore, MD, 2Pinney
Associates, Bethesda, MD, 3Alkermes, Inc., Cambridge, MA
113 Smoking cessation services in drug abuse treatment: A national study
H. K. Knudsen, J. L. Studts, Behavioral Science, University of Kentucky, Lexington, KY
114 Addressing nicotine dependence in drug treatment settings: Organizational change
J. Guydish1, D. Ziedonis2, B. Tajima1, G. Brigham4, L. Zamarelli3, 1University of California,
San Francisco, San Francisco, CA, 2University of Massachusetts, Worcester, MA, 3Willamette
Family, Inc, Eugene, OR, 4Maryhaven, Inc., Columbus, OH
115 Heroin purchasing is income, price and arrest-rate sensitive
J. K. Roddy1, C. L. Steinmiller2, M. K. Greenwald2, 1Social Sciences, University of Michigan
Dearborn, Dearborn, MI, 2Psychiatry and Behavioral Neurosciences, Wayne State University,
Detroit, MI
116 Disaster preparedness for disruptions in methadone treatment
D. Podus1, J. C. Maxwell2, 1UCLA-ISAP, Los Angeles, CA, 2University of Texas, Austin, TX
117 Adoption of medications in substance abuse treatment: Access, integration and workforce
development
T. Rieckmann, M. Gholson, D. McCarty, W. Nash, J. Kohon, H. Fussell, Public Health and
Preventive Medicine, Oregon Health and Science University, Portland, OR
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118 New York drug policies and the lived experiences of African American women in distressed
households
L. C. Windsor1, E. Dunlap2, 1School of Social Work, Rutgers: The State University of New
Jersey, New Brunswick, NJ, 2National Development and Research Institutes, New York, NY
119 Do organizational process improvement interventions significantly change motivational
interviewing knowledge, attitudes, and use by substance abuse treatment counselors?
S. Stevens Manser, D. Travis, E. Borah, R. Spence, Center for Social Work Research,
Addiction Research Institute, University of Texas at Austin, Austin, TX
120 Assessing participation in a randomized trial evaluating improvement strategies in addiction
treatment
A. Quanbeck1, J. H. Ford1, A. Pulvermacher1, J. Robinson1, A. Wheelock1, J. McConnell2,
K. Hoffman2, D. McCarty2, D. Gustafson1, V. Sviridova1, J. Kadunc1, 1University of Wisconsin,
Madison, WI, 2Oregon Health and Science University, Portland, OR
121 Current drug-scheduling reviews reported by the Drug Enforcement Administration
S. R. Tella, S. Ghozland, A. Sancho, C. Prioleau, S. Carr, C. Sannerud, Office of Diversion
Control, Drug Enforcement Administration, Washington, DC
122 Drug combinations seized by law enforcement, emerging trends and undetermined effects to the
unsuspecting user
T. L. Boos, L. L. Wong, S. M. Carr, C. A. Sannerud, Drug and Chemical Evaluation
Section/ODE, Drug Enforcement Administration, Springfield, VA
TREATMENT OUTCOME
123 The day treatment modality applied to patients with substance use disorders: Comparison with
outpatient enhanced methadone service using a controlled, prospective matched pair-design
R. R. Kowalewski, L. Bösch, M. Schaub, R. Stohler, Division of Substance Use Disorders,
Psychiatric University Hospital Zurich, Zurich, Switzerland
124 Characteristics and nine-month outcomes of discharged methadone maintenance clients
D. M. Coviello1, D. A. Zanis1,2, S. A. Wesnoski1, 1Psychiatry/Addictions, University of
Pennsylvania, Philadelphia, PA, 2Social Administration, Temple University, Philadelphia, PA
125 Redefining retention: Three pathways for extending a treatment episode beyond a methadone
program’s boundaries
S. G. Mitchell1, R. P. Schwartz1, H. S. Reisinger1, J. A. Peterson1, S. M. Kelly1, S. Lotfi1,
M. H. Agar3, K. O’Grady2, B. S. Brown4, 1Friends Research Institute, Baltimore, MD,
2University of Maryland, College Park, MD, 3Ethknoworks, Santa Fe, NM, 4University of
North Carolina, Wilmington, NC
126 Preliminary outcomes of a behavioral treatment trial among opiate IDU in central Ukraine
J. E. Schumacher1, K. Dumchev2, O. Zezyulin2, P. Slobodyanyuk2, S. Chandler1, L. Moroz3,
M. Wang4, 1Division of Preventive Medicine, University of Alabama at Birmingham,
Birmingham, AL, 2Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine,
3Vinnitsya National Medical University Pirogov, Vinnitsya, Ukraine, 4Expert Health Data
Systems, Inc., Silver Spring, MD
127 Preliminary functioning outcomes of a behavioral treatment trial in opiate IDU in Ukraine
K. Dumchev1, J. Schumacher2, O. Zezyulin1, P. Slobodyanyuk1, S. Chandler2, L. Moroz3,
M. Wang4, 1Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine, 2University of
Alabama at Birmingham, Birmingham, AL, 3Vinnitsya National Medical University Pirogov,
Vinnitsya, Ukraine, 4Expert Health Data Systems, Silver Spring, MD
Monday, June 22, 2009
23
128 The effect of treatment setting on outcome in treating opioid dependence with buprenorphine
S. Schroeder, K. Miotto, M. Hillhouse, C. Manneh, C. Domier, W. Ling, Integrated Substance
Abuse Programs, University of California, Los Angeles, Los Angeles, CA
129 Efficacy of the Manualized Cognitive-Behavioral Treatment Program CANDIS for cannabis use
disorders
A. Ruehlmann, E. Hoch, R. Noack, J. Henker, A. Pixa, H. Rohrbacher, M. Höfler,
G. Bühringer, H. U. Wittchen, Institut fuer Klinische Psychologie und Psychotherapie,
Technische Universitaet Dresden, Germany, Dresden, Germany
130 Effects of psychosocial treatment dose on outcomes in stimulant-dependent adults
S. Glasner-Edwards, D. Farabee, L. Brecht, R. A. Rawson, Integrated Substance Abuse
Programs, University of California, Los Angeles, CA
131 The impact of directive and non-directive drug counseling approaches as a function of patient
trait reactance
D. J. Farabee, R. Rawson, V. J. Pearce, S. J. Cousins, A. Bellows, J. Hemberg, University of
California, Los Angeles, CA
132 Medical outcomes in methamphetamine-dependent adults 3 years after treatment
L. Mooney1, S. Glasner-Edwards1, P. Marinelli-Casey1, M. Hillhouse1, A. Ang1, J. Hunter1,
W. Haning2, P. Colescott2, W. Ling1, R. Rawson1, 1University of California, Los Angeles, CA,
2University of Hawaii, Honolulu, HI
133 An analysis of substance abuse treatment outcomes between a sample of American
Indians/Alaska Natives and a comparison group
D. L. Dickerson, S. E. Spear, MS, P. Marinelli-Casey, R. A. Rawson, Ph.D., Y. Hser, Integrated
Substance Abuse Program, University of California, Los Angeles, CA
134 Emotional abuse as a risk factor for poor treatment outcome in residential substance abuse
treatment
S. M. Gorka1, M. A. Bornovalova2, K. Kochanska1, S. B. Daughters1, 1School of Public Health,
University of Maryland, College Park, MD, 2Psychology, University of Minnesota,
Minneapolis, MN
135 Outcomes of substance abuse treatment adjusting for selection bias
M. Brecht, R. Gonzales, R. Rawson, Integrated Substance Abuse Programs, University of
California, Los Angeles, CA
136 The risk and responsivity principles as moderators of drug abuse treatment outcomes: A meta-
analysis
F. S. Pearson1, M. Prendergast2, D. Podus2, L. Greenwell2, 1National Development and
Research Institutes, New York, NY, 2UCLA Integrated Substance Abuse Programs, Los
Angeles, CA
Symposium VI Rose Ballroom A
2:00 - 4:00 PM
PRECLINICAL STUDIES OF SEX DIFFERENCES IN 
RESPONSE TO COCAINE IN ADOLESCENTS:
ARE THEY DIFFERENT FROM ADULTS?
Chairs: Cora Lee Wetherington and Jill Becker
2:00 Aquisition and maintenance of cocaine self-administration in adolescent rats: Effects of sex and
gonadal hormones
Wendy Lynch, University of Virginia, Charlottsville, VA
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2:25 Adolescence and sex differences in reinstatement of drug-seeking and impulsivity for drug and
non-drug rewards
Marilyn Carroll, University of Minnesota, Minneapolis, MN
2:50 Environmental effects on cocaine reward: Sex and age matter
Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL
3:15 Emergence of sex differences in dopamine function in adolescence
Cynthia Kuhn, Duke University Medical Center, Durham, NC
3:40 Adolescence and sex differences in drug abuse: A synthesis
Jill Becker, University of Michigan, Ann Arbor, MI
Symposium VII Ponderosa B
2:00 - 4:00 PM
INTERNATIONAL RESEARCH PRIORITIES FOR SCALING UP
EFFECTIVE INTERVENTIONS FOR DRUG USE AND DEPENDENCE
Chairs: Vladimir Poznyak (WHO) and Sharon L. Walsh 
2:00 The global epidemiology of injecting drug use and HIV among people who inject drugs: What
do we know?
Louisa Degenhardt, National Drug and Alcohol Research Center, University of New South
Wales, Sydney, NSW, Australia
2:25 The potential impact of scaling up effective substance abuse treatment in HIV/AIDS prevention
and care
George E. Woody, University of Pennsylvania and Treatment Research Institute,
Philadelphia, PA
2:50 Pharmacotherapy for opioid dependence: Gaps in the evidence and priorities for future research
Nicholas Clark, Management of Substance Abuse, World Health Organization (WHO),
Geneva, Switzerland
3:15 Effectiveness of interventions based on WHO ASSIST package in different cultural contexts:
Implications for future research
R. Ali, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia
3:40 Discussant
Thomas Babor, Community Medicine and Healthcare, University of Connecticut Health
Center, Farmington, CT
Oral Communications 8 Rose Ballroom B
2:00 - 4:00 PM
NEUROPATHIC CONSEQUENCES OF ACUTE AND 
CHRONIC EXPOSURE
Chairs: Ratna Sircar and Shane A. Perrine
2:00 Long-term alterations of stress responsive and opioid systems in rat hypothalamus and
amygdala during chronic heroin withdrawal
Y. Zhou, J. Choi, J. Huynh, A. Ho, M. J. Kreek, Rockefeller University, New York, NY
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2:15 Gamma-hydroxybutyric acid impairs spatial memory and alters NMDA receptor subunits in
adolescent female rats
R. Sircar1,2, A. Basak1, L. Wu1, K. Reddy1, 1Feinstein Institute for Medical Research,
Manhasset, NY, 2Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine,
Bronx, NY
2:30 Chronic toluene exposure differentially regulates amino acid neurotransmitters in the adolescent
rat brain following acute or prolonged drug abstinence
S. A. Perrine1, S. K. O’Leary-Moore1,2, M. P. Galloway1, J. H. Hannigan2, S. E. Bowen2,
1Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine,
Detroit, MI, 2Psychology and OB/GYN, Wayne State University, Detroit, MI
2:45 MDMA use is associated with increased basal ganglia-thalamocortical circuit activation during
motor task performance in humans: An fMRI study
J. Karageorgiou, M. S. Dietrich, E. J. Charboneau, N. D. Woodward, J. U. Blackford,
R. M. Salomon, R. L. Cowan, Psychiatry, Vanderbilt University, Nashville, TN
3:00 Cortisol secretion profile is associated with drop-out and more persistent cocaine craving
during a trial of mirtazapine for the treatment of depressed cocaine abusers
L. C. Sanfilippo, W. N. Raby, E. V. Nunes, Psychiatry, New York Psychiatric Institute, New
York, NY
3:15 Chronic marijuana users have decreased responsiveness to emotionally charged visual stimuli
M. J. Wesley, C. A. Hanlon, L. J. Porrino, Physiology and Pharmacology, Wake Forest
University School of Medicine, Winston Salem, NC
3:30 Alterations in microstructure of the isthmus in midsagittal corpus callosum is associated with
duration of cocaine use in the cocaine-dependent subjects
L. Ma1, K. M. Hasan2, J. L. Steinberg1, P. A. Narayana2, S. D. Lane1, E. A. Zuniga1,
L. A. Kramer2, F. G. Moeller1, 1Psychiatry and Behavioral Sciences, University of Texas Health
Science Center, Houston, TX, 2Diagnostic and Interventional Imaging, University of Texas
Health Science Center, Houston, TX
3:45 Are there cognitive sequelae to callosal damage in chronic cocaine users?
C. A. Hanlon, M. J. Wesley, M. C. Torrence, A. Liguori, L. J. Porrino, Physiology and
Pharmacology, Wake Forest University, Winston-Salem, NC
Oral Communications 9 Bonanza
2:00 - 4:00 PM
MUSING ABOUT MU: PRECLINICAL STUDIES WITH OPIOIDS
Chairs: Jean M. Bidlack and Pouya Tahsili-Fahadan
2:00 Anatomical and functional interactions between chemokine and µ-opioid receptors in
periaqueductal grey neurons
L. G. Kirby, J. Palma, S. Heinisch, Anatomy and Cell Biology and Center for Substance Abuse
Research, Temple University School of Medicine, Philadelphia, PA
2:15 Inhibition of Gβγ signaling to phospholipase β3 enhances antinociception mediated by the µ
opioid receptor but does not affect respiration or locomotion
J. M. Bidlack1, J. P. McLaughlin2, 1Pharmacology and Physiology, University of Rochester,
Rochester, NY, 2Psychology, Northeastern University, Boston, MA
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2:30 Opioid receptor mediation of morphine’s discriminative stimulus effects in the inbred Fischer
344 and Lewis rat strains
C. M. Davis1, K. C. Rice2, A. L. Riley1, 1Psychology, American University, Washington, DC,
2Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute
on Drug Abuse and National Institute on Alcoholism and Alcohol Abuse, Rockville, MD
2:45 Morphine antinociception in combination with metabotropic glutamate receptor (mGluR)
antagonists
D. E. Daugherty1, L. L. Miller1, M. J. Picker1, L. A. Dykstra1,2, 1Psychology, University of
North Carolina at Chapel Hill, Chapel Hill, NC, 2Pharmacology, University of North Carolina
at Chapel Hill, Chapel Hill, NC
3:00 Changes in mGluR5 surface expression: Comparison between repeated morphine and
methamphetamine
A. A. Herrold1,2,4, A. L. Mickiewicz1,3,4, T. C. Napier1,4, 1Pharmacology, Rush University
Chicago, Chicago, IL, 2Neuroscience, Loyola University Chicago, Maywood, IL,
3Pharmacology, Loyola University Chicago, Maywood, IL, 4Center for Compulsive Behavior
and Addiction, Rush University Chicago, Chicago, IL
3:15 Modafinil blocks morphine-primed reinstatement of conditioned place preference
P. Tahsili-Fahadan1, G. V. Carr2, G. C. Harris2, G. Aston-Jones1, 1Medical University of South
Carolina, Charleston, SC, 2University of Pennsylvania, Philadelphia, PA
3:30 Assessment of individual differences in the aversive and rewarding effects of morphine
A. Verendeev, A. L. Riley, Psychopharmacology Laboratory, Psychology, American University,
Washington, DC
3:45 Differential modification of the antinociceptive and discriminative stimulus effects of morphine
by 5-HT1A and 5-HT2A receptor agonists in rhesus monkeys
J. Li1, K. C. Rice3, W. Koek1,2, C. P. France1,2, 1Pharmacology, University of Texas Health
Science Center, San Antonio, TX, 2Psychiatry, University of Texas Health Science Center, San
Antonio, TX, 3Chemical Biology Research Branch, NIDA and NIAAA, National Institutes of
Health, Rockville, MD
Marian W. Fischman Memorial 
Award Lecture Rose Ballroom A
4:15 - 5:15 PM
Presentation of the Marian W. Fischman Memorial Award to 
Harriet de Wit 
Introduction by Chris-Ellyn Johanson 
Lecture: Determinants of drug preference in humans 
Harriet de Wit
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
NIDA/CPDD Pre- and Post-Doc Mixer Genoa
5:30 - 7:00 PM
NETWORKING GET-TOGETHER FOR ALL STUDENTS,
TRAINEES, AND MENTORS
Workshop V Bonanza
8:00 - 10:00 PM
15TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP
Chairs: Stacey C. Sigmon and Kelly Dunn
Workshop VI Rose Ballroom A
8:00 - 10:00 PM
EVALUATING THE ABUSE POTENTIAL OF NOVEL 
COMPOUNDS AND ABUSE-RESISTANT FORMULATIONS
Chair: Michael A. Nader
Emerging drugs of abuse as identified by the DEA
Srihari R. Tella, Drug and Chemical Evaluation Section, Arlington, VA
The role of NIDA in the evaluation of emerging drugs of abuse
Jane B. Acri, National Institute on Drug Abuse, Bethesda, MD
Limitations of current preclinical abuse assessment strategies and possible future approaches
Patrick Beardsley, Virginia Commonwealth, Richmond, VA
Clinical research issues in the evaluation of novel compounds and formulations
John D. Roache, University of Texas Health Science Center at San Antonio, San Antonio, TX
Workshop VII Ponderosa B
8:00 - 10:00 PM
SUBSTANCE USE DISORDERS IN DSM-V:
A PROGRESS REPORT
Chairs: Thomas J. Crowley and Charles O’Brien
Combining abuse with dependence
Thomas J. Crowley, University of Colorado Denver, School of Medicine, Aurora, CO
Inclusion of cannabis withdrawal and related issues
Alan Budney, University of Arkansas for Medical Sciences, Little Rock, AR
Addiction vs dependence for DSM V
Charles O’Brien, University of Pennsylvania School of Medicine, Philadelphia, PA
Consumption level as a diagnostic criterion?
Guilherme Borges, Instituto Nacional de Psiquiatria and Universidad Autonoma
Metropolitana, San Lorenzo Huipulco, Mexico
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Workshop VIII Rose Ballroom B
8:00 - 10:00 PM
FOUR PRACTICAL INTERVENTIONS TO MAKE 
OUTPATIENT TREATMENT ATTRACTIVE AND 
ACCOUNTABLE - TRANSLATIONAL RESEARCH 
IN THE REAL WORLD
Chair: A. Thomas McLellan and David Festinger
Concurrent recovery monitoring as a clinical activity
John Cacciola, University of Pennsylvania School of Medicine, Philadelphia, PA
Telephone counseling to support recovery following residential treatment
Deni Carise, Treatment Research Institute and University of Pennsylvania, Philadelphia, PA
Improving monitoring and evaluation in drug courts: TRI Court Evaluation Program
David Festinger, Treatment Research Institute and University of Pennsylvania,
Philadelphia, PA
CRAFT: Helping families motivate loved ones to enter treatment
Kimberly C. Kirby, Treatment Research Institute and University of Pennsylvania,
Philadelphia, PA
NIDA International Meeting Poster Session Rose Foyer
8:00 - 10:00 PM
Chair: Steven W. Gust
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
POSTER SESSION II (Breakfast) Pavilion
8:00 - 10:00 AM
Odd-numbered posters manned first hour;
Even-numbered, second hour
Set-up time begins Monday no earlier than 3:00 PM
Must be removed by Tuesday no later than 3:00 PM
NICOTINE: ANIMALS
1 Sex differences in nicotine self-administration and reinstatement in rats
M. W. Feltenstein, R. E. See, Neurosciences, Medical University of South Carolina,
Charleston, SC
2 Enrichment-induced differences in nicotine drug discrimination in rats is nicotinic receptor-
mediated
D. J. Stairs1, C. S. Bockman2, J. Fosdick1, B. Mittelstet1, L. Schwarzkopf1, 1Psychology,
Creighton University, Omaha, NE, 2Pharmacology, Creighton University, Omaha, NE
3 Effects of acute nicotine on delay discounting in rats
J. L. Perry, M. G. LeSage, Minneapolis Medical Research Foundation, Minneapolis, MN
4 Nicotine conditioned place preference in adolescence differs as a function of sex
M. Lenoir, E. Zakharova, J. Ledon, A. Rhodes, C. Booth, S. Izenwasser, Psychiatry and
Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL
5 Preweanling rats exhibit deficits in prepulse inhibition of the startle reflex when gestationally
exposed to nicotine
R. T. Lacy, C. F. Mactutus, S. B. Harrod, Psychology, University of South Carolina,
Columbia, SC
6 Transfer of extinction learning for the conditioned stimulus of nicotine by nicotinic receptor
agonists
C. Reichel, J. Murray, J. Barr, S. Sanderson, M. Tracy, R. Bevins, Psychology, University of
Nebraska-Lincoln, Lincoln, NE
7 Behavioral characterization of novel nicotinic receptor compounds based on the structure of
cytisine
E. M. Jutkiewicz1, F. Sparatore2, B. Tasso2, J. H. Woods1, 1Pharmacology, University of
Michigan, Ann Arbor, MI, 2Pharmaceutical Sciences, University of Genoa, Genoa, Italy
8 The effects of nicotine preexposure during periadolescence on the aversive and physiological
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provider engagement
A. R. Knowlton1, J. Arnsten2, J. Wilkinson3, S. Shade4, D. Purcell5, 1Johns Hopkins University,
Baltimore, MD, 2Albert Einstein College of Medicine, Bronx, NY, 3University of Miami,
Miami, FL, 4University of California, San Francisco, CA, 5CDC, Atlanta, GA
98 Characteristics of heroin users in methadone maintenance treatment clinics in Wuhan, China
W. Zhou1, P. Liu1, L. Luo1, R. S. Schottenfeld2, M. C. Chawarski2, 1Division of HIV/AIDS
Prevention, Wuhan Center for Disease Control and Prevention, Wuhan, China, 2Psychiatry,
Yale University School of Medicine, New Haven, CT
99 Patterns of cognitive impairments among heroin and cocaine users and the association with
preexisting developmental conditions and hepatitis status
S. G. Severtson, S. L. Hedden, D. Whitaker, W. W. Latimer, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD
100 An investigation of sexual partnerships and HCV prevalence among regular users of cocaine
and heroin
D. Whitaker, B. Mancha, L. Floyd, S. L. Hedden, W. W. Latimer, Mental Health, Johns
Hopkins School of Public Health, Baltimore, MD
101 Relapse and recovery among hepatitis C-infected patients with a history of cocaine or heroin use
A. Y. Walley1, T. Heeren2, C. Bliss2, P. R. Skolnik1, S. Stuver2, D. Nunes1, D. Cotton1, 1Boston
University School of Medicine, Boston, MA, 2Boston University School of Public Health,
Boston, MA
102 Hepatitis C Virus knowledge, attitudes, beliefs, and experiences in methadone treatment patients
with HCV infection
K. M. Canfield1, S. L. Batki2,3,1, E. Smyth1, R. Ploutz-Snyder4, 1Psychiatry, State University of
New York Upstate Medical University, Syracuse, NY, 2Psychiatry, University of California,
San Francisco, CA, 3San Francisco VA Medical Center, San Francisco, CA, 4NASA,
Houston, TX
103 Medical comorbidity and HCV treatment eligibility in Methadone Maintenance Treatment vs
non-Methadone Maintenance Treatment patients seeking treatment for HCV infection
S. L. Batki1,2,3, K. M. Canfield3, E. Smyth3, R. J. Ploutz-Snyder4, 1Psychiatry, University of
California, San Francisco, San Francisco, CA, 2San Francisco VA Medical Center, San
Francisco, CA, 3Psychiatry, State University of New York Upstate Medical University,
Syracuse, NY, 4NASA, Houston, TX
104 Illicit drug use and dependence among patients referred to a hepatology clinic in an urban
academic medical center
C. Jackson1, J. Varon1, A. Ho1, A. Talal2, M. J. Kreek1, 1The Laboratory of the Biology of
Addictive Diseases, Rockefeller University, New York, NY, 2Center for the Study of Hepatitis
C, Weill Cornell Medical College, New York, NY
105 Prevalence and factors associated with HCV-positive saliva test in injecting drug users in North
and East France
J. Harbonnier1,2, E. Lavie3, M. Auriacombe3, 1Centre Boris Vian, Lille, France, 2North and East
IVDU HCV Study Group, Lille, France, 3Addiction Psychiatry, Universite de Bordeaux,
Bordeaux, France
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TREATMENT PROVIDERS AND PROGRAMS
106 Staff reports of program structure in relation to client retention, alliance, and drug/alcohol
outcomes
B. McClure1, A. Kulaga1, J. Rotrosen1, R. Forman3, C. Temes2, S. Ring-Kurtz2, R. Gallop2,
P. Crits-Christoph2, 1New York University School of Medicine, New York, NY, 2University of
Pennsylvania, Philadelphia, PA, 3Alkermes, Inc., Boston, MA
107 The impact of a three-hour curriculum infusion on university students’ knowledge and attitudes
about the neuroscience of addiction: Results from the two-year NIDA Enters College Project
N. A. Roget1, J. A. Hartje1, M. S. Berry1, W. L. Woods1, A. D. Broadus1, P. Riggs2, 1Center for
the Application of Substance Abuse Technologies, University of Nevada, Reno, NV,
2University of Colorado Health Sciences Center, Denver, CO
108 A comparison of three methods for training South African substance abuse counselors in
Cognitive Behavioral Therapy
R. Sodano1, D. Watson2, S. Rataemane3, L. Rataemane4, R. Rawson1, 1University of California
& Integrated Substance Abuse Program, Los Angeles, CA, 2FRI, Los Angeles, CA, 3University
of Limpopo, Sovenga, South Africa, 4MEHADIC, Pretoria, South Africa
109 Outcomes of a Swiss practitioner network survey on the current use of U.S. treatment
approaches to cocaine addiction
R. Stohler1, M. P. Schaub1,2, T. Berthel1, 1Psychiatric University Hospital, Zurich, Switzerland,
2Research Institute for Public Health and Addiction, Zurich, Switzerland
110 Treatment vs non-treatment groups: Validation of the Addiction Belief Inventory
A. D. Broadus1, J. A. Hartje1, N. A. Roget1, S. S. Clinkinbeard2, 1Center for the Application of
Substance Abuse Technologies, University of Nevada, Reno, NV, 2University of Nebraska,
Omaha, NE
111 Attitudes toward 12-step groups and referral practices in a culture naive to 12-step ideology
J. Vederhus1, T. Clausen1,2, A. Laudet3, O. Kristensen1, 1Addiction Unit, Sørlandet Hospital,
Kristiansand, Norway, 2Norwegian Centre for Addiction Research (SERAF), Institute of
Psychiatry, University of Oslo, Oslo, Norway, 3C-STAR Studies on Recovery, National
Development and Research Institutes, Inc., New York, NY
112 Field clinician reports of implementation of evidence-based practice
C. Barrick1, G. Homish2, 1Research Institute on Addictions, University at Buffalo,
Buffalo, NY, 2University at Buffalo, Buffalo, NY
113 Substance abuse treatment needs, service utilization, and the role of culture among American
Indians/Alaska Natives in recovery: Perspectives of clients and service providers
C. Teruya, D. Dickerson, F. Wu, Y. Hser, University of California Integrated Substance Abuse
Programs, Los Angeles, CA
114 Problem severity and treatment needs among Native American/Alaska Native and Asian
American/Pacific Islander drug abusers
F. Wu1, Y. Hser2, P. Marinelli-Casey2, R. Rawson2, 1Social Welfare, UCLA, Los Angeles, CA,
2Integrated Substance Abuse Programs, University of California, Los Angeles, CA
115 Racial disparities in residential substance abuse treatment programs
A. Duncan1, G. Melnick2, 1Behavioral Science Training in Drug Abuse Research, Public
Health Solutions, New York, NY, 2Center for the Integration of Research and Practice,
National Development and Research Institutes, Inc., New York, NY
116 Experiential avoidance predicts substance abuse treatment entry
K. L. Williams1,2, K. M. Carpenter1,2, F. R. Levin1,2, E. V. Nunes1,2, 1Psychiatry, Columbia
University, New York, NY, 2Substance Abuse, New York State Psychiatric Institute, New
York, NY
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117 Predictors of treatment retention in a community substance abuse clinic
R. Vandrey1, J. Fry1, P. Stabile2, M. Stitzer1, 1Johns Hopkins University, Baltimore, MD,
2Harbel Treatment and Recovery Center, Baltimore, MD
EPIDEMIOLOGY I
118 Five-year follow-up of a group of Brazilian ecstasy users: Is MDMA use a transient phenomenon?
M. C. Battisti, A. R. Noto, Psychobiology, UNIFESP, Sao Paulo, Brazil
119 Brazilian roadside survey for alcohol and other drugs – interim analysis
F. Pechansky1, R. DeBoni1, D. Benzano1, C. G. Leukefeld2, 1Psychiatry, Center for Drug and
Alcohol Research, UFRGS, Porto Alegre, Brazil, 2Behavioral Sciences, Center for Drug and
Alcohol Research, University of Kentucky, Lexington, KY
120 Influences of medicines, stress events, and narcissistic personality on relapse risk in Japanese
alcohol-dependent inpatients
Y. Ogai1, Y. Kakibuchi2, E. Senoo1, K. Ikeda1, 1Tokyo Institute of Psychiatry, Tokyo, Japan,
2Narimasu Kosei Hospital, Tokyo, Japan
121 Epidemiology of substance use disorders in Australia: Findings from the 2007 National Survey
of Mental Health and Wellbeing
T. Slade, M. Teesson, A. Johnston, K. Mills, National Drug and Alcohol Research Centre,
University of New South Wales, Sydney, NSW, Australia
122 The prevalence and onset of alcohol use disorders during older adulthood: Findings from a 3-
year national study in the United States
S. Novak1, E. Johnson1, L. Simoni-Wastila2, 1Behavioral Epidemiology, RTI International,
Research Triangle Park, NC, 2School of Pharmacy, University of Maryland, Baltimore, MD
123 Leisure time activities that predict initiation, persistence, progression, and reduction of cannabis
use: A prospective, population-based panel survey
M. P. Schaub1, B. Annaheim2, M. Mueller3, D. Schwappach1, G. Gmel2, 1Research Institute for
Public Health and Addiction, Zurich, Switzerland, 2Swiss Institute for the Prevention of
Alcohol and Drug Problems, Lausanne, Switzerland, 3Social and Market Research Institute,
Zurich, Switzerland
124 Drug use in individuals screened for participation in human behavioral pharmacology
laboratory studies
F. Wagner1, W. W. Stoops1, C. R. Rush1,2,3, 1Behavioral Science, University of Kentucky,
Lexington, KY, 2Psychiatry, University of Kentucky, Lexington, KY, 3Psychology, University
of Kentucky, Lexington, KY
125 Validating self-reports of illegal drug use to evaluate National Drug Control Policy
S. Magura, Evaluation Center, Western Michigan University, Kalamazoo, MI
126 Characteristics of opiate injection drug users with and without amphetamine type stimulate
abuse in Kuala Lumpur, Malaysia
M. Mazlan1, V. Balasingam Kasinather2, M. C. Chawarski3, R. S. Schottenfeld3, 1Substance
Abuse Center, Muar, Malaysia, 2University Sains Malaysia, Penang, Malaysia, 3Psychiatry,
Yale University School of Medicine, New Haven, CT
127 Regional variations and factors associated with late injection drug use initiation in California
R. Bluthenthal1, L. Wenger2, P. Bourgois3, M. Iguchi4, A. Kral2, 1RAND Corporation, Santa
Monica, CA, 2RTI International, San Francisco, CA, 3University of Pennsylvania,
Philadelphia, PA, 4University of California, Los Angeles, CA
128 Spatial analysis of injection drug use, drug treatment, and HIV in Baltimore City
M. Smart, A. Milam, D. Whitaker, C. Furr-Holden, Mental Health, Johns Hopkins School of
Public Health, Baltimore, MD
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129 Disaggregating a neighborhood perception scale by heroin dependence
J. Gass, D. C. Ompad, V. Nandi, D. Vlahov, Center for Urban Epidemiologic Studies, New York
Academy of Medicine, New York, NY
130 Reductions in heroin use frequency following Hurricane Katrina
B. D. Johnson1, E. Dunlap1, N. Tiburcio1, R. Twiggs2, 1Special Populations Research, National
Development and Research Institutes, New York, NY, 2School of Social Work, Fordham
University, New York, NY
131 Motivators of change among drug-using New Orleans evacuees
R. Twiggs2, N. Tiburcio1, B. D. Johnson1, E. Dunlap1, 1Special Populations Research, National
Development and Research Institutes, New York, NY, 2Social Work, Fordham University, New
York, NY
132 Methamphetamine-related vs cocaine-related emergency department visits in urban vs rural
counties in California
T. J. Florence2, K. G. Heinzerling1, A. Swanson1, S. Shoptaw1, 1Family Medicine, University of
California, Los Angeles, CA, 2University of Southern California, Los Angeles, CA
133 WITHDRAWN
R. Falck, R. Carlson, J. Wang, Community Health, Wright State University School of
Medicine, Dayton, OH
134 Quality of life and severity of problems related to alcohol misuse
S. Faller, F. Kessler, N. S. Rocha, D. Benzano, M. P. Santos, F. Pechansky, Center for Drug and
Alcohol Research - Federal University of Rio Grande do Sul, Porto Alegre, Brazil
135 Higher psychiatric comorbidity and severity of problems among substance abusers with ADHD
F. H. Kessler, S. Faller, D. B. Benzano, H. Moura, C. Szobot, L. V. Diemen, M. P. Santos,
F. Pechansky, Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Symposium VIII Rose Ballroom A
10:00 AM - 12:00 PM
THIS IS YOUR BRAIN ON GAMBLING (AND DRUGS)...
PARSING DRUG AND ADDICTION INFLUENCES BY 
CONTRASTING “BEHAVIORAL” AND DRUG ADDICTIONS
Chairs: Marc N. Potenza and Robert Rogers
10:00 The clinical features and neurobiological substrates of casino gambling
Robert Rogers, Oxford University and Warneford Hospital, Oxford, United Kingdom
10:25 Neural correlates of decision-making in substance-dependent subjects with and without
pathological gambling
Jody Tanabe, University of Colorado at Denver Health Sciences, Aurora, CO
10:50 Pathological gambling and substance use disorders: Similarities and differences in
neurocognitive and neuroimaging parameters
Wim van den Brink, Academic Medical Center University of Amsterdam, Amsterdam,
Netherlands
11:15 Problem gamblers share deficits in impulsive decision-making with substance-dependent
subjects
Luke Clark, University of Cambridge, Cambridge, United Kingdom
11:40 Discussant
Marc N. Potenza, Yale School of Medicine, New Haven, CT
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Symposium IX Bonanza
10:00 AM - 12:00 PM
THE ACETYLCHOLINE SYSTEM AS THERAPEUTIC 
TARGET IN DRUG DEPENDENCE: MOLECULAR BIOLOGY,
NEUROCHEMISTRY, ANIMAL AND HUMAN BEHAVIORAL
PHARMACOLOGY
Chairs: Gerald Zernig and Richard De La Garza, II
10:00 Acetylcholinergic receptors and cocaine addiction: Neuroanatomical, genomic and proteomic
perspectives
Scott E. Hemby, Wake Forest University School of Medicine, Winston-Salem, NC
10:25 Activation of nicotinic and muscarinic acetylcholine receptors in nucleus accumbens core are
necessary for the acquisition of drug seeking but not food reinforcement
Gerald Zernig, Experimental Psychiatry Unit, Medical University Innsbruck, Innsbruck, ACT,
Australia
10:50 Sustained decreases in cocaine self-administration following chronically administered
acetylcholinesterase inhibitors
Kenneth Grasing, Substance Abuse Research Laboratory, Kansas City VA Medical Center,
Kansas City, MO
11:15 Laboratory-based clinical evaluation of the safety and preliminary efficacy of
acetylcholinesterase inhibitors as a treatment for methamphetamine dependence
Richard De La Garza, II, Baylor College of Medicine, Houston, TX
11:40 Limbic disruptions identified by cholinergic probes in cocaine-addicted subjects
Bryon Adinoff, University of Texas Southwestern Medical Center, VA North Texas Health
Care System, Dallas, TX
Oral Communications 10 Ponderosa B
10:00 AM - 12:00 PM
TAKING THE POT: CANNABINOIDS
Chairs: Sandra P. Welch and Prashanthi N. Mainampally
10:00 A BOLD fMRI study of cannabinoid action in rat brain
A. S. Bloom1, H. Cios1, W. Collier1, K. Douville1, S. Durgerian1, S. J. Li1, L. Chang2, 1Medical
College of Wisconsin, Milwaukee, WI, 2University of Hawaii, Honolulu, HI
10:15 Endocannabinoid alterations in the hippocampus and nucleus accumbens following chronic
cocaine treatment, during withdrawal and following cocaine challenge
S. L. Amen, C. J. Hillard, Pharmacology and Toxicology, Medical College of Wisconsin,
Milwaukee, WI
10:30 Forced Swim Test and the endogenous cannabinoid receptor system: Effects of an anandamide
reuptake inhibitor and a fatty acid amide hydrolase metabolism inhibitor
T. Culmer1, L. Miller2, L. Dykstra1,2, 1Pharmacology, UNC-Chapel Hill, Chapel Hill, NC,
2Psychology, UNC-Chapel Hill, Chapel Hill, NC
10:45 Interaction of S1P and FTY720 with opioid systems in the production of antinociception and
opioid tolerance
S. P. Welch, D. E. Selley, L. J. Sim-Selley, Pharmacology and Toxicology, Virginia
Commonwealth University, Richmond, VA
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11:00 Abuse potential of taranabant, a cannabinoid 1 receptor inverse agonist: A randomized, double-
blind, crossover study in recreational polydrug users
K. A. Schoedel1, B. Chakraborty1, C. Addy2, K. Rosko2, A. Maes2, N. Chen1, E. Sellers1,
1Clinical Pharmacology, Kendle Early Phase, Toronto, ON, Canada, 2Merck & Co, Inc,
Whitehouse Station, NJ
11:15 Persistence of cannabis use once it starts: Initial findings from epidemiological research
P. N. Mainampally, J. C. Anthony, Michigan State University, East Lansing, MI
11:30 Is early alcohol and nicotine use associated with the risk of cannabis use and transition to
cannabis use disorders in adolescence?
S. Behrendt1, H. U. Wittchen1,2, M. Höfler1, R. Lieb2,3, K. Beesdo1, 1Institute of Clinical
Psychology and Psychotherapy, Technische Universitaet Dresden, Dresden, Germany, 2Max
Planck Institute of Psychiatry, Munich, Germany, 3Institute of Psychology, University of Basel,
Basel, Switzerland
11:45 The role of temperament in the relationship between early onset of cigarette smoking and
cannabis use. The TRAILS study
H. E. Creemers1, T. Korhonen2,3, J. Kaprio2,3, W. Vollebergh4,5, J. Ormel6, F. Verhulst1,
A. Huizink1,6, 1Child and Adolescent Psychiatry, Erasmus Medical Center/Sophia Children’s
Hospital, Rotterdam, Netherlands, 2Public Health, University of Helsinki, Helsinki, Finland,
3Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland,
4Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands, 5Social Sciences,
Utrecht University, Utrecht, Netherlands, 6University Medical Center Groningen, University of
Groningen, Groningen, Netherlands
Symposium X Rose Ballroom B
10:00 - 11:00 AM
RACIAL AND ETHNIC DISPARITIES IN SUBSTANCE ABUSE AND
ADDICTION: NATIVE AMERICANS AND NATIVE HAWAIIANS
Chairs: Lula A. Beatty and Rumi Price
10:00 Racial/ethnic health disparities in drug addiction: Highlights on Native Americans and Native
Hawaiians
Rumi Price, Washington University in St. Louis, School of Medicine, St. Louis, MO
10:20 Can religious use of psychoactive substances reduce disparities in illicit and licit substance
abuse among Native Americans?
John H. Halpern, Harvard Medical School, McLean Hospital, Belmont, MA
10:40 Physiological and neuroimaging abnormalities in Native Hawaiians exposed to
methamphetamine
William Haning, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI
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Symposium XI Rose Ballroom B
11:15 AM - 12:15 PM
HIV RISK PREVENTION IN THE 
NIDA CLINICAL TRIALS NETWORK
Chair: Raul Mandler
11:15 Comparative HIV prevention effects between methadone maintenance and psychosocial
outpatient programs for male drug users
Donald A. Calsyn, Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA
11:35 Comparative HIV prevention intervention effects between methadone maintenance and
psychosocial outpatient programs for female drug users
Susan Tross, Columbia University, New York State Psychiatric Institute, New York, NY
11:55 Discussant: Implications of the results of CTN protocols 0018 and 0019 for future HIV
prevention interventions in drug abuse treatment protocols
Lisa Metsch, University of Miami Miller School of Medicine, Miami, FL
Late-Breaking Research News Rose Ballroom A
12:15 - 1:35 PM
Chair: Sari Izenwasser
12:15 α6β2*nAChRs regulate progressive ratio responding for nicotine 
D. H. Brunzell, K. Boschen, E. S. Hendrick, P. Taylor, P. M. Beardsley, and J. M. McIntosh,
Virginia Commonwealth University, Richmond, Virginia; University of Utah, Salt Lake City,
Utah 
12:20 Smoking-associated cues decrease dopamine D2/3 binding potential in tobacco-dependent
individuals: A preliminary [11C]-(+)-PHNO PET study 
L. Chiuccariello, I. Boileau, P. Rusjan, A. Wilson, S. Houle, L. Zawertailo, B. Busto, and
B. Le Foll, Centre for Addiction and Mental Health, Pharmacology and Toxicology, University
of Toronto, Pharmaceutical Sciences, University of Toronto, Canada 
12:25 Responses to smoking cues increase with duration of abstinence 
H. de Wit, G. Bedi, A.C. King, D.H. Epstein, S.J. Heishman, G. Marrone, and K.L. Preston,
University of Chicago,IL, Columbia University, NY, NIDA Intramural Research Program,
Baltimore, MD 
12:30 Cigarette smokers and non-smokers with serious mental illness: A cross-sectional comparison of
neurocognitive function by diagnosis and smoking status 
D. Morisano, K.A. Sacco, and T.P. George, Division of Addiction Psychiatry, Psychiatry,
University of Toronto, Canada, Schizophrenia Program, Centre for Addiction and Mental
Health, Program for Research in Smokers with Mental Illness (PRISM), Psychiatry, Yale
University 
12:35 (R)-cis-N-(2,3)—Dihydroxpropyl)-2,6-di-(4-methoxyphenylethyl)piperidine hemisulfate (UK-
793A) selectively blocks methamphetamine reinforcement without producing tolerance in rats 
J. Beckmann, D. Horton, K. Siripurapu, E. Denehy, G. Zheng, P. Crooks, L. Dwoskin, and
M. Bardo, University of Kentucky, KY 
12:40 Self-administered cocaine causes lasting increases in impulsive choice in a delay discounting task
I.A. Mendez, N.W. Simon, N. Hart, M.R. Mitchell, J.R. Nation, P.J. Wellman, and B. Setlow,
Psychology, Texas A&M University, TX 
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12:45 Neural correlates of spatial learning in chronic cocaine users 
G. Tau, R. Marsh, F. Garcia, X. Hao, D. Xu, S. Yu, M. Packard, Z. Wang, Y. Duan, A. Kangarlu,
F. Levin, D. Martinez, and B. Peterson, Division of Child and Adolescent Psychiatry, Division
on Substance Abuse, Psychiatry, Columbia University and The New York State Psychiatric
Institute, New York, NY, Psychology, Texas A&M University, College Station, TX 
12:50 Neurobehavioral plasticity in stimulant addiction: Initial results of executive function therapy 
W.K. Bickel and R. Yi, University of Arkansas for Medical Science, AK 
12:55 Third outpatient pharmacogenetic clinical trial of disulfiram (DS) for cocaine 
T.R. Kosten, X. Zhang, D. Nielsen, G. Wu, N. Rubio, W. Huang, G. Gonzalez, and J. Poling,
Baylor College of Medicine, Psychiatry, ME Debakey VA Medical Center, Houston, TX 
1:00 Abuse potential of nabiximols oromucosal spray in recreational marijuana users 
K. Schoedel, N. Chen, and E. Sellers, Kendle Early Phase, Toronto, Canada 
1:05 Sleep dysfunction during cannabis withdrawal 
R. Vandrey, U. McCann, M. Smith, and A. Budney, Johns Hopkins University School of
Medicine, Baltimore, MD, and University of Arkansas for Medical Sciences, Little Rock, AR 
1:10 Cue reactivity in response to alcohol odors is associated with a reduction in brain activation in
treatment-seeking chronic alcohol-dependent individuals: An fMRI study 
S.E. Lukas, S.B. Lowen, D. Penetar, K.P. Lindsey, J. Rodolico, W. Tartarini, R. MacLean,
N. Conn, C. Palmer, and G. Mallya, Brain Imaging Center, McLean Hospital, Harvard Medical
School, Belmont, MA 
1:15 Personality and alcohol dependence: A community-based study on older adults 
G. Narayanan, T. Oltmanns, and L.B. Cottler, Washington University, St. Louis, MO 
1:20 Gabapentin improves cold-pressor pain tolerance in methadone-maintained patients 
W. Ling, P.A. Compton, and P. Kehoe, Integrated Substance Abuse Programs, University of
California, Los Angeles, CA, School of Nursing, University of California, Los Angeles, CA 
1:25 Pharmacy willingness to conduct random buprenorphine pill counts for office-based opioid
dependence treatment practices 
M.R. Lofwall, M. J. Wunsch, and S.L. Walsh, Psychiatry, University of Kentucky, Lexington,
KY, Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky,
Lexington, KY 
1:30 Delivering substance abuse treatment services in frontier states: Examining treatment costs and
reimbursement structures 
J.A. Hartje, M. Zagidullin, N.A. Roget, W. Wendt, and A.H. Skinstad, University of Nevada,
Reno; Signal Behavioral Health; University of Iowa, IA 
Grant-Writing Workshop Genoa
(Pre-Registrants Only) 1:30 - 4:00 PM
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FILM NIGHT
FIGHTING THE DRAGON WITH LUCK Celebrity Showroom
6:30 - 8:00 PM
A documentary about treatment of heroin addiction in Australia
Screening followed by discussion with Angelo Pricolo 
CLEAN AND SOBER (1988) Celebrity Showroom
8:00 - 10:00 PM
Michael Keaton, Kathy Baker, Morgan Freeman
Workshop IX Rose Ballroom A
8:00 - 10:00 PM
CAREER DEVELOPMENT: A PERSPECTIVE FROM JUNIOR 
AND SENIOR RESEACHERS
Chairs: Gerald McLaughlin, Scott Chen, Jose Ruiz and Elaine Lazar-Wesley
Speakers: Mary Jeanne Kreek, Hendree Jones,  and David Herin
Workshop X Ponderosa B
8:00 - 10:00 PM
MATHEMATICAL AND SIMULATION MODELING IN 
BIOLOGICAL AND EPIDEMIOLOGICAL STUDIES OF 
DRUG ADDICTION
Chairs: Georgiy Bobashev and Boris Gutkin
A synthetic model of addiction and control theory
David Newlin, RTI International, Baltimore, MD
Computational models of nicotine addiction: From circuit dynamics to behavior
Boris Gutkin, Group for Neural Theory, DEC, ENS, Paris, France
Projecting risk factors into the future with agent-based modeling
Georgiy Bobashev, RTI International, Research Triangle Park, NC
Measuring levels of proteins by PET and other technologies: Is that the whole story?
Michael Kuhar, Emory University, Atlanta, GA
Physiologically based pharmacokinetic modeling of cocaine and other psychostimulants
Vladimir Tsibulsky, University of Cincinnati, Cincinnati, OH
Baseline differences in cortico-striatal-thalamic network coherence in chronic cocaine users
Colleen A. Hanlon, Wake Forest University School of Medicine, Winston Salem, NC
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Workshop XI Rose Ballroom B
8:00 - 10:00 PM
COMMUNICATING THE RISKS OF OPIOID ANALGESICS:
HOW CAN WE DO BETTER?
Chairs: Meredith Smith and Michael Wolf
Opioid analgesic risk communication to healthcare prescribers: Best practices
Gary Kreps, George Mason University, Fairfax, VA
Communicating the risks and benefits of opioid analgesics to pain patients
Lorraine Wallace, University of Tennessee Graduate School of Medicine-Knoxville,
Knoxville, TN
The Internet as a communication tool for conveying risk information concerning opioid
analgesics: How best used, How best evaluated?
Emil Chiauzzi, Inflexxion, Newton, MA
Conveying information regarding the risks of opioid analgesics to the general public:
Challenges and opportunities
Michael Wolf, Feinberg School of Medicine, Northwestern University, Chicago, IL
Workshop XII Bonanza
8:00 - 10:00 PM
ADVANCES IN IMPLEMENTATION SCIENCE RELATED TO
ADOLESCENT SUBSTANCE ABUSE TREATMENT
Chairs: Ashli J. Sheidow and Michael L. Dennis
Adolescent substance abuse treatment: Quality of implementation and outcome
Mark Lipsey, Vanderbilt Institute, Nashville, TN
Therapist training and changes in knowledge for contingency management for adolescents and
their families
Ashli J. Sheidow, MUSC, Charleston, SC
A Phase 4 replication of MET/CBT5 in 36 sites to examine how findings vary by site, client
characteristics, and implementation fidelity
Michael L. Dennis, Chestnut Health Systems, Normal, IL
The relationship between exposure to A-CRA treatment procedures and adolescent substance
abuse treatment outcomes
Susan H. Godley, Chestnut Health Systems, Normal, IL
Society for Adolescent Substance Abuse Treatment Effectiveness business meeting
Michael L. Dennis, Chestnut Health Systems, Normal, IL
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Public Policy Forum Rose Ballroom A
8:30 - 9:55 AM
Chairs: Martin Iguchi and William Dewey
8:30 Introduction
Martin Iguchi
8:40 Hope and change and biomedical research: The Obama Administration and the 111th Congress
Ed Long
8:55 Presentation of the Distinguished Service Award to William L. Dewey 
Introduction by Sharon L. Walsh
9:00 The role of Friends of NIDA and CPDD in Public Policy
William Dewey
9:15 Reconsidering addiction treatment
A. Thomas McLellan
9:45 Discussion
Symposium XII Rose Ballroom A
10:00 AM - 12:00 PM
REGULATING NICOTINE IN TOBACCO PRODUCTS:
STATE OF THE SCIENCE AND FUTURE POLICY
Chairs: Dorothy Hatsukami and Jack Henningfield
10:00 Regulating the nicotine content of tobacco: Joining the science with policy
Mitch Zeller, Pinney and Associates, Bethesda, MD
10:25 Characterizing the effects of nicotine dose reduction on nicotine self-administration in animals
Mark G. LeSage, Minneapolis Medical Research Foundation, Minneapolis, MN
10:50 Reducing nicotine content in cigarettes: Effects on compensatory smoking
Neal Benowitz, University of California, San Francisco, CA
11:15 Denicotinized cigarettes as a cessation strategy
Jed Rose, Center for Nicotine and Smoking Cessation Research, Duke University,
Durham, NC
11:40 Discussant: Key issues and research recommendations
Dorothy Hatsukami, Tobacco Use Research Center, Minneapolis, MN
Oral Communications 11 Ponderosa B
10:00 AM - 12:00 PM
UPPING THE ANTE: CRAVING STIMULANTS
Chairs: Yasmin Mashhoon and Anna Rose Childress
10:00 Poor fronto-limbic connectivity: A brain endophenotype for rapid relapse to cocaine?
J. J. Suh1,2, R. N. Ehrman1,2, Y. Li1, Z. Wang1, W. Jens1, T. Franklin1, A. Hole1,2, M. Goldman1,
C. P. O’Brien1,2, A. R. Childress1,2, 1University of Pennsylvania, Philadelphia, PA, 2VA Medical
Center, Philadelphia, PA
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10:15 Circuits in methamphetamine cue craving and cue extinction
R. Malcolm1, X. Li1, H. Myrick1, S. Henderson1, P. W. Kalivas2, R. E. See2, 1Psychiatry,
Medical University of South Carolina, Charleston, SC, 2Neurosciences, Medical University of
South Carolina, Charleston, SC
10:30 The rostral basolateral amygdala and prelimbic prefrontal cortex are serially connected to
regulate reinstatement of cocaine-seeking behavior in rats
Y. Mashhoon, A. M. Wells, K. M. Kantak, Psychology: Brain, Behavior, and Cognition,
Boston University, Boston, MA
10:45 Stimulation of medial prefrontal cortex 5-HT2C receptors attenuates cocaine seeking, but not
cocaine self-administration
N. S. Pentkowski, F. Duke, S. Weber, E. C. Hamilton, L. A. Pockros, J. L. Neisewander,
Psychology, Arizona State University, Tempe, AZ
11:00 Enhanced brain metabolic effects of acute cocaine administration following an extended period
of cocaine self-administration in nonhuman primates
L. L. Howell1,2, P. K. Henry1, K. S. Murnane1, J. R. Votaw1,3, 1Yerkes National Primate
Research Center, Emory University, Atlanta, GA, 2Psychiatry and Behavioral Sciences, Emory
University, Atlanta, GA, 3Radiology, Emory University, Atlanta, GA
11:15 Dramatic elevations in extracellular glutamate within the medial prefrontal cortex of rats during
extended access to cocaine self-administration
J. DeMartini, G. A. Carosso, K. D. Lominac, A. W. Ary, K. K. Szumlinski, O. M. Ben-Shahar,
Psychology, University California Santa Barbara, Santa Barbara, CA
11:30 Cocaine-addicted individuals with prior trauma have a “cue-sensitive” brain
A. Childress1,2, C. A. Rudoy1, J. J. Suh1,2, Y. Li1, Z. Wang1, R. N. Ehrman1,2, T. Franklin1,
M. Goldman1, W. Jens1, D. D. Langleben1,2, C. P. O’Brien1,2, 1Psychiatry, University of
Pennsylvania School of Medicine, Philadelphia, PA, 2VA VISN 4 MIRECC, Philadelphia VA
Medical Center, Philadelphia, PA
11:45 Role of dorsal hippocampus and rostral basolateral amygdala in cocaine cue extinction learning
J. J. Szalay1, N. P. Morin2, K. M. Kantak1,2, 1Neuroscience, Boston University, Boston, MA,
2Psychology, Boston University, Boston, MA
Oral Communications 12 Rose Ballroom B
10:00 AM - 12:00 PM
SUBSTITUTION TREATMENT: A SAFE BET
Chairs: Kelly Dunn and Robert P. Schwartz
10:00 Comparing jurisdictional policies to buprenorphine-naloxone in Australia
K. Mammen1,2, J. Bell1,2, A. Quigley4, N. Lintzeris3, 1Langton Centre, Sydney, NSW, Australia,
2National Drug and Alcohol Research Centre, Sydney, NSW, Australia, 3Drug Health Services
RPAH, Sydney, NSW, Australia, 4Next Step Drug and Alcohol Services, Perth, WA, Australia
10:15 Transdermal buprenorphine to switch patients from higher-dose methadone to buprenorphine
without severe withdrawal symptoms
M. Hess, R. Leisinger, L. Boesch, M. Schaub, R. Stohler, Research Group on Substance Use
Disorders, Psychiatry, University Hospital, Zurich, Switzerland
10:30 Predictors of outcome in buprenorphine treatment for opioid-dependent youth
L. Marsch1,2, S. K. Moore1,2, R. Solhkhah2, G. J. Badger3, 1Center for Technology and Health,
National Development and Research Institutes, New York, NY, 2St. Luke’s-Roosevelt Hospital
Center, New York, NY, 3University of Vermont, Burlington, VT
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10:45 Randomized controlled trial using contingency management to promote smoking abstinence
among opioid-maintained patients
K. Dunn1, S. Sigmon1,2, E. Reimann2, K. Saulsgiver2, S. Higgins1,2, 1Psychology, University of
Vermont, Burlington, NY, 2Psychiatry, University of Vermont, Burlington, VT
11:00 Motivation for physical activity and leg disease in methadone maintenance patients
T. N. Templin1, B. Pieper1, R. S. Kirsner2, T. J. Birk1, 1Wayne State University, Detroit, MI,
2University of Miami, Miami, FL
11:15 Interim vs. comprehensive vs. restored methadone treatment: Preliminary findings
R. P. Schwartz1,2, J. H. Jaffe1,3, S. A. Kelly1, D. Gandhi3, E. Weintraub3, J. Urbaitis4,
S. Harrison4, K. E. O’Grady5, 1Friends Research Institute, Baltimore, MD, 2Open Society
Institute-Baltimore, Baltimore, MD, 3University of Maryland School of Medicine,
Baltimore, MD, 4Sinai Hospital, Baltimore, MD, 5University of Maryland, College Park, MD
11:30 Objective sleep (polysomnography) on entry to methadone maintenance treatment and following
6 months of treatment
E. Peles, S. Schreiber, M. Adelson, Adelson Clinic for Drug Abuse Treatment and Research,
Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
11:45 Are methadone dose and “take home” status associated with hospital admission?
J. H. Samet1,2,3, D. M. Cheng2, G. Johnson1, T. Filippell1, C. A. Chen2, C. Pierce1, D. P. Alford1,
A. Y. Walley1,3, 1Boston University School of Medicine, Boston, MA, 2Boston University
School of Public Health, Boston, MA, 3Boston University Public Health Commission,
Boston, MA
Oral Communications 13 Bonanza
10:00 AM - 12:00 PM
MDMA: NOT EXACTLY ECSTASY
Chairs: Elena Zakharova and Anthony Riley
10:00 Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to
methylenedioxymethamphetamine in the striatum
K. B. Scheidweiler1, B. Ladenheim2, J. L. Cadet2, M. A. Huestis1, 1Chemistry and Drug
Metabolism Section, NIDA-IRP, NIH, Baltimore, MD, 2Molecular Neuropsychiatry Branch,
NIDA-IRP, NIH, Baltimore, MD
10:15 Social and environmental factors alter the effects of MDMA on activity and cocaine conditioned
place preference in adolescent rats
E. Zakharova, J. Kelley, J. Ledon, I. Kichko, D. Wade, S. Izenwasser, University of Miami
Miller School of Medicine, Miami, FL
10:30 Antidepressant-like effects of MDMA in a animal model of depression
I. Majumder, J. M. White, R. J. Irvine, Pharmacology, The University of Adelaide,
Adelaide, SA, Australia
10:45 The effects of MDMA preexposure on MDMA-induced taste aversions
D. L. Albaugh, J. A. Rinker, A. L. Riley, Psychology, American University, Washington, DC
11:00 Non-linear kinetics of (±)-3,4-methylenedioxymethamphetamine in rats
M. H. Baumann1, D. Zolkowska1, I. Kim2, K. B. Scheidweiler2, R. B. Rothman1,
M. A. Huestis2, 1Clinical Psychopharmacology Section, NIDA/IRP, Baltimore, MD,
2Chemistry and Drug Metabolism Section, NIDA/IRP, Baltimore, MD
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11:15 Comparison of the pharmacology of methylenedioxyamphetamine and 3,4-
methylendioxymethamphetamine consumed in a recreational setting
K. M. Morefield1, R. J. Irvine1, M. Keane1, P. Felgate3, J. White1, R. Roberts2, 1Pharmacology,
University of Adelaide, Adelaide, SA, Australia, 2University of Otago, Christchurch, New
Zealand, 3Forensic Sciences, Adelaide, SA, Australia
11:30 Gender differences in ecstasy use, abuse and dependence
V. Satyanarayana, A. B. Abdallah, L. B. Cottler, Washington University School of Medicine,
St.Louis, MO
11:45 3,4-Methylendioxymethamphetamine decreases plasma asymmetric dimethylarginine: 
A placebo-controlled study in humans
A. Kielstein1, M. J. Baggott2, J. C. Lopez2, R. H. Boeger3, E. Schwedhelm3, J. T. Kielstein4,
G. P. Galloway2, J. Mendelson2, 1Psychotherapeutic Medicine and Psychotherapy,
Universitätsklinik der Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany,
2Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research
Institute, San Francisco, CA, 3Institut für Experimentelle und Klinische Pharmakologie,
Universitätsklinikum Eppendorf, Hamburg, Germany, 4Nephrology, Medizinische Hochschule
Hannover, Hannover, Germany
POSTER SESSION III (Lunch) Pavilion
12:00 - 2:00 PM
Odd-numbered posters manned first hour;
Even-numbered, second hour
Set-up time begins Tuesday no earlier than 3:30 PM
Must be removed by Wednesday no later than 4:00 PM
COCAINE: ANIMALS I
1 Qualitative differences in the self-administration of rats running an alley for intra-PFC and
intra-NAcc cocaine
J. M. Wenzel, A. Ettenberg, Psychology, University of California, Santa Barbara, CA
2 Cocaine-seeking after cocaine self-administration is associated with plasticity of the serotonin
5-HT2C receptor in the prefrontal cortex
B. M. Witkin2, B. A. Nic Dhonnchadha2, S. J. Stutz1, P. K. Seitz1, R. G. Fox1,
K. A. Cunningham1, 1Pharmacology, University of Texas Medical Branch, Galveston, TX,
2Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
3 Involvement of basolateral amygdala dopamine D1 and D2 receptors on the expression of
cocaine-induced conditioned place preference in rats
M. Itasaka1,2, N. Takahashi1, N. Hironaka1, K. Ikeda3, 1SHIMOJO Implicit Brain Function
Project, Japan Science and Technology Agency, Atsugi-shi, Japan, 2Psychology, Graduate
School of the Humanities, Senshu University, Kawasaki-shi, Japan, 3Molecular Psychiatry
Research, Tokyo Institute of Psychiatry, Setagaya-ku, Japan
4 Behavioral sensitization to cocaine in rats: Evidence for temporal differences in dopamine D3
and D2 receptor sensitivity
G. T. Collins1, Y. N. Truong1, B. Levant2, J. H. Woods1, 1University of Michigan Medical
School, Ann Arbor, MI, 2University of Kansas Medical Center, Kansas City, KS
5 WITHDRAWN
M. A. Balda1, Y. Itzhak1,2, 1Neuroscience Program, University of Miami, Miami, FL,
2Psychiatry, University of Miami, Miami, FL
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6 Psychostimulant behavioral and neurochemical effects are more rapid in adolescent than adult
rats
Q. D. Walker, A. E. Arrant, C. M. Kuhn, Pharmacology, Duke Medical Center, Durham, NC
7 Exposure to alcohol during adolescence or adulthood alters the aversive and locomotor-
activating effects of cocaine in adult rats
M. A. Hutchison, D. L. Albaugh, A. L. Riley, American University, Washington, DC
8 Self-administered cocaine does not result in locomotor sensitization in monkeys
N. M. Shinday1,2, D. M. Platt1, J. K. Rowlett1,2, W. D. Yao1,2, 1New England Primate Research
Center-Harvard Medical School, Southborough, MA, 2Neuroscience and Behavior, University
of Massachusetts at Amherst, Amherst, MA
9 Access to a nondrug alternative reinforcer produces a rightward shift in the cocaine
discriminative stimulus
S. Kohut, A. Riley, American University, Washington, DC
10 Effects of cross-drug preexposure on cocaine- and desipramine-induced conditioned taste
aversions
K. M. Serafine, A. L. Riley, Psychology- Psychopharmacology Laboratory, American
University, Washington, DC
11 Effects of the tetrahydroprotoberberines l-tetrahydropalmatine and l-stepholidine on cocaine
self-administration under fixed- and progressive-ratio schedules and cocaine discrimination in
rats
S. Wisniewski1, Z. Yang2, S. J. Li3, J. R. Mantsch1, 1Biomedical Sciences, Marquette University,
Milwaukee, WI, 2Psychiatry, Beijing Institute of Basic Medical Science, Beijing, China,
3Biophysics, Medical College of Wisconsin, Milwaukee, WI
12 Dose preference and dose escalation of cocaine in extended-access self-administration in
Fischer and Lewis rats
R. Picetti, M. J. Kreek, The Rockefeller University, New York, NY
13 Effort to obtain cocaine modulates the effects of a differential-reinforcement-of-alternative-
behavior schedule of alternative nondrug reinforcement on cocaine self-administration in rats
M. G. LeSage, 1Minneapolis Medical Research Foundation, Minneapolis, MN, 2University of
Minnesota, Minneapolis, MN
14 Effects of chronic modafinil on cocaine and food self-administration in rhesus monkeys
J. Newman1, S. S. Negus3, J. Bergman1, T. Prisinzano2, N. Mello1, 1Alcohol and Drug Abuse
Research Center, McLean Hospital, Harvard Medical School, Belmont, MA, 2Medicinal
Chemistry, University of Kansas, Lawrence, KS, 3Pharmacology and Toxicology, Virginia
Commonwealth University, Richmond, VA
15 Aerobic exercise attenuates the escalation of cocaine intake under extended-access conditions
M. A. Smith, K. L. Walker, K. T. Cole, Davidson College, Davidson, NC
PEPTIDES/NEUROTRANSMITTERS
16 Alterations in the density of group II mGluRs in the striatum of nonhuman primates following
chronic cocaine self-administration
T. J. Beveridge, H. R. Smith, M. A. Nader, L. J. Porrino, Physiology and Pharmacology, Wake
Forest University School of Medicine, Winston Salem, NC
17 Activation of mGluR2/3 selectively attenuates cocaine cue-mediated behavior in a novel
nonhuman primate model of relapse
D. Manvich, L. L. Howell, Division of Neuroscience, Yerkes National Primate Research
Center, Emory University, Atlanta, GA
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18 Homer2 expression bidirectionally regulates PFC glutamate levels: Relation to cocaine reward
A. W. Ary1, K. D. Lominac1, M. Klugmann2, K. K. Szumlinski1, 1Psychology, University of
California Santa Barbara, Santa Barbara, CA, 2Physiological Chemistry, University Mainz,
Mainz, Germany
19 Effects of the competitive NMDA receptor antagonist LY235959 on the antinociceptive response
to acute and chronic morphine in WT and NR1 KD mice
R. E. Balter1, L. L. Miller2, K. T. Schmidt2, L. A. Dykstra1,2, 1Curriculum in Neurobiology,
University of North Carolina- Chapel Hill, Chapel Hill, NC, 2Psychology, University of North
Carolina- Chapel Hill, Chapel Hill, NC
20 Morphine decreases innate immunity responses in an endotoxemia model in two strains of mice
S. L. Cruz, I. K. Madera-Salcedo, C. Gonzalez-Espinosa, Pharmacobiology, Cinvestav, IPN,
Mexico DF, Mexico
21 The effect of gp120 on the antinociception induced by opioids in the cold water tail-flick test
X. Chen, J. Palma, E. B. Geller, T. K. Eisenstein, M. W. Adler, Center for Substance Abuse
Research, Temple University School of Medicine, Philadelphia, PA
22 Intrahypothalamic administration of gp120 induces fever via CXCR4 receptors
K. Benamar, M. Yondorf, S. Addou, J. Palma, E. Geller, T. Eisenstein, M. Adler, Center for
Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
23 Involvement of dopamine system on psychostimulant-like properties of p-fluoroamphetamine in
mice
M. Funada, N. Aoo, Y. Akitake, K. Wada, Drug Dependence Research, NIMH, NCNP,
Kodaira, Japan
24 Decreases in dopamine D2 receptor availability are associated with age in juvenile rhesus
monkeys
K. E. Gill, A. J. Bennett, P. J. Pierre, M. A. Nader, L. J. Porrino, Physiology and Pharmacology,
Wake Forest University, Winston Salem, NC
25 Generality of disruption of prepulse inhibition by the dopamine agonist apomorphine
L. Moran, C. F. Mactutus, R. M. Booze, Psychology, Behavioral Neuroscience, University of
South Carolina, Columbia, SC
26 Effects of neuropeptide Y on the reinforcing efficacy of water and cocaine
A. P. Caven1, A. M. Gancarz1, J. M. DiPirro2, J. B. Richards3, A. C. Thompson3, 1Psychology,
University at Buffalo, Buffalo, NY, 2Psychology, Buffalo State College, Buffalo, NY,
3Research Institute on Addictions, University at Buffalo, Buffalo, NY
27 Detection and quantification of endogenous arginine vasopressin in blood using mass
spectrometry
B. Reed1,2, J. Varon1, B. T. Chait2, M. J. Kreek1, 1Laboratory of the Biology of Addictive
Diseases, The Rockefeller University, New York, NY, 2Laboratory of Mass Spectrometry and
Gaseous Ion Chemistry, The Rockefeller University, New York, NY
28 Development of a plate assay to immuno-histochemically detect brain proteins in receptor and
signaling pathways associated with addiction
M. T. Reilly, R. A. Alyea, C. S. Watson, P. K. Seitz, K. Cunningham, Pharmacology, University
of Texas Medical Branch, Galveston, TX
NICOTINE: HUMAN STUDIES
29 Effect of nicotine on attentional networks in smokers and nonsmokers
S. Heishman, C. S. Myers, R. C. Taylor, B. J. Salmeron, Nicotine Psychopharmacology,
National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD
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30 Initiating and maintaining smoking abstinence via the Internet
P. A. Nuzzo1,4, N. E. Schoenberg1, C. A. Martin2, J. Dallery3, C. J. Wong1, W. W. Stoops1,4,
1Behavioral Science, University of Kentucky, Lexington, KY, 2Psychiatry, University of
Kentucky, Lexington, KY, 3Psychology, University of Florida, Gainsville, FL, 4Center on Drug
and Alcohol Research, University of Kentucky, Lexington, KY
31 The reinforcing efficacy of 3 vs. 6 puffs in smokers: Comparing traditional and demand analysis
E. T. Mueller1, W. Bickel1, R. Yi1, G. Badger2, 1Psychiatry, University of Arkansas for Medical
Sciences, Little Rock, AR, 2University of Vermont, Burlington, VT
32 Craving and use of tobacco and cocaine: Findings from an ecological momentary assessment
study with polydrug users
K. L. Preston, S. J. Heishman, R. Evans, G. F. Marrone, D. H. Epstein, NIDA Intramural
Research Program, Baltimore, MD
33 Could low dependent smokers be more cue reactive than high dependent smokers?
N. L. Watson1, M. J. Carpenter1, M. E. Saladin1, K. M. Gray1, S. A. McCullough1,
E. M. Klintworth1, C. E. Horne1, H. P. Upadhyaya1,2, 1Medical University of South Carolina,
Charleston, SC, 2Eli Lilly and Company, Indianapolis, IN
34 Menstrual phase differences in nicotine response after acute smoking abstinence
A. M. Allen1, S. S. Allen1, M. al’Absi1, D. K. Hatsukami2, 1Family Medicine and Community
Health, University of Minnesota, Minneapolis, MN, 2Psychiatry, University of Minnesota,
Minneapolis, MN
35 Sex differences in brain responses to smoking cues vary as a function of smoking
satiety/abstinence
B. Froeliger, R. V. Kozink, A. M. Lutz, F. J. McClernon, Psychiatry, Duke University Medical
Center, Durham, NC
36 Acute negative affect relief from smoking may be related to the situation and unrelated to
nicotine intake
K. Perkins, J. L. Karelitz, C. A. Conklin, M. A. Sayette, A. Grottenthaler, Psychiatry,
University of Pittsburgh, Pittsburgh, PA
37 Influence of acute methylphenidate administration on cigarette smoking behavior in ADHD-
diagnosed adults
A. R. Vansickel1, M. Poole1, W. W. Stoops1, P. E. A Glaser2, C. R. Rush1,2, 1Psychology,
Behavioral Science, University of Kentucky, Lexington, KY, 2Psychiatry, University of
Kentucky, Lexington, KY
38 Pre-quit brain fMRI responses to tobacco smoking-related cues predict slips during smoking
cessation treatment
A. C. Janes1, B. Frederick1, S. Richardt1, E. Merlo-Pich3, A. E. Evins2, M. Fava2,
P. F. Renshaw1, M. J. Kaufman1, 1Brain Imaging Center, McLean Hospital, Belmont, MA,
2Massachusetts General Hospital, Boston, MA, 3Psychiatry-CEDD, GlaxoSmithKline, Verona,
Italy
39 The regulation of craving for cigarettes vs. food: An fMRI study of cigarette smokers
H. Kober1, E. Kross2, P. Mende-Siedlecki1, W. Mischel1, C. Hart1, K. Ochsner1, 1Psychology,
Columbia University, New York, NY, 2Psychology, University of Michigan, Ann Arbor, MI
40 Smoking abstinence increases posterior insula–default network functional connectivity
F. J. McClernon, B. E. Froeliger, R. V. Kozink, A. M. Lutz, Duke University Medical Center,
Durham, NC
41 Ecological Momentary Assessment of smoking cessation in smokers with schizophrenia
J. W. Tidey1, C. J. Gwaltney2, S. M. Colby1, 1Psychiatry and Human Behavior, Brown
University, Providence, RI, 2Community Health, Brown University, Providence, RI
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42 Nicotine occupancy of beta2*-nicotinic acetylcholine receptors after use of nicotine inhaler:
Relationship to craving
I. Esterlis1, E. Mitsis4, J. Batis3, F. Bois1, S. Stiklus1, T. Kloczynski1, E. Perry1, G. Tamagnan3,1,
J. Seibyl3,1, J. Staley1,2, 1Psychiatry, Yale University and VACHS, W Haven, CT, 2Diagnostic
Radiology, Yale University and VACHS, West Haven, CT, 3Institute Neurodegen, New
Haven, CT, 4Mount Sinai, New York, NY
43 Reduced carbon monoxide in treatment-seeking cigarette smokers undergoing contingency
management: Preliminary analysis
D. M. Ledgerwood, C. L. Arfken, Psychiatry, Wayne State School of Medicine, Detroit, MI
44 Do participants in randomized clinical trials for nicotine dependence reflect the general
population of smokers?
N. Dasgupta1, A. C. Andorn2, H. D. Chilcoat2, 1Epidemiology, University of North Carolina
School of Public Health at Chapel Hill, Chapel Hill, NC, 2Worldwide Epidemiology,
GlaxoSmithKline, Honolulu, HI
45 A randomized, double-blind, placebo-controlled clinical trial of selegiline hydrochloride for
smoking cessation: Preliminary results
A. H. Weinberger1, E. L. Reutenauer1, M. N. Potenza1, S. S. O’Malley1, T. P. George2,3,
1Psychiatry, Yale University School of Medicine, New Haven, CT, 2Psychiatry, University of
Toronto, Toronto, ON, Canada, 3Schizophrenia Program, Centre for Addiction and Mental
Health, Toronto, ON, Canada
CANNABINOIDS/MARIJUANA
46 Stopping marijuana increases alcohol use: An experimental verification of drug substitution
E. N. Peters1, J. R. Hughes2, 1Psychology, University of Vermont, Burlington, VT, 2Psychiatry,
University of Vermont, Burlington, VT
47 Life course trajectories of employment: Exploring the impacts of drug use
Y. Hser1, Y. C. Huang1, M. Hara1, R. Weiss2, 1Integrated Substance Abuse Programs,
University of California, Los Angeles, CA, 2School of Public Health, Biostatistics, University
of California, Los Angeles, CA
48 Greater psychiatric symptoms in young marijuana users
C. C. Cloak, I. Chin, D. Alicata, T. Ernst, L. Chang, University of Hawaii at Manoa, John A
Burns School of Medicine, Honolulu, HI
49 Male- female variations in cannabis smoking for U.S.-born vs. foreign-born Latinos and Asians
in the United States, 2002-2003
H. Cheng, J. C. Anthony, Michigan State University, East Lansing, MI
50 The negative prognostic impact of cannabis dependence in a study of patients with bipolar
disorder and substance use disorders
W. B. Jaffee, M. Griffin, L. McDonald, S. Putnins, G. Fitzmaurice, R. Weiss, Alcohol and
Drug Abuse Treatment Program, Harvard Medical School, McLean Hospital, Belmont, MA
51 Beyond abstinence: Can Cognitive Behavioral Therapy reduce cannabis-related problems?
K. Dittmer, E. Hoch, R. Noack, H. Rohrbacher, J. Henker, G. Bühringer, H. U. Wittchen,
Institut für Klinische Psychologie und Psychotherapie, Technische Universität Dresden,
Dresden, Germany
52 Childhood predictors of first chance to use and use of cannabis by young adulthood
C. L. Storr1,2, F. A. Wagner3, C. Y. Chen4, J. C. Anthony5, 1University of Maryland,
Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Morgan State University, Baltimore, MD,
4National Health Research Institute, Taipei, Taiwan, 5Michigan State University, East
Lansing, MI
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53 Prediction of cannabis use disorder between childhood and young adulthood using cortisol
reactivity, transmissible and non-transmissible liability indices
L. Kirisci, R. Tarter, M. Vanyukov, M. Reynolds, A. Mezzich, T. Ridenour, Pharmaceutical
Sciences, University of Pittsburgh, Pittsburgh, PA
54 Smoked marijuana discrimination in humans
L. H. Lundahl, C. L. Steinmiller, L. Sander, M. K. Greenwald, C. E. Johanson, Psychiatry and
Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI
55 Gender differences in response to marijuana cues and stress in marijuana-dependent individuals
K. Price, A. McRae-Clark, M. Saladin, R. Carter, K. Brady, Psychiatry, Medical University of
South Carolina, Charleston, SC
56 The substitution profile of the cannabinoid agonist nabilone in human subjects discriminating
∆9-THC
J. A. Lile, L. R. Hays, T. H. Kelly, University of Kentucky College of Medicine,
Lexington, KY
57 Amygdala volumes in adolescent marijuana users
T. McQueeny1, C. B. Padula1, J. S. Price1, K. L. Medina1, S. F. Tapert2, 1University of
Cincinnati, Cincinnati, OH, 2University of California, San Diego, La Jolla, CA
58 The effects of marijuana on creative problem solving
S. K. Vosburg, R. W. Foltin, M. Haney, Substance Abuse, Columbia University/New York State
Psychiatric Institute, New York, NY
59 The effects of IV prenatal tetrahydrocannabinol exposure on passive avoidance performance in
male and female juvenile rats
L. C. Harte, A. Jackson, M. Iijima, N. Zhao, D. Dow-Edwards, Program on Neural and
Behavioral Sciences, Physiology/Pharmacology, State University of New York Downstate,
Brooklyn, NY
PREGNANCY AND DRUG ABUSE
60 Neonatal abstinence syndrome and gender: Does sex matter?
K. Kaltenbach, A. Holbrook, V. Nguyen, Pediatrics, Thomas Jefferson University,
Philadelphia, PA
61 Resilience to adolescent behavioral risk after intrauterine cocaine exposure
J. Liebschutz, D. A. Frank, R. Rose-Jacobs, J. Gerteis, S. Soenksen, T. Heeren, B. Martin,
H. Cabral, D. Appugliese, Boston University, Boston, MA
62 Correlates of prenatal tobacco use in a treatment sample of pregnant drug-dependent women
J. Gray1, L. Phipps1, N. Haug2, M. Stitzer2, D. Svikis1, 1Psychology, Virginia Commonwealth
University, Richmond, VA, 2Psychiatry, Johns Hopkins, Baltimore, MD
63 Social discounting among pregnant cigarette smokers
M. Bradstreet1, S. T. Higgins1,2, 1University of Vermont, Burlington, VT, 2Psychiatry,
University of Vermont, Burlington, VT
64 Smoking opinions and attitudes among pregnant smokers and spontaneous quitters
E. Herrmann1, S. Heil2, S. Higgins1,2, L. Solomon3, I. Bernstein4, 1Psychology, University of
Vermont, Burlington, VT, 2Psychiatry, University of Vermont, Burlington, VT, 3Family
Medicine, University of Vermont, Burlington, VT, 4OB/Gyn, University of Vermont,
Burlington, VT
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
65 Legal issues among drug-using pregnant women
T. Linares Scott1, S. Heil1, H. Jones2, M. Wagner3, G. Fischer4, K. Kaltenbach5, S. Stine6,
P. Martin7, M. Coyle8, P. Selby9, 1U of Vermont, Burlington, VT, 2Johns Hopkins U,
Baltimore, MD, 3U of Maryland, College Park, MD, 4Medical U of Vienna, Vienna, Austria,
5Thomas Jefferson U, Philadelphia, PA, 6Wayne State U, Detroit, MI, 7Vanderbilt U,
Nashville, TN, 8Brown U, Providence, RI, 9U of Toronto, Toronto, ON, Canada
66 Predictors of initial abstinence in newly pregnant women
J. H. Yoon1, S. T. Higgins2,3, G. J. Badger4, M. P. Bradstreet3, 1Psychiatry and Behavioral
Research, Baylor College of Medicine, Houston, TX, 2Psychiatry, University of Vermont,
Burlington, VT, 3Psychology, University of Vermont, Burlington, VT, 4Medical Biostatistics,
University of Vermont, Burlington, VT
67 Using a community coalition to develop a smoking cessation program to reduce infant mortality
A. L. Sepulveda, M. G. Kennedy, J. B. Bradford, S. L. Garland, S. W. Masho, D. S. Svikis,
W. R. Smith, Virginia Commonwealth University, Richmond, VA
68 Characteristics associated with smoking severity during pregnancy
S. H. Heil1, S. Higgins1, L. Solomon2, I. Berstein3, 1Psychiatry, University of Vermont,
Burlington, VT, 2Family Practice, University of Vermont, Burlington, VT, 3OB/Gyn, University
of Vermont, Burlington, VT
69 Low educational attainment and cigarette smoking during pregnancy
Y. Washio, S. T. Higgins, S. H. Heil, J. M. Skelly, G. J. Badger, L. J. Solomon, University of
Vermont, Burlington, VT
70 Women’s perspectives on screening for alcohol and drug use in prenatal care
S. Roberts, 1School of Public Health, University of California, Berkeley, Berkeley, CA,
2Alcohol Research Group, Emeryville, CA
71 Pregnant women in methadone maintenance: Barriers to treatment and treatment engagement
L. Oberleitner, L. H. Lundahl, School of Medicine, Wayne State University, Detroit, MI
72 Psychosocial functioning in methadone- and nonmethadone-maintained pregnant women:
Relationships to treatment engagement and retention
B. C. Jancaitis1,2, J. May1,2, S. Masho2, D. Svikis2, 1Richmond Behavioral Health Authority,
Richmond, VA, 2Virginia Commonwealth University, Richmond, VA
73 There is no window of opportunity: Pregnancy and disparities in treatment need vs. receipt
E. J. Smith, M. Terplan, Obstetrics and Gynecology, University of Chicago, Chicago, IL
74 Preliminary findings on the efficacy of an HIV prevention intervention for pregnant African-
American women in substance abuse treatment in the South
F. Browne1, R. Middlesteadt-Ellerson1, A. Gentry1, H. Jones2, D. Haller3, W. Wechsberg1, 1RTI
International, Research Triangle Park, NC, 2The Johns Hopkins University, Baltimore, MD,
3Columbia University, New York, NY
75 Multidimensions of HIV risk for drug-dependent pregnant patients
H. E. Jones1, W. Wechsberg2, K. O’Grady3, R. Chaudhury1, M. Tuten1, 1Johns Hopkins
University, Baltimore, MD, 2RTI International, Durham, NC, 3University of Maryland, College
Park, MD
76 Victimization, mental distress, crime, and substance use among pregnant adolescent girls
V. H. Coleman, M. Dennis, Lighthouse Institute, Chestnut Health Systems, Normal, IL
IMPULSIVITY
77 Effects of prenatal stress on lever-press acquisition, delay discounting, and ethanol self-
administration in rats
N. R. Bruner, K. G. Anderson, Psychology, West Virginia University, Morgantown, WV
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78 Impulsivity does not correlate with working memory or alcohol preference in rats bred for
alcohol preference
G. R. Wenger, Pharmacology and Toxicology, University of Arkansas for Medical Sciences,
Little Rock, AR
79 The effect of long and short access to d-amphetamine self-administration on a delay discounting
task in rats
C. Gipson, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
80 Effects of signaled delays, delay order, and d-amphetamine on delay discounting
J. M. Slezak, K. Anderson, Psychology, West Virginia University, Morgantown, WV
81 Striatal dopamine D2/D3 receptors, impulsivity, and methamphetamine dependence
B. Lee1, R. A. Poldrack3, G. Tabibnia1, M. A. Mandelkern4,5, A. V. Bokarius1, J. R. Monterosso6,
A. Aron7, J. Farahi5, M. Dahlbom2, R. M. Bilder1, A. L. Brody1,5, E. D. London1,2, 1Psychiatry
and Biobehavioral Science, University of California, Los Angeles, CA, 2Molecular and
Medical Pharmacology, University of California, Los Angeles, CA, 3Psychology, University of
California, Los Angeles, CA, 4Physics, UCI, Los Angeles, CA, 5PET Center, VA, Los
Angeles, CA, 6Psychology, USC, Los Angeles, CA, 7Psychology, UCSD, San Diego, CA
82 The relationship between the responsivity to cocaine-related stimuli and other cognitive
performance
S. Liu1, F. G. Moeller1, S. D. Lane1, K. A. Cunningham2, 1Psychiatry and Behavioral Sciences,
University of Texas Houston, Houston, TX, 2Pharmacology and Toxicology, University of
Texas Galveston, Galveston, TX
83 Relationship of impulsivity and decision-making measures in cocaine dependence
K. L. Kjome, S. D. Lane, J. M. Schmitz, C. Green, L. Ma, I. Prasla, A. C. Swann,
F. G. Moeller, Psychiatry, University of Texas-Houston, Houston, TX
84 Impulsivity, completion status, and ethnicity in a clinical trial for cocaine dependence
W. V. Lechner1, M. S. Schuler2, S. D. Larowe1, L. R. Rogers1, R. J. Malcolm1, 1Psychiatry,
Center for Drug and Alcohol Problems, Medical University of South Carolina, Charleston, SC,
2Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina,
Charleston, SC
85 Impact of adult ADHD and cocaine dependence on measures of attention and impulsivity
D. J. Brooks1, S. M. Evans2,1, F. R. Levin2,1, 1Substance Abuse, New York State Psychiatric
Institute, New York, NY, 2Psychiatry, Columbia University, New York, NY
86 Characteristics of psychopathy in adolescent nonsmokers and smokers: Relations to delay
discounting and self-reported impulsivity
S. Melanko1, B. Reynolds2, 1West Virginia University, Morgantown, WV, 2The Ohio State
University, Columbus, OH
87 Impulsive disinhibition in adolescent smokers and nonsmokers
S. Fields, C. Collins, K. Leraas, S. Imhoff, B. Reynolds, Nationwide Childrens Hospital,
Columbus, OH
88 Depression and impulsivity in adolescent smokers and nonsmokers
S. Imhoff, C. Collins, K. Leraas, S. Fields, B. Reynolds, Nationwide Childrens Hospital,
Columbus, OH
89 The effects of multimodal treatment on delay discounting in opioid-dependent individuals
D. R. Christensen, R. D. Landes, W. K. Bickel, University of Arkansas for Medical Sciences,
Little Rock, AR
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90 Delayed discounting and questionnaire measures of impulsive and inattentive behaviors are
heterogeneous
C. L. Steinmiller, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State
University School of Medicine, Detroit, MI
91 Impulsivity, risk-taking, and behavioral problems in treatment-seeking adolescents
J. VanScoyoc, C. Stanger, A. J. Budney, University of Arkansas for Medical Sciences, Little
Rock, AR
92 Measuring impulsive behavior and cognition in inner-city substance abusers using translation
procedures based on preclinical research
M. E. Mattila-Evenden1, J. Shack1, C. Heeney-Buggey1, J. Evenden2, 1Psychiatry and
Behavioral Science, Temple University Hospital, Philadelphia, PA, 2WiltonLogic, Media, PA
93 Head injury and intimate partner violence perpetration among alcohol-treatment-seeking men
J. A. Schumacher1, S. F. Coffey1, K. E. Leonard2, 1Psychiatry and Human Behavior, University
of Mississippi Medical Center, Jackson, MS, 2Research Institute on Addictions, University at
Buffalo, Buffalo, NY
HIV/AIDS RISK
94 Using latent class analysis to examine patterns of HIV risk behaviors among women with
lifetime histories of illicit drug use
C. E. Cavanaugh, C. Graham, S. Hedden, W. Latimer, Bloomberg School of Public Health,
Mental Health, Johns Hopkins University, Baltimore, MD
95 Chaos: The root of the problem for female crack users
L. B. Cottler, C. C. O’Leary, S. E. Bradford, C. W. Striley, A. Ben Abdallah, Psychiatry,
Washington University School of Medicine, St. Louis, MO
96 Social network correlates of unprotected sex in Russian injection drug-using sexual partnerships
V. Gyarmathy1, N. Li2, K. E. Tobin2, I. F. Hoffman3, A. P. Kozlov4, A. B. Laudet5, C. A. Latkin2,
1European Centre for Drugs and Drgu Addiction, Lisbon, Portugal, 2Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, 3University of North Carolina at Chapel Hill, Chapel
Hill, NC, 4Biomedical Center, St. Petersburg State University, St. Petersburg, Russia, 5National
Development and Research Institutes, Inc., New York, NY
97 Double jeopardy for drug-using women in Russia: Injecting and sexual risks reported in a small
trial
W. M. Wechsberg1, E. Krupitsky2, T. Romanova2, E. Zvartau2, A. Gentry1, F. Browne1,
R. Middlesteadt Ellerson1, 1RTI International, Durham, NC, 2St. Petersburg Pavlov State
Medical University, St. Petersburg, Russia
98 Risk behaviors of a sample of female injection drug users in Malaysia
V. B. Kasinather1, M. Mazlan2, M. C. Chawarski3, R. S. Schottenfeld3, 1Centre for Drug
Research, University Sains Malaysia, Penang, Malaysia, 2Substance Abuse Research Centre,
Muar, Malaysia, 3School of Medicine, Yale University, New Haven, CT
99 Intervening to address drug use and sexual HIV risk among female sex workers in Durban,
South Africa
P. M. Petersen, T. Carney, A. Plüddemann, C. Parry, Alcohol and Drug Abuse Research Unit,
Medical Research Council, Cape Town, South Africa
100 The impact of social and emotional isolation on risky behaviors among women injection drug
users in Portland, OR
A. Hilde, J. Lapidus, Y. Michael, Public Health and Preventative Medicine, Oregon Health and
Science University, Portland, OR
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101 Associations between sexual risk behavior patterns and HIV in female South African drug users
S. L. Hedden, C. Cavanaugh, C. Graham, L. Floyd, W. W. Latimer, Mental Health, Johns
Hopkins School of Public Health, Baltimore, MD
102 HIV-positive drug users less likely to use condoms in South Africa
C. Graham, S. L. Hedden, C. E. Cavanaugh, W. W. Latimer, Mental Health, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD
103 The moderating effects of sex trade on the relationship between poly substance use and HIV
among South Africans
L. J. Floyd, C. Cavanaugh, A. Lawson, W. W. Latimer, Mental Health, Johns Hopkins
University, Baltimore, MD
104 HIV risk behaviors by sexual orientation after treatment for methamphetamine dependence
C. Manneh, M. Hillhouse, S. Schroeder, R. Rawson, Integrated Substance Abuse Programs,
University of California, Los Angeles, Los Angeles, CA
105 Sexual orientation, drug use during sex, and HIV risk practices/preferences among men who use
the Internet to find men for unprotected sex
H. Klein, Center for the Study and Prevention of Drug Use, Morgan State University,
Baltimore, MD
106 HIV risk behaviors among substance-dependent non-gay-identifying men and women with same-
gender sex experiences
D. Allensworth-Davies1, J. H. Samet2, D. M. Cheng1,2, A. Fitzgerald2, T. W. Kim2, J. Witas2,
R. Saitz2, 1Boston University School of Public Health, Boston, MA, 2Boston University School
of Medicine/Boston Medical Center, Boston, MA
107 The role of social context in the relationship between drug use and risky sexual behavior among
individuals who use both heroin and crack/cocaine
C. Kopetz1, E. Reynolds1, C. W. Lejuez1, A. W. Kruglanski2, 1Center for Addiction, Personality
and Emotion Research, University of Maryland, College Park, MD, 2Psychology, University of
Maryland, College Park, MD
108 Racial differences in HIV discordant sexual partnerships and sexual mixing between individuals
with different social, drug use, and sexual risk
M. Khan1,2, M. Bolyard3, P. Mateu-Gelabert1, S. R. Friedman1, 1National Development and
Research Institutes, New York, NY, 2Public Health Solutions, New York, NY, 3Emory College
of Arts and Sciences, Atlanta, GA
109 Predicting recent event-level condom use using behavioral assessment among urban, minority
substance users
J. Magidson, E. Reynolds, C. Fuchs, S. Gorka, M. Bornovalova, S. Daughters, C. Lejuez,
Psychology, University of Maryland, College Park, College Park, MD
110 Factors associated with needle exchange program and pharmacy use among heroin and cocaine
injectors in Baltimore, MD
B. E. Mancha1, D. Whitaker1, S. G. Severtson1, A. Nandi2, S. Hedden1, L. Floyd1,
W. W. Latimer1, 1Mental Health, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, 2Center for Population and Development Studies, Harvard School of Public
Health, Boston, MA
111 Buprenorphine detoxification: Effects on problem severity and AIDS risk behaviors
S. J. Lookatch1, E. M. Dunne1, B. S. Brown2,3, R. Schwartz3, S. D. King3, K. O’Grady4,
D. Gandhi4, E. C. Katz1,3, 1Psychology, Towson University, Towson, MD, 2University of North
Carolina, Wilmington, NC, 3Friends Research Institute, Baltimore, MD, 4University of
Maryland, Baltimore, MD
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112 HIV sexual risk behaviors and physician screening in office-based buprenorphine treatment
L. Sullivan, B. Moore, S. Cawley, R. Schottenfeld, D. Fiellin, Yale University, New Haven, CT
OPIATES: HUMAN STUDIES
113 Behavioral naltrexone therapy plus depot naltrexone for heroin dependence: A randomized
controlled trial
M. A. Sullivan, K. M. Carpenter, J. M. Manubay, J. Kurtz, J. Lazar, E. V. Nunes,
Columbia/New York State Psychiatric Institute, New York, NY
114 Naltrexone-induced protracted opioid withdrawal
J. J. Mariani, M. Sullivan, A. Bisaga, K. Carpenter, K. A. Murray, F. R. Levin, E. V. Nunes,
Psychiatry/Division on Substance Abuse, Columbia University/New York State Psychiatric
Institute, New York, NY
115 Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone film
strips
E. C. Strain, G. E. Bigelow, J. Harrison, Psychiatry and Behavioral Sciences, Johns Hopkins
University School of Medicine, Baltimore, MD
116 Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid
dependence
W. M. Aklin1, G. Severtson2, A. Umbricht3, M. Fingerhood3, G. E. Bigelow3, K. Silverman3,
1Behavioral and Integrative Treatment Branch, NIDA, Bethesda, MD, 2Public Health, Johns
Hopkins University, Baltimore, MD, 3Psychiatry, Johns Hopkins University, Baltimore, MD
117 Employment-based reinforcement of adherence to depot naltrexone pharmacotherapy
J. Everly, A. Defulio, A. Umbricht, M. Fingerhood, G. Bigelow, K. Silverman, Johns Hopkins
University School of Medicine, Baltimore, MD
118 One year of sustained-release naltrexone treatment for opioid dependence
N. Kunøe1, P. P. Lobmaier1, J. K. Vederhus2, Ø. Kristensen2, B. Hjerkinn2, S. Hegstad3,
M. Gossop4,1, H. Waal1, 1Norwegian Centre for Addiction Research, University of Oslo, Oslo,
Norway, 2The Addiction Unit, Sørlandet Hospital, Kristiansand, Norway, 3Division of Forensic
Toxicology and Drug Abuse, Norwegian Institute of Public Health, Oslo, Norway, 4National
Addiction Centre, Institute of Psychiatry, King’s College, London, United Kingdom
119 Memory functioning of opiate-dependent individuals during Methadone Maintenance Treatment
with Cognitive Behavioral Treatment
M. C. Chawarski1, B. Garnet2, R. S. Schottenfeld1, 1Psychiatry, Yale University School of
Medicine, New Haven, CT, 2APT Foundation, Inc., New Haven, CT
120 Cognitive performance and methadone maintenance patients
B. A. Kleykamp, R. Vandrey, G. Bigelow, M. Stitzer, E. Strain, M. Mintzer, School of
Medicine, Johns Hopkins University, Baltimore, MD
121 The provision of drug counseling services in office-based buprenorphine treatment
J. E. Egan1, J. Netherland1, R. Finkelstein1, D. Fiellin2, T. Pugh1, L. Weiss1, 1New York
Academy of Medicine, New York, NY, 2Yale University School of Medicine, New Haven, CT
122 Variation in retention by behavioral condition in buprenorphine treatment for opioid dependence
M. P. Hillhouse, J. Fahey, J. Jenkins, W. Ling, R. Rawson, Integrated Substance Abuse
Programs, University of California, Los Angeles, Los Angeles, CA
123 Retention and transition to long-term treatment in opioid-dependent patients: Impact of
Intensive Role Induction
E. C. Katz1,3, B. S. Brown2,3, R. Schwartz3, S. D. King3, K. O’Grady4, D. Gandhi4, 1Psychology,
Towson University, Towson, MD, 2University of North Carolina, Wilmington, NC, 3Friends
Research Institute, Baltimore, MD, 4University of Maryland, Baltimore, MD
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124 Treatment options for opiate dependence: Choices between buprenorphine and methadone
M. R. Polen1, D. McCarty2, C. Green1,2, 1Center for Health Research, Kaiser Permanente,
Portland, OR, 2Public Health and Preventive Medicine, Oregon Health & Science University,
Portland, OR
125 Treatment entry among individuals on a waiting list for methadone maintenance
J. Gryczynski1, R. P. Schwartz1, K. E. O’Grady2, J. H. Jaffe3, 1Social Research Center, Friends
Research Institute, Baltimore, MD, 2Psychology, University of Maryland, College Park,
College Park, MD, 3School of Medicine, University of Maryland, Baltimore, MD
126 Relationship between patient attitudes toward methadone and methadone treatment program
retention
S. Kelly1, R. P. Schwartz1, K. E. O’Grady2, B. S. Brown3, 1Friends Research Institute,
Baltimore, MD, 2University of Maryland, College Park, MD, 3University of North Carolina,
Wilmington, NC
127 Satisfaction with methadone treatment centers of heroin-dependent patients who show poor
response to this treatment
J. Pérez de los Cobos, N. Siñol, J. Trujols, F. Batlle, M. Cardús, A. Rodríguez, Addictive
Behaviors Unit (Psychiatry Department), Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain
128 The contribution of the quality of staff-patients’ relationships to patients’ satisfaction with
methadone service
S. Levit1, M. Schiff2, R. C. Moreno3, 1Methadone Clinic in Jerusalem, Jerusalem, Israel,
2School of Social Work, Hebrew University, Jerusalem, Israel, 3Central Bureau of Statistics,
Jerusalem, Israel
129 The relation between illicit drug use in methadone maintenance treatment patients, psychopathic
aspects and sense of coherence
Y. Abramsohn, D. Potik, E. Peles, S. Schreiber, M. Adelson, Adelson Clinic, Tel-Aviv Sourasky
Medical Center, Tel Aviv, Israel
130 Use of complementary and alternative therapies among methadone maintenance patients
C. L. Masson1, L. Coffin2, N. Pepper1, C. McKnight2, A. Morganstern1, A. Jordan2, D. C. Des
Jarlais2,3, D. C. Perlman2,3, 1Psychiatry, University of California, San Francisco, CA, 2Beth
Israel Medical Center, New York, NY, 3NDRI, Inc., New York, NY
131 Distribution of chronic venous disorders in a methadone-maintenance-treated sample
B. Pieper1, T. N. Templin1, R. S. Kirsner2, T. J. Birk1, 1College of Nursing, Wayne State
University, Detroit, MI, 2School of Medicine, University of Miami, Miami, FL
132 Medical care utilization and opiate dependence
J. Fahey, M. Hillhouse, J. Jenkins, M. Torrington, C. Domier, W. Ling, Integrated Substance
Abuse Programs, University of California, Los Angeles, Los Angeles, CA
133 “For my daughter”: Interpersonal motivators of heroin cessation in a community-based sample
L. Weiss, J. Egan, J. Gass, C. Trezza, D. Vlahov, D. Ompad, Center for Urban Epidemiology
Studies, The New York Academy of Medicine, New York, NY
134 Quality of life in inpatients undergoing an opioid maintainance therapy after release from an
addiction clinic
B. Winklbaur, R. Loipl, S. Klug, V. Metz, D. Radler, G. Fischer, Psychiatry and Psychotherapy,
Medical University Vienna, Vienna, Austria
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Oral Communications 14 Rose Ballroom A
2:00 - 4:00 PM
BEFORE HITTING 21: DRUGS IN ADOLESCENCE
Chairs: Rajeev Ramchand and Yan Wang
2:00 Developmental trajectories of HIV sexual risk behaviors from adolescence to young adulthood
Y. D. Huang, D. Murphy, Y. Hser, Integrated Substance Abuse Programs, University of
California, Los Angeles, CA
2:15 Sustained abstinence in adolescence is associated with future economic well-being among high-
risk adolescents
B. Griffin, R. Ramchand, M. O. Edelen, D. McCaffrey, A. Morral, RAND Corporation,
Arlington, VA
2:30 Early childhood aggressive behavior, initial tobacco exposure opportunity and transition from
opportunity to first tobacco use: A prospective study in urban African American youth
Y. Wang1, N. S. Ialongo2, 1School of Medicine, University of Maryland at Baltimore,
Baltimore, MD, 2Mental Health, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD
2:45 Dispelling the myth of smart drugs: Cannabis use problems and nonmedical use of prescription
stimulants for studying
A. Arria1, H. Wilcox2, K. Caldeira1, K. Vincent1, E. Wish1, K. O’Grady3, 1Center for Substance
Abuse Research, University of Maryland, College Park, MD, 2Psychiatry, Johns Hopkins
School of Medicine, Baltimore, MD, 3Psychology, University of Maryland, College Park, MD
3:00 Anxious arousal and anhedonic depression symptoms and the frequency of current marijuana
use: Testing the mediating role of marijuana use coping motives among active users
K. Johnson1, M. O. Bonn-Miller2,3, T. M. Leyro1, M. J. Zvolensky1, 1Psychology, University of
Vermont, Burlington, VT, 2Center for Health Care Evaluation, VA Palo Alto Healthcare
System, Palo Alto, CA, 3Psychiatry, Stanford University, Stanford, CA
3:15 Conduct disorder predicts early but not late onset cocaine use and dependence: Evidence from
the Family Study of Cocaine Dependence in St. Louis
N. Presnall, J. Strickland, L. Cottler, L. Bierut, Psychiatry, Washington University in St. Louis,
Saint Louis, MO
3:30 Impact of adolescents’ exposure to negative life events, poverty and war in Israel
M. Schiff1, R. Benbenishty2, R. B. Hamburger3, 1School of Social Work, Hebrew University
and Columbia University, Jerusalem, Israel, 2School of Social Work, Hebrew University and
Bar Ilan University, Jerusalem, Israel, 3The Israel Anti Drug and Alcohol Authority, Jerusalem,
Israel
3:45 Adolescent outpatient substance abuse treatment: Are manual-guided interventions superior to
usual care?
R. Ramchand1, A. R. Morral1, D. F. McCaffrey1, M. Dennis2, 1RAND, Arlington, VA, 2Chestnut
Health Systems, Bloomington, IL
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Oral Communications 15 Ponderosa B
2:00 - 4:00 PM
GABBING ABOUT GABA
Chairs: Donna Platt and Wouter Koek
2:00 GABA-A receptor subtype mechanisms in the discriminative stimulus effects of ethanol in
monkeys
D. Platt1, M. Van Linn2, S. Rallapalli2, T. Clayton2, J. Cook2, 1Harvard Medical School/NE
Primate Research Center, Southborough, MA, 2University of Wisconsin-Milwaukee,
Milwaukee, WI
2:15 A glutamatergic role in withdrawal from benzodiazepines as detected via drug discrimination
analysis
N. A. Ator1, S. J. Kohut1,2, 1Psychiatry & Behavioral Sciences, Johns Hopkins School of
Medicine, Baltimore, MD, 2Psychology, American University, Washington, DC
2:30 The role of GABAA receptors in sex differences in cocaine-stimulated locomotion
N. Siegal, D. Dow-Edwards, Physiology and Pharmacology, State University of New York
Downstate College of Medicine, Brooklyn, NY
2:45 Reversible inactivation of the basolateral amygdala, but not the dorsolateral caudate-putamen,
attenuates the consolidation of cocaine-cue associative learning in an animal model of relapse
A. Gabriele, A. M. Pacchioni, R. E. See, Neurosciences, Medical University of South
Carolina, Charleston, SC
3:00 Opiate history sensitizes dorsal raphe serotonin neurons to GABAergic synaptic inputs following
stress-induced reinstatement
J. W. Lunden, D. R. Staub, E. L. Freeman-Daniels, L. G. Kirby, Anatomy and Cell Biology and
Center for Substance Abuse Research, Temple University School of Medicine,
Philadelphia, PA
3:15 GHB- and baclofen-induced hypothermia in mice: Interactions with the GABA-B receptor
positive modulator CGP7930, the GABA-B receptor antagonist CGP35348, and the NOS
inhibitor L-NAME
W. Koek1,2, P. S. Campos2, C. P. France2,1, K. Cheng3, K. C. Rice3, 1Psychiatry, University of
Texas Health Science Campsu, San Antonio, TX, 2Pharmacology, University of Texas Health
Science Center, San Antonio, TX, 3Chemical Biology Research Branch, NIDA, Bethesda, MD
3:30 The posterior cingulate: A functional and structural correlate of chronic administration of the
GABA B agonist, baclofen in smokers
T. Franklin1, Z. Wang1, D. Harper1, K. Kampman1, Y. Li1, W. Jens1, R. Viana1, M. Goldman1,
J. Suh1, J. Detre2, C. O’Brien1, A. Childress1, 1Psychiatry, University of Pennsylvania,
Philadelphia, PA, 2Radiology, University of Pennsylvania, Philadelphia, PA
3:45 Comparative neurochemical analysis of accumbens and ventral tegmentum during “speedball,”
cocaine and heroin self-administration
S. E. Hemby1, S. McIntosh1, K. Egan1, B. Horman1, C. Co1, L. Parsons2, 1Physiology and
Pharmacology, Wake Forest University, Winston-Salem, NC, 2Committee on the Neurobiology
of Addictive Disorders, The Scripps Research Institute, La Jolla, CA
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium XIII Rose Ballroom B
2:00 - 3:00 PM
RISK MANAGEMENT AND POST-MARKETING SURVEILLANCE 
OF CNS DRUGS
Chair: Robert L. Balster
2:00 Introduction
Robert L. Balster, Virginia Commonwealth University, Richmond, VA
2:05 Monitoring risk: Post-marketing surveillance and signal detection
Richard Dart, Denver Health, Rocky Mountain Poison and Drug Center, Denver, CO
2:25 What constitutes a signal: Quantitative and qualitative aspects
Sidney Schnoll, Pinney Associates, Bethesda, MD
2:45 Recommendations and conclusions of the expert panel
Charles Schuster, Chris-Ellyn Johanson, CRS Associates, LLC, Chicago, IL
Oral Communications 16 Bonanza
2:00 - 3:00 PM
GENES AND MOLECULES: THEY’RE IN OUR CARDS
Chairs: Nadezhda A. German and Ella M. Nikulina
2:00 Mu-opioid receptor A118G polymorphism in healthy volunteers affects HPA-axis ACTH stress
response to metyrapone
E. A. Ducat, B. Ray, G. Bart, Y. Umemura, J. Varon, A. Ho, M. J. Kreek, Laboratory of the
Biology of Addictive Disease, Rockefeller University, New York, NY
2:15 Impact of CYP2D6 genotype on the pharmacodynamic effects of oxycodone in humans: 
A retrospective analysis
J. D. Jones, W. J. Kowalczyk, M. A. Sullivan, S. K. Vosburg, S. D. Comer, Psychiatry,
Columbia University and New York State Psychiatric Institute, New York, NY
2:30 Des-formylflustrabromine and its analogs as positive allosteric modulators of α4β2 neuronal
nicotinic receptors
N. A. German1, J. S. Kim1, A. Pandya2, M. Weltzin2, M. Schulte2, R. A. Glennon1, 1Medicinal
Chemistry, Virginia Commonwealth University, Richmond, VA, 2Chemistry and Biochemistry,
University of Alaska Fairbanks, Fairbanks, AK
2:45 Up-regulation of brain-derived neurotrophic factor in the ventral tegmental area induces
FosB/∆FosB immunoreactivity in mesolimbic projections and facilitates sensitization after social
stress
E. M. Nikulina1,2, S. Fanous2, C. E. Bass3, X. Ren3, E. F. Terwilliger3, R. P. Hammer, Jr1,2,
1Basic Medical Sciences, University of Arizona, Phoenix, AZ, 2Tufts University, Boston, MA,
3Harvard Medical School, Boston, MA
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium XIV Rose Ballroom B
3:15 - 4:15 PM
DEVELOPMENT OF PROTEIN-BASED 
PHARMACOTHERAPIES FOR DRUG ADDICTION
Chairs: Thomas R. Kosten and C. Nora Chiang
3:15 Cocaine and nicotine vaccines: Human studies and pre-clinical improvements
Thomas R. Kosten, Baylor College of Medicine, Houston, TX
3:35 Active and passive immunization for treating methamphetamine abuse
W. B. Gentry, University of Arkansas for Medical Science, Llittle Rock, AR
3:55 Bioengineered human butyrylcholinesterase as a protein therapeutic for cocaine addiction
William S. Brimijoin, Mayo Foundation, Rochester, MN
Oral Communications 17 Bonanza
3:15 - 4:15 PM
DRUGS FOUND IN SPADES IN CLUBS
Chairs: Danielle C. Ompad and Rodney J. Irvine
3:15 The effects of sublingual Salvinorin A, a naturally occurring kappa opioid receptor agonist, in
humans
J. Mendelson1, J. C. Lopez1, M. J. Baggott1,3, K. Flower1, E. Everhart2, T. Munro4, B. Cohen4,
G. Galloway1, 1Addiction Pharmacology, California Pacific Medical Center Research Institute,
San Francisco, CA, 2Psychiatry, University of California, San Francisco, CA, 3Neuroscience,
Unversity of California Berkeley, Berkeley, CA, 4Psychiatry, Harvard Medical School,
Belmont, MA
3:30 Trends in ecstasy seizures and purity of seized ecstasy in Canada
B. J. Sauvé, K. Richard, Office of Research and Surveillance, Health Canada, Ottawa, ON,
Canada
3:45 Availability and use of club drugs in New York City: A multi-level analysis
D. C. Ompad1, S. Galea2, V. Nandi1, D. Vlahov1, 1Center for Urban Epidemiologic Studies,
New York Academy of Medicine, New York, NY, 2School of Public Health, University of
Michigan, Ann Arbor, MI
4:00 An objective quantitative method of monitoring illicit drug use
R. J. Irvine1, C. Kostakis2, P. Felgate2, J. M. White1, 1Pharmacology, University of Adelaide,
Adelaide, SA, Australia, 2Forensic Sciences, Deptartment of Justice, Adelaide, SA, Australia
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
POSTER SESSION IV (Breakfast) Pavilion
8:00 - 10:00 AM
Odd-numbered posters manned first hour;
Even-numbered, second hour
Set-up time begins Wednesday no earlier than 4:30 PM
Must be removed by Thursday no later than 1:30 PM
BENZODIAZEPINES
1 Changes in pregnanolone discriminative stimulus as a function of training dose in rats
A. K. Eppolito, L. R. Gerak, Pharmacology, University of Texas Health Science Center San
Antonio, San Antonio, TX
2 Differential attenuation of the discriminative stimulus effects of benzodiazepines and neuroactive
steroids by flumazenil or pentylenetetrazole in diazepam-treated rhesus monkeys
L. R. Gerak, C. P. France, Pharmacology, University of Texas Health Science Center, San
Antonio, TX
3 Role of GABAA receptor subtypes in benzodiazepine self-administration by rhesus monkeys
B. D. Fischer1, D. M. Platt1, M. L. Van Linn2, S. Rallapalli2, T. Clayton2, J. M. Cook2,
J. K. Rowlett1, 1Harvard Medical School/New Eangland Primate Research Center,
Southborough, MA, 2Chemistry, University of Wisconsin, Milwaukee, Milwaukee, WI
4 Abuse liability of chronic hypnotic use in insomniacs
S. Randall, T. Roehrs, R. Maan, T. Roth, Sleep Disorders & Research Center, Henry Ford
Health System, Detroit, MI
5 Absence of rebound insomnia following chronic hypnotic use
T. Roehrs, S. Randall, R. Maan, T. Roth, Sleep Disorders & Research Center, Henry Ford
Health System, Detroit, MI
6 Neuronal correlates of oral zolpidem administration: Magnetic resonance imaging studies in
healthy volunteers
S. C. Licata1, S. B. Lowen1, R. R. MacLean1, D. M. Penetar1, B. B. Frederick2, S. E. Lukas1,2,
1Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical
School, Belmont, MA, 2Brain Imaging Center, McLean Hospital/Harvard Medical School,
Belmont, MA
7 Progesterone modulation of triazolam effects in healthy women
S. Babalonis1,3, J. A. Lile1, C. A. Martin2, T. H. Kelly1,2,3, 1Behavioral Science, University of
Kentucky, Lexington, KY, 2Psychiatry, University of Kentucky, Lexington, KY, 3Psychology,
University of Kentucky, Lexington, KY
8 Is pregabalin (Lyrica®) a drug of abuse or protection against drug abuse? A comparison with
gabapentin within the Norwegian prescription database
J. G. Bramness1,3, P. Sandvik2, A. Engeland3, S. Skurtveit3, 1Centre for Addiction Research,
University of Oslo, Oslo, Norway, 2Norwegian University of Science and Technology,
Trondheim, Norway, 3Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo,
Norway
HALLUCINOGENS
9 Comparative pharmacology of dextromethorphan and triazolam
C. J. Reissig1, L. P. Carter2, M. Z. Mintzer1, M. W. Johnson1, R. R. Griffiths1, 1Psychiatry and
Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 2Clinical Research and
Development, Jazz Pharmaceuticals Inc., Palo Alto, CA
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10 Discriminative stimulus effects of the hallucinogen 5-methoxy-N-isopropyl-N-methyltryptamine
M. B. Gatch, T. Carbonaro, M. Rutledge, C. Elsken, M. J. Forster, Pharmacology and
Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
11 Tolerance development to hallucinogen-elicited head twitch behavior in mice
W. E. Fantegrossi, Pharmacology and Toxicology, University of Arkansas for Medical
Sciences, Little Rock, AR
12 Behavioral and mechanistic studies of the hallucinogens DiPT and 4-OH-DiPT
T. Carbonaro, T. Machu, M. B. Gatch, Pharmacology and Neuroscience, University of North
Texas Health Science Center, Fort Worth, TX
COCAINE: ANIMALS II
13 The effects of chronic cocaine on delay-discounting in rats
K. L. Dandy1, J. Miller1, M. Gatch1,2, 1Psychology, Texas Christian University, Fort Worth, TX,
2Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort
Worth, TX
14 Progesterone attenuates chronic cocaine-induced rearing responses but not dendritic spine
increases in the nucleus accumbens core of female rats
S. E. Diaz1,2, S. Nygard1,2, S. Jenab1,2, V. Quinones-Jenab1,2, 1Psychology, Graduate Center of
New York, City University of New York, New York, NY, 2Psychology, Hunter College, New
York, NY
15 Effect of sex and estrous on choice between food and cocaine in male and female rats
K. A. Kerstetter, M. A. Wade, T. E. Kippin, Psychology and Neuroscience Research Institute,
University of California, Santa Barbara, Santa Barbara, CA
16 Progesterone metabolite allopregnanolone attenuates the escalation of cocaine-seeking behavior
in female rats
J. J. Anker, M. E. Carroll, University of Minnesota, St Paul, MN
17 Effects of the combination of metyrapone and oxazepam on cue-induced reinstatement of
cocaine seeking
C. Keller1, M. Vaswani2,1, G. F. Guerin1, N. E. Goeders1, 1Louisiana State University Health
Sciences Center, Shreveport, LA, 2All India Institute of Medical Sciences, New Delhi, India
18 Protective effects of environmental enrichment on cocaine-seeking behavior during abstinence
K. J. Thiel, M. Painter, D. Hills, A. Crow, C. Cuhaciyan, F. Sanabria, N. S. Pentkowski,
J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ
19 Effectiveness of cocaine esterases against cardiovascular toxicity and lethality produced by
intravenous administration of cocaine in rats
M. C. Ko1,2, D. Narasimhan1, R. K. Sunahara1, J. H. Woods1, 1Pharmacology, University of
Michigan, Ann Arbor, MI, 2Psychology and Institute of Neuroscience, National Cheng Chi
University, Tapei City, Taiwan
20 D-cycloserine delays reacquisition of cocaine self-administration by augmenting consolidation
of extinction learning
B. A. Nic Dhonnchadha1, R. D. Spealman2, K. M. Kantak1, 1Psychology, Boston University,
Boston, MA, 2New England Primate Research Center, Harvard Medical School,
Southborough, MA
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21 A new broad-spectrum anti-methamphetamine monoclonal antibody reverses acute METH
effects in rats
W. B. Gentry1, S. M. Owens2, J. C. Frank3, E. M. Laurenzana2, 1Anesthesiology, Pharmacology
and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 2Pharmacology
and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 3College of
Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
COCAINE: HUMAN
22 Effects of modafinil on sleep architecture in chronic cocaine users
P. Morgan1, E. Pace-Schott2, R. Stickgold2, R. T. Malison1, 1Psychiatry, Yale University, New
Haven, CT, 2Psychiatry, Harvard University, Boston, MA
23 Valproate treatment enhances cue-induced cocaine craving
M. S. Reid, E. Weinstein, V. Thakkar, Psychiatry, New York University, New York, NY
24 Safety of oral aripiprazole alone and in combination with intravenous cocaine in humans
L. Middleton1, M. Lofwall1,2, P. A. Nuzzo1, S. L. Walsh1,2, 1Behavioral Science, Center on Drug
and Alcohol Research, University of Kentucky, Lexington, KY, 2Psychiatry, University of
Kentucky, Lexington, KY
25 The acetylcholinesterase inhibitor donepezil modifies cocaine-induced cardiovascular and
subjective effects
K. Grasing1,2, D. Mathur1, T. F. Newton3, C. DeSouza1, 1Substance Abuse Research Laboratory,
Kansas City VA Medical Center, Kansas City, MO, 2Clinical Pharmacology, University of
Kansas School of Medicine, Kansas City, KS, 3Psychiatry and Behavioral Science, Baylor
College of Medicine, Houston, TX
26 Female vs. male prolactin response to dynorphin A1-13 in normal volunteer and cocaine-
dependent subjects
G. Bart1,2, E. Ducat1, B. Ray1, J. Varon1, J. Cassin1, A. Ho1, M. Kreek1, 1The Laboratory of the
Biology of Addictive Diseases, The Rockefeller University, New York, NY, 2Medicine,
Hennepin County Medical Center, Minneapolis, MN
27 Employment-based abstinence reinforcement as a maintenance intervention for the treatment of
persistent cocaine use in methadone patients with 24-month follow-up
A. DeFulio, W. D. Donlin, C. J. Wong, K. Silverman, Johns Hopkins University School of
Medicine, Baltimore, MD
28 Consistency of self-reported drug use and urine drug screening for homeless men and women in
a cocaine dependence treatment program
M. Burns1, J. B. Milby1, D. Wallace2, J. E. Schumacher1, S. Mennemeyer1, R. E. Vuchinich1,
1University of Alabama at Birmingham, Birmingham, AL, 2RTI International, Raleigh, NC
29 Community reinforcement approach for cocaine dependence in a community setting: Individual-
vs. group-based intervention
R. Secades-Villa1, E. Sánchez-Hervás2, F. Zacarés Romaguera1, O. García-Rodríguez3,
F. J. Santonja Gómez4, G. García Fernandez1, 1Psychology, University of Oviedo, Oviedo,
Spain, 2Dept 10, Valencia State Health Agency, Valencia, Spain, 3Clinical Psychology,
University of Barcelona, Barcelona, Spain, 4Miguel Hernández University, Elche, Spain
ADOLESCENTS II
30 Does crack cocaine increase sexual desires? Perceptions of HIV-positive crack cocaine users
and gender differences
L. Metsch1, G. Cardenas1, E. Valverde3, C. Bell2, L. Gooden1, E. Scharf2, C. del Rio2,
A. Rodriguez1, 1University of Miami, Miami, FL, 2Emory University, Atlanta, GA, 3Centers for
Disease Control and Prevention, Atlanta, GA
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31 Developing science-based treatment for opioid-dependent youth: Lessons learned
S. K. Moore1,2, L. A. Marsch1,2, 1Center for Technology and Health, National Development and
Research Institutes, Inc., New York, NY, 2Behavioral Science Research, St. Luke’s-Roosevelt
Hospital, New York, NY
32 Temporal and probabilistic discounting in adolescent substance users and controls
S. K. Mikulich-Gilbertson1,2, L. L. Thompson1, T. J. Crowley1, 1Psychiatry, University of
Colorado Denver, Aurora, CO, 2Biometrics/Informatics, University of Colorado Denver,
Aurora, CO
33 Moderators of the relationship between risk-taking propensity, substance use, and other risk
behaviors in early adolescents
F. L. Wang1, L. MacPherson1, E. K. Reynolds1, N. Calvin1, S. Daughters1, J. Cassidy1,
L. Mayes2, C. W. Lejuez1, 1Psychology, University of Maryland, College Park, College
Park, MD, 2Child Study Center, Yale University School of Medicine, New Haven, CT
34 Substance-dependent antisocial boys: Brain processing of reward/loss
T. J. Crowley1, M. Dalwani1, S. K. Mikulich-Gilbertson1, Y. Du1, K. Raymond1, M. T. Banich1,2,
1University of Colorado Denver, Denver, CO, 2University of Colorado Boulder, Boulder, CO
35 Reward-seeking task performance: A validation study
D. C. Lee, G. Robbins, T. H. Kelly, Behavioral Science, University of Kentucky,
Lexington, KY
36 Amygdala volumes and craving in adolescent marijuana users
C. B. Padula1, T. McQueeny1, J. Price1, K. L. Medina1, S. F. Tapert2, 1University of Cincinnati,
Cincinnati, OH, 2University of California, San Diego, La Jolla, CA
37 Changes in HPA axis function and psychiatric symptoms in adolescent methamphetamine users
G. R. King1, D. Alicata2, C. Cloak1, I. Chin1, J. Spiess2, L. Chang1, 1Medicine, University of
Hawaii, Honolulu, HI, 2Psychiatry, University of Hawaii, Honolulu, HI
38 Attention-deficit/hyperactivity disorder and nicotine withdrawal symptoms among treatment-
seeking adolescent smokers
A. L. Lewis1, K. M. Gray1, M. J. Carpenter1, N. L. Baker1, E. M. Klintworth1, A. S. Leinbach1,
H. P. Upadhyaya1,2, 1Medical University of South Carolina, Charleston, SC, 2Eli Lilly &
Company, Indianapolis, IN
ALCOHOL
39 Kudzu extract treatment does not increase the intoxicating effects of alcohol in human volunteers
S. Lukas, R. R. MacLean, D. Lee, D. M. Penetar, Psychiatry, McLean Hospital/Harvard
Medical School, Belmont, MA
40 Zolmitriptan and its relationship to the aggression-heightening effects of alcohol
J. Gowin, S. D. Lane, F. G. Moeller, J. Steinberg, A. Swann, University of Texas Health
Science Center Houston, Houston, TX
41 Dopamine and serotonin transporter availability during acute alcohol withdrawal: Effects of
comorbid tobacco smoking
K. Cosgrove1,2, E. Frohlich1,2, S. Stiklus1,2, B. Pittman1, G. Tamagnan3, R. Baldwin1,2, F. Bois1,2,
J. Seibyl3, J. Krystal1,2, S. O’Malley1, J. Staley1,2, 1Psychiatry, Yale University School of
Medicine, New Haven, CT, 2VA Connecticut Healthcare System, West Haven, CT, 3Institute for
Neurodegenerative Disorders, New Haven, CT
42 Patterns of alcohol consumption among college football tailgaters
L. J. Merlo1,2, A. M. Stone2, A. Holtzman2, C. Klingman2, K. Alvarez2, R. Gilbertson2,
R. Prather2, A. Bibbey2, F. Kobeissy2, N. Graham2, M. S. Gold2, 1Psychiatry, Washington
University, St. Louis, MO, 2Psychiatry, University of Florida, Gainesville, FL
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43 Identifying poor prognosis patients in cocaine-alcohol dependence treatment trials
L. C. Sacerio, K. M. Kampman, K. Lynch, H. M. Pettinati, Psychiatry, University of
Pennsylvania, Philadelphia, PA
44 Alcohol and substance use in traffic accident victims of Porto Alegre, Brazil
R. De Boni1, D. Benzano1, G. Baldisserotto1, B. Holmer1, M. Soibelman1, S. Porto Jr2,
T. Sousa2, E. Correa2, F. Santos3, J. Goldim3, F. Pechansky1,3, 1Psychiatry, CPAD- Federal
University Rio Grande do Sul, Porto Alegre, Brazil, 2Economic Science, Federal University
Rio Grande do Sul, Porto Alegre, Brazil, 3Clinicas Hospital, Porto Alegre, Brazil
45 Pattern of alcohol use and associated factors: A cross-sectional study in a French emergency
room
R. Debrabant1, F. Serre1, M. Fatseas1,2, C. Denis1, P. Thoueilles2, B. Fleury1, M. Auriacombe1,2,
1Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2,
Bordeaux, France, 2Addiction Medicine, CHU de Bordeaux, Bordeaux, France
46 A study of substance abuse in the Asian Indian community in Ontario, Canada
M. Hussain1,2, A. Kaur2, 1Addiction Services, William Osler Health Centre, Brampton, ON,
Canada, 2South Asian Addiction Program, Punjabi Community Health Services,
Brampton, ON, Canada
47 Alcohol abuse and dependence criteria among students at two schools in Puerto Rico: A latent
class analysis
A. Hulbert, B. E. Mancha, S. Hedden, S. G. Severtson, W. W. Latimer, Mental Health, John
Hopkins Bloomberg School of Public Health, Baltimore, MD
48 Validation of triage criteria for deciding which apparently inebriated persons require emergency
department care
K. Flower1, J. Mendelson1, J. Sussman2, N. Tangherlini3, M. Pletcher2, 1Addiction
Pharmacology Research Lab, California Pacific Medical Center Research Institute, San
Francisco, CA, 2Epidemiology and Biostatistics, University of California, San Francisco, CA,
3San Francisco Fire Department/EMS, City and County of San Francisco, San Francisco, CA
49
50 Reduction of addiction severity in alcohol and drugs: A bivariate multilevel modeling approach
M. Hara1,2, Y. Huang1, Y. Hser1, 1Integrated Substance Abuse Programs, University of
California, Los Angeles, Los Angeles, CA, 2Graduate School of Education and Information
Studies, University of California, Los Angeles, Los Angeles, CA
EPIDEMIOLOGY II
51 The Mexican migration to the U.S. and substance use in Northern Mexico
G. Borges1, M. Medina-Mora1, R. Orozco1, C. Fleis1, C. Cherpitel2, J. Breslau3, 1Epidemiology,
Instituto Nacional de Psiquiatria, Mexico, Mexico, 2Alcohol Research Group, Emeryville, CA,
3Center for Reducing Health Disparities, University of California, Davis, School of Medicine,
Sacramento, CA
52 Substance use of French university students at exam periods: A cross-sectional survey in
Bordeaux
J. Alexandre1, M. Fatseas1, C. Denis1, E. Lavie1, B. Merle2, F. Touchard3, S. Maurice-Tison2,
M. Auriacombe1, 1Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen
Bordeaux 2, Bordeaux, France, 2INSERM U330, Universite Victor Segalen Bordeaux 2,
Bordeaux, France, 3Student Health Care Service, Universite Bordeaux 4, Bordeaux, France
53 Factors of drug abuse for Black and Caribbean emerging adults
B. Longmire-Avital, 1Public Health Solutions, New York, NY, 2National Development and
Research Institutes, Inc., New York, NY
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54 Irish travellers and drug use
M. A. Van Hout, Health, Waterford, Waterford, Ireland
55 South Asian women and domestic violence: Isolation, social support, help-seeking, and
addressing risks of co-occurrence of substance abuse among intimate partners
N. Mahapatra, School of Social Work, The University of Texas at Austin, Austin, TX
56 Back out there: Subject retrieval among recovering populations
N. J. Tiburcio, B. D. Johnson, National Development and Research Institutes, Inc., New
York, NY
57 Conditional odds of recent drug use disorders in relation to PTSD history: USA, 2004-5
K. M. Bohnert, N. Breslau, J. C. Anthony, Epidemiology, Michigan State University, East
Lansing, MI
58 Stigma feelings attached to drug dependence and depression vary as a function of medical
students’ own depression history
V. Cruz1,2, G. F. Alvarado1,3, D. Barondess1, M. Radovanovic1,4, J. C. Anthony1, 1Epidemiology,
Michigan State University, East Lansing, MI, 2Office of Epidemiology, Peruvian National
Institute of Mental Health, Lima, Peru, 3Cayetano Heredia Peruvian University, Lima, Peru,
4Psychiatric Clinic Rudnik, Ljubljana, Slovenia
59 Stigma attached to drug dependence and depression: Perceptions of future health professionals
B. K. Ahmedani1,4, S. P. Kubiak1, C. F. Rios-Bedoya2, M. A. Mickus3, J. C. Anthony4, 1School
of Social Work, Michigan State University, East Lansing, MI, 2Family Medicine, Michigan
State University, East Lansing, MI, 3Psychiatry, Michigan State University, East Lansing, MI,
4Epidemiology, Michigan State University, East Lansing, MI
60 Ethnicity and recent-onset tobacco smoking: Epidemiological evidence, 2004-06
D. A. Barondess, M. Radovanovic, J. C. Anthony, Epidemiology, Michigan State University,
College of Human Medicine, East Lansing, MI
61 Race and gender trends of CPDD members and meeting attendees
G. Widner, R. K. Price, Psychiatry, Washington University School of Medicine, St. Louis, MO
CRIMINAL JUSTICE
62 The impact of the Inmate Pre-Release Assessment on rural inmate’s 12-step attendance and
treatment entry
C. B. Oser, J. Havens, K. Harp, M. Staton-Tindall, H. Knudsen, J. Mooney, J. Duvall,
C. Leukefeld, University of Kentucky, Lexington, KY
63 Examining the relationship between risk of criminal recidivism and substance use and treatment
history in a sample of probationers
A. J. Trotman1, M. E. Wilson2, F. S. Taxman1, 1Administration of Justice, George Mason
University, Manassas, VA, 2Friends Research Institute, Baltimore, MD
64 Gender differences in criminal rationalization among prison-based substance abuse treatment
participants nearing community re-entry
J. Mooney, C. Oser, C. Leukefeld, Center on Drug and Alcohol Research, University of
Kentucky, Lexington, KY
65 Strengths-based case management for drug-abusing parolees: Outcomes at three and nine
months using two causal models
M. Prendergast1, J. Sacks2, L. Frisman3, M. Staton-Tindall4, L. Greenwell1, H. Lin3, 1University
of California Los Angeles Integrated Substance Abuse Programs, Los Angeles, CA, 2National
Development and Research Institutes, New York, NY, 3Connecticut Department of Mental
Health and Addiction Services, Hartford, CT, 4University of Kentucky, Lexington, KY
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66 Predictors of risky sexual behavior in incarcerated drug users in Sri Lanka
A. Stadlin1, L. O. Dissabandara1, S. Dias2, H. Gamini3, N. J. Loxton4, 1School of Medical
Science, Griffith University, Southport, QLD, Australia, 2Psychiatry, University of Perideniya,
Kandy, Sri Lanka, 3Faculty of Medicine, University of Perideniya, Kandy, Sri Lanka,
4Psychology, University of Queensland, Brisbane, QLD, Australia
67 Deconstructing HIV interventions among female offenders
C. O’Leary, L. B. Cottler, Psychiatry, Washington University School of Medicine, St.
Louis, MO
68 HIV risk behaviors: Results from a randomized study of methadone maintenance for prisoners
M. E. Wilson1, T. W. Kinlock1, R. P. Schwartz1, M. S. Gordon1, K. E. O’Grady2, 1Friends
Research Institute, Baltimore, MD, 2University of Maryland College Park, College Park, MD
69 Cost offset analysis of an enhanced HIV intervention for rural probationers
J. L. Duvall, C. Oser, C. Leukefeld, University of Kentucky, Lexington, KY
DIAGNOSIS AND ASSESSMENT
70 The Addiction Potential Scale: A validation study
E. R. Grekin1, S. J. Ondersma2, D. S. Svikis3, P. K. Lam2, V. M. Connors2, 1Psychology, Wayne
State University, Detroit, MI, 2Psychiatry and Behavioral Neuroscience, Wayne State
University, Detroit, MI, 3Psychology, Virginia Commonwealth University, Richmond, VA
71 Development of an indirect screener for perinatal drug use (Wayne Indirect Drug Use Screener)
S. J. Ondersma1, D. S. Svikis2, P. K. Lam1, V. M. Connors1, E. R. Grekin3, 1Psychiatry and
Behavioral Neuroscience, Wayne State University, Detroit, MI, 2Psychology, Virginia
Commonwealth University, Richmond, VA, 3Psychology, Wayne State University, Detroit, MI
72 Reliability and validity of the Short Inventory of Problems modified for drug use
R. Saitz1, D. Allensworth-Davies2, D. M. Cheng2,1, P. C. Smith1, J. H. Samet1, 1Boston
University School of Medicine/Boston Medical Center, Boston, MA, 2Boston University
School of Public Health, Boston, MA
73 Effect size, time and dose-response profiles of drugs of abuse in human abuse potential studies
D. Milovan1, K. A. Schoedel1, M. K. Romach1, E. M. Sellers1,2, 1Kendle Early Stage,
Toronto, ON, Canada, 2Pharmacology, Psychiatry, and Medicine, University of Toronto,
Toronto, ON, Canada
74 Identifying prescription drug disorder in primary care chronic pain patients prescribed opioids:
Diagnostic characteristics of the Current Opioid Misuse Measure
E. C. Meltzer, D. Rybin, R. Saitz, J. H. Samet, S. Schwartz, S. Butler, J. Liebschutz, Section of
General Internal Medicine, Boston University Medical Center, Boston, MA
75 Validation of the clinical opiate withdrawal scale
D. A. Tompkins1, J. A. Harrison1, G. E. Bigelow1, R. E. Johnson2, P. J. Fudala2, L. J. Felch1,
E. C. Strain1, 1Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD,
2Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA
76 Inter-rater reliability and validity of DSM-IV opioid dependence in a Hmong isolate using the
Semi-Structured Assessment for Drug Dependence and Alcoholism Thai version
R. T. Malison1, R. Kalayasiri4, K. Sanichwankul6, A. Sughondhabirom4, A. Mutirangura5,
B. Pittman1, R. Gueorguieva1,3, H. Kranzler7, J. Gelernter1,2, 1Psychiatry, Yale School of
Medicine, New Haven, CT, 2Genetics, and Neurobiology, Yale School of Medicine, New
Haven, CT, 3Yale School of Public Health, New Haven, CT, 4Psychiatry, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand, 5Anatomy, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand, 6Suan Prung Psychiatric Hospital, Chiang Mai, Thailand,
7Psychiatry, University of Connecticut School of Medicine, Farmington, CT
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77 Substance dependence criteria (DSM-IV) in daily cannabis users
L. A. Maciel, A. R. Noto, Psicobiologia, UNIFESP-EPM, São Paulo, Brazil
78 Assessment of nicotine dependence among adolescent smokers: A comparison of measures
M. J. Carpenter1, N. L. Baker1, K. M. Gray1, A. L. Lewis1, E. Klintworth1, A. Leinbach1,
H. P. Upadhyaya1,2, 1Medical University of South Carolina, Charleston, SC, 2Eli Lilly &
Company, Indianapolis, IN
79 Validation of Comprehensive Health Assessment Tool: An interactive, multimedia scale to assess
alcohol and substance addiction severity among adolescents
K. J. Trudeau1, S. Lord1,2, R. A. Black1, L. Lorin1, B. Cooney1, A. Villapiano1, S. F. Butler1,
1Inflexxion, Inc., Newton, MA, 2National Development and Research Institutes, New York, NY
80 Utility of various screening instruments for attention-deficit hyperactivity disorder in research
participants seeking treatment for cocaine dependence
A. L. Mahony1,2, S. S. Berhane1,2, D. J. Brooks1,2, J. J. Mariani1,2, F. R. Levin1,2, 1New York State
Psychiatric Institute, New York, NY, 2Columbia University, New York, NY
81 Crossvalidation and integration of four mental health screeners using item response theory
B. Riley1, B. R. Rush2,4, S. Castel3,4, B. Brands5,4, S. Velduizen2, M. Dennis1, 1Chestnut Health
Systems, Normal, IL, 2Centre for Addiction and Mental Health, Toronto, ON, Canada,
3Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 4University of Toronto,
Toronto, ON, Canada, 5Health Canada, Ottawa, ON, Canada
82 Impact of recent drug use on the validation of screening tools for mental disorders
B. R. Rush1,4, S. Castel2,4, B. Brands3, S. Velduizen1, 1Centre for Addiction and Mental Health,
Toronto, ON, Canada, 2Sunnybrook Health Sciences, Toronto, ON, Canada, 3Health Canada,
Toronto, ON, Canada, 4Psychiatry, University of Toronto, Toronto, ON, Canada
THEORETICAL
83 Mathematical model of effects of first-order schedules on drug self-administration
V. L. Tsibulsky, A. B. Norman, Psychiatry, University of Cincinnati, Cincinnati, OH
84 Assessment of effort on neuropsychological testing in drug abuse research
A. M. Horton, Neuropsychology Section, Psych Associates, Bethesda, MD
85 A potential method for examining the stimulus properties of drugs under conditions comparable
to those used with exteroceptive stimuli
G. M. Sizemore, D. Morgan, Psychiatry, University of Florida, Gainesville, FL
86 An in vitro pharmacological model of maintained agonist self-administration
A. B. Norman, M. K. Norman, V. L. Tsibulsky, Psychiatry, University of Cincinnati,
Cincinnati, OH
87 Development of cognitive behavioral therapy platform targeting both cocaine dependence and
ADHD
D. V. Herin1, N. J. Moukaddam2, J. M. Schmitz2, P. M. McCleary2, D. V. Rinker2, C. Malcolm2,
F. R. Levin3, J. Grabowski1, 1Psychiatry, University of Minnesota, Minneapolis, MN,
2Psychiatry, University of Texas Health Science Center Houston, Houston, TX, 3Psychiatry,
Columbia University, New York, NY
88 Cocaine and well-being: Entries, exits
P. Pharo1, B. Badin de Montjoye2, P. Podevin3, 1CNRS - Université Paris Descartes, Paris,
France, 2Hôpital Cochin, Paris, France, 3Centre Hospitalier Léon Binet, Provins, France
89 Methamphetamine use: Does it increase violent sexual activity in women?
N. E. Goeders1, A. B. Hamilton2, 1Pharmacology, Toxicology and Neuroscience, Louisiana
State University Health Sciences Center, Shreveport, LA, 2Psychiatry, University of California
Los Angeles, Los Angeles, CA
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90 Use of an adaptive treatment research design in a CTN study of prescription opioid dependence
treatment
R. D. Weiss1, J. Potter1, M. Byrne2, C. Sullivan2, W. Ling3, 1McLean Hospital, Belmont, MA,
2West Virginia University School of Medicine, Morgantown, WV, 3University of California Los
Angeles School of Medicine, Los Angeles, CA
91 Participation in substance abuse clinical trials: Comparing gender and racial/ethnic groups
C. L. Rosa, P. G. Wakim, CCTN, NIDA, Bethesda, MD
92 Cross-country variations in illegal drug involvement and DSM-IV clinical features of drug abuse
in the Americas
F. A. Fiestas1, M. Radovanovic1, M. E. Medina-Mora2, J. Posada-Villa3,4, J. C. Anthony1,
1Epidemiology, Michigan State University, East Lansing, MI, 2Institute of Psychiatry, Mexico
DF, Mexico, 3Colegio Mayor de Cundinamarca University, Bogota, Colombia, 4The Social
Protection Ministry, Bogota, Colombia
93 Assessment of addictive behavior among the elderly: What about “geriatric addiction”?
M. Fatseas, R. Icick, M. Auriacombe, Addiction Psychiatry EA4139/INSERM-IFR99,
Universite Victor Segalen Bordeaux 2, Bordeaux, France
94 Drug court and treatment: An ethnographic exploration
K. Kaye, 1Social and Cultural Analysis, New York University, New York, NY, 2Behavioral
Sciences Training in Drug Abuse Research, Public Health Solutions, New York City, NY
95 Legalization of marijuana use in México
A. Gutierrez-Padilla2,1, O. Campollo1,3, 1Center of Studies on Alcohol and Addictions,
University of Guadalajara, Guadalajara, Mexico, 2Unidad de Cuidados Intensivos Neonatales,
Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico, 3Clínica para Dejar de Fumar,
Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
96 Re-entry strategies for California ex-offenders
W. Tsai1, D. Watson1, E. Williams2, 1University of California Los Angeles/Friends Research
Institute, Torrance, CA, 2Regional Congregations Neighborhood Organizations, Los
Angeles, CA
97 Methods for assessing the cumulative treatment effect on subsequent drug use abstinence
L. Li, E. Evans, Y. Hser, University of California Los Angeles Integrated Substance Abuse
Programs, Los Angeles, CA
98 Measuring the impact of change: Developing statewide Process Improvement Performance
Measurement systems
J. H. Ford1, A. Quanbeck1, C. Kraeff2, M. Stathum3, T. Molfenter1, 1University of Wisconsin -
Madison, Madison, WI, 2South Carolina Department of Alcohol and Other Drug Abuse
Services, Columbia, SC, 3Oklahoma Department of Mental Health and Substance Abuse
Services, Oklahoma City, OK
99 The power of eliciting consumer input to design effective treatment systems
L. Madden1, A. Quanbeck2, S. O. Farnum2, J. H. Ford2, S. Ball1, 1APT Foundation and Yale
University, New Haven, CT, 2University of Wisconsin, Madison, WI
100 Times, Organizations, Offices, Lives and Systems Evolution Project
M. Neely2, C. Branch2, D. Watson1, W. Tsai1, D. Osborne2, 1University of California Los
Angeles/Friends Research Institute, Torrance, CA, 2Los Angeles Metropolitan Churches, Los
Angeles, CA
Thursday, June 25, 2009
76
PROGRAM DESCRIPTION
101 WITHDRAWN
102 Los Angeles Youth Collaborative for substance use and violence prevention among gang-exposed
youth
C. Branch2, D. Osborne2, C. Jones2, T. Mcfollins2, D. W. Watson1, M. Mouttapa3, W. Tsai1,
A. Asghar3, 1University of California Los Angeles/Friends Research Institute, Torrance, CA,
2Los Angeles Metropolitan Churches, Los Angeles, CA, 3California State University at
Fullerton, Fullerton, CA
103 Supporting Opportunities for Adolescent Recovery
H. Hatanaka1, H. Levy1, C. Wright1, J. Schott1, D. Malak-Lopez1, F. McKinney1, L. Cosio1,
D. Montenegro1, E. Vasquez1, D. Watson2, M. Mouttapa3, W. Tsai2, 1Special Service for
Groups/Homeless Outreach Program Family Center, Los Angeles, CA, 2University of
California Los Angeles Integrated Substance Abuse Programs/Friends Research Institute,
Torrance, CA, 3California State University at Fullerton, Fullerton, CA
104 Group Reality Therapy: Is it an effective tool in working with opioid-dependent young adults in
methadone maintenance treatment?
M. Lawental Schori1, E. Lawental2,3, L. Altus2, M. Gur2, 1School of Social Policy and Practice,
University of Pennsylvania, Philadelphia, PA, 2Haifa Drug Abuse Treatment Center, Haifa,
Israel, 3School of Social Work, Tel Hai Academic College, Upper Galilee, Israel
105 Patterns of buprenorphine dose reduction in opioid-dependent patients
J. Manubay1,2, S. K. Vosburg1,2, E. Yango1, H. D. Kleber1,2, 1Psychiatry, Columbia University,
New York, NY, 2Substance Abuse, New York State Psychiatric Institute, New York, NY
106 NIDA’s Clinical Trials Network delivers evidence-based treatments through comparative
effectiveness research
S. Sparenborg, U. Ghitza, B. Tai, Center for the Clinical Trials Network, National Institute on
Drug Abuse, Rockville, MD
107 A clinical trial comparison of two formulations of depot buprenorphine for pain
W. Ling, M. Hillhouse, J. Jenkins, K. Miotto, L. Mooney, M. Torrington, S. Reed, L. McGraw,
D. Chim, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
108 Clinical guidelines for the management of cannabis use disorder
A. Frewen, J. Copeland, National Cannabis Prevention and Information Centre, University of
NSW, Sydney, NSW, Australia
109 Assessment of a process improvement initiative in substance abuse treatment settings
A. M. Williams, R. Springer, T. G. Durham, The Danya Institute, Inc., Silver Spring, MD
110 Building momentum for improving client engagement and retention in treatment: The California
experience
B. A. Rutkowski1, S. Gallon2, R. A. Rawson1, T. E. Freese1, A. Bruehl3, D. Crevecoeur-
MacPhail1, W. Sugita3, K. Johnson4, T. Molfenter4, F. Cotter5, 1Integrated Substance Abuse
Programs, University of California, Los Angeles, Los Angeles, CA, 2Oregon Health and
Science University, Portland, OR, 3Alcohol and Drug Program Administration, County of Los
Angeles Department of Public Health, Alhambra, CA, 4University of Wisconsin-Madison,
Madison, WI, 5SAMHSA/CSAT, Rockville, MD
111 Assessing addiction treatment information systems in Maryland: Gaps and redundancies
P. Sheikhattari, T. Rice, F. A. Wagner, Center for Health Disparity Solutions, Morgan State
University, Baltimore, MD
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112 Implementation of an electronic information system to enhance practice at an opioid treatment
program
M. Chu, S. A. Kritz, C. John-Hull, B. Louie, C. Madray, L. S. Brown, Medical Services,
Research and Information Technology, Addiction Research and Treatment Corporation,
Brooklyn, NY
113 Can opiate pharmacotherapy improve virological response to anti-hepatitis C treatment in
former drug abusers (Injecting Drug Users)? Case report about 3 ex-IDU
L. Gourarier1, J. Jungman1, A. Gervais2, J. L. Boujenah3, S. Pol4, 1CASAT, La Terrasse /
Maison Blanche, Paris, France, 2Maladies Infectieuses & Tropicales, Bichat/APHP, Paris,
France, 3Hépatologie, Pitié-Salpétrière/APHP, Paris, France, 4Hépatologie, Cochin/APHP,
Paris, France
114 A brief culturally sensitive HIV and hepatitis prevention intervention for urban American
Indians: Development and preliminary evaluation
D. Caldwell1, J. Johnson1, J. Gryczynski1, K. Lessard2, S. Wiechelt3, S. Roth4, 1Social Research
Center, Friends Research Institute, Baltimore, MD, 2Chase Brexton Health Services,
Baltimore, MD, 3Social Work, University of Maryland, Baltimore County, Baltimore, MD,
4LifeLines Foundation, Baltimore, MD
115 Using respondent-driven sampling to enhance recruitment of dually diagnosed adolescent
clinical trial participants
B. W. Holmes1, K. Pressley1, L. Haynes2, C. Tyson2, P. Riggs, MD3, 1NIDA Clinical Trials
Network, Lexington Richland Alcohol and Drug Abuse Council, Columbia, SC, 2Psychiatry
and Behavioral Sciences, Medical University of South Carolina, Columbia, SC, 3Health
Sciences Center, University of Colorado, Denver, CO
116 Disseminating evidence-based practices for treating co-occurring disorders in children and their
caregivers
T. E. Freese, S. Larkins, R. Rawson, J. Peck, Integrated Substance Abuse Programs, University
of California, Los Angeles, Los Angeles, CA
117 Using Web-based technology to enhance practical applications: Increasing access to problem
gambling resources
J. W. Hays, J. E. Norland, S. J. Asteriadis, J. A. Hartje, N. A. Roget, Center for the Application
of Substance Abuse Technologies, University of Nevada, Reno, Reno, NV
118 WITHDRAWN
119 Gender and the global drug trade: The case of incarcerated women in Lima, Peru
S. Campos, NDRI/Public Health Solutions, New York City, NY
120 Gender differences in employment and employment barriers among drug abusers
M. Webster1,2, M. Staton-Tindall3,2, M. Dickson1,2, C. Leukefeld1,2, J. Wilson1, 1Behavioral
Science, University of Kentucky, Lexington, KY, 2Center on Drug and Alcohol Research,
University of Kentucky, Lexington, KY, 3Social Work, University of Kentucky, Lexington, KY
121 Workforce development for faith-based substance abuse treatment providers
D. W. Watson1, B. Finnerty1, C. Branch2, T. Freese1, R. Rawson1, W. Tsai1, 1University of
California Los Angeles Integrated Substance Abuse Programs, Torrance, CA, 2Los Angeles
Metropolitan Churches, Los Angeles, CA
122 Research opportunities in NIDA’s Division of Epidemiology, Services and Prevention Research
W. Compton, K. P. Conway, Division of Epidemiology, Services and Prevention Research,
National Institute on Drug Abuse, Bethesda, MD
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123 How useful is what we have? Limitations of Cochrane reviews, the case of substance treatment
in pregnancy
M. Terplan1, E. J. Smith1, S. Lui2, 1Obstetrics and Gynecology, University of Chicago,
Chicago, IL, 2Human and Health Sciences, University of Huddersfield, Queensgate, United
Kingdom
124 Systematic review of computer-based treatments for drug abuse and dependence
B. A. Moore1, B. Garnet2, C. Cutter1, D. Barry1, 1Psychiatry, Yale University, New Haven, CT,
2APT Foundation, New Haven, CT
125 The interaction between opioids and alcohol: Results from a global literature review
B. Setnik1, R. Colucci2, C. Mannino1, S. Siegel1, L. Wase1, 1King Pharmaceuticals®, Inc.,
Bridgewater, NJ, 2Colucci & Associates, LLC, Newtown, CT
126 HIV prevention in problem-solving courts: A review
J. L. Sorensen, M. Chartier, S. E. Larios, J. Dilley, D. McNiel, C. Masson, J. Guydish,
S. Fordwood, Psychiatry, University of California, San Francisco, CA
127 A systematic review of gender differences in HIV sexual risk behaviors among stimulant and
opioid abusers
J. S. Potter1,2,3, C. S. Meade2,3, A. T. Peterson2, 1University of Texas Health Science Center, San
Antonio, TX, 2McLean Hospital, Belmont, MA, 3Harvard Medical School, Boston, MA
128 Methamphetamine use and sexual HIV risk behavior in Cape Town, South Africa: A review of
data from 8 studies (2004-2007)
C. D. Parry1, A. Pluddemann1, B. J. Myers-Franchi1, W. M. Wechsberg2, A. J. Flisher3, 1Alcohol
and Drug Abuse Research Unit, Medical Research Council, Cape Town, South Africa,
2Substance Abuse Treatment Evaluations and Interventions Research, RTI International,
Research Triangle Park, NC, 3Psychiatry and Mental Health, University of Cape Town, Cape
Town, South Africa
129 What is best practice in the treatment of co-occurring substance use and post traumatic stress
disorder?
K. L. Mills, National Drug and Alcohol Research Centre, University of New South Wales,
Sydney, NSW, Australia
Symposium XV Rose Ballroom A
10:00 AM - 12:00 PM
FROM TRIALS TO PRACTICE: THE IMPLICATIONS OF 
INCLUSION AND EXCLUSION CRITERIA IN CLINICAL 
TRIALS OF PHARMACOTHERAPIES TO TREAT 
DRUG DEPENDENCE
Chairs: Howard Chilcoat and Anne Andorn
10:00 Generalizability of clinical trials for alcohol dependence to community samples
Carlos Blanco, New York State Psychiatric Institute/College of Physicians and Surgeons of
Columbia University, New York, NY
10:25 Generalizing from laboratory and clinical studies of nicotine dependence pharmacotherapies
Caryn Lerman, Transdisciplinary Tobacco Use Research Center, University of Pennsylvania,
Philadelphia, PA
10:50 Using epidemiologic data on natural history of drug dependence to evaluate necessity of clinical
trial exclusion/inclusion criteria
Howard Chilcoat, Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC
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11:15 Impact of inclusion and exclusion criteria on clinical trials of drug abuse pharmacotherapies
Ivan Montoya, National Institute on Drug Abuse/National Institutes of Health, Bethesda, MD
11:40 Discussant
Frank Vocci, Friends Research Institute, Baltimore, MD
Oral Communications 18 Ponderosa B
10:00 AM - 12:00 PM
PULLING THE LEVER FOR STIMULANTS: BEHAVIORAL STUDIES
Chairs: Deanne Buffalari and Francesco Leri
10:00 Effect of modafinil on stress-induced cocaine seeking and cocaine cross-sensitization in
laboratory rats
F. Leri1, Y. Zhou2, M. J. Kreek2, D. Jacklin1, 1Psychology, University of Guelph, Guelph, ON,
Canada, 2Rockefeller University, New York, NY
10:15 Methylphenidate as an intravenous reinforcer in rats: Individual differences in impulsivity
predict self-administration
J. A. Marusich, M. T. Bardo, University of Kentucky, Lexington, KY
10:30 Reinstatement of nicotine-seeking behavior in rats: Effects of nicotine cues, priming, stress, and
their combination
X. Liu, Psychiatry and Human Behavior, University of Mississippi Medical Center,
Jackson, MS
10:45 Role of inhibitory neurosteroids in reducing cocaine self-administration and cue-induced
reinstatement
C. D. Schmoutz1, S. P. Runyon2, N. E. Goeders1, 1Pharmacology, Toxicology, and
Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, 2Organic
and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
11:00 A novel cue reinstates extinguished cocaine-seeking behavior
P. R. Kufahl, K. Heintzelman, C. Vargas, M. Painter, V. Routt, K. J. Thiel, J. L. Neisewander,
Psychology, Arizona State University, Tempe, AZ
11:15 Stress and cue interaction in the reinstatement of cocaine-seeking in female rats
D. Buffalari, M. W. Feltenstein, R. E. See, Neuroscience, Medical University of South
Carolina, Charleston, SC
11:30 Effects of extended access and withdrawal on the reinforcing strength of cocaine using a cocaine
vs. food concurrent-choice procedure in rhesus monkeys
M. Banks1, S. Negus1,2, 1Pharmacology and Toxicology, Virginia Commonwealth University,
Richmond, VA, 2Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical
School, Belmont, MA
11:45 D-Cycloserine attenuates reactivity to smoking cues in nicotine-dependent smokers
E. Santa Ana, B. Rounsaville, T. Frankforter, C. Nich, T. Babuscio, J. Poling, K. Gonsai,
K. Hill, K. Carroll, Psychiatry, Yale University School of Medicine and VA CT Healthcare
System, New Haven, CT
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Oral Communications 19 Bonanza
10:00 AM - 12:00 PM
IMPULSIVITY AND AGGRESSION
Chairs: Joseph T. Sakai and Staci Gruber
10:00 Structural brain differences between male adolescent patients with serious substance and
conduct problems and controls: Comparing two automated analytic methods and examining
cortical thickness
J. T. Sakai1, M. Dalwani1, S. K. Mikulich-Gilbertson1, J. Tanabe1, K. Raymond1,
S. McWilliams1, L. Thompson1, M. Banich2, T. J. Crowley1, 1University of Colorado Denver
School of Medicine, Aurora, CO, 2Institute of Cognitive Science, University of Colorado
Boulder, Boulder, CO
10:15 fMRI brain activation during a delay discounting task in HIV-positive adults with cocaine
dependence
C. S. Meade1,2, S. B. Lowen2, R. R. MacLean2, S. E. Lukas2, 1Psychiatry and Behavioral
Sciences, Duke University, Durham, NC, 2Psychiatry, Harvard Medical School, Belmont, MA
10:30 Neural correlates of aggressive responding in alcohol-dependent and control subjects
S. D. Lane1, J. L. Steinberg1, N. Rathnayaka1, D. R. Cherek1, L. A. Kramer2, P. A. Narayana2,
F. G. Moeller1, 1Psychiatry and Behavioral Sciences, University of Texas Health Science
Center, Houston, Houston, TX, 2Diagnostic and Interventional Imaging, University of Texas
Health Science Center, Houston, Houston, TX
10:45 Impulsivity is correlated with white matter alterations in chronic marijuana smokers
S. Gruber1, M. Silveri1, M. Dahlgren1, D. Yurgelun-Todd2, 1Neuroimaging Center/Psychiatry,
McLean Hospital/Harvard Medical School, Belmont, MA, 2Brain Institute, University of Utah,
Salt Lake City, UT
11:00 Temporal discounting and procrastination as predictors in a laboratory model of smoking
abstinence
R. Yi, A. E. Carter, Center for Addiction Research, University of Arkansas for Medical
Sciences, Little Rock, AR
11:15 Negative affect interacts with impulsivity to predict distress tolerance in a sample of inner-city
substance users
J. M. Richards, C. W. Lejuez, S. B. Daughters, E. Reynolds, M. Bornovalova, Clinical
Psychology, University of Maryland, College Park, College Park, MD
11:30 Substance use and aggression in the adolescent offspring of teenage mothers
N. M. De Genna, M. Cornelius, Psychiatry, University of Pittsburgh, Pittsburgh, PA
11:45 Differences in D2 receptor availability in high and low impulsive monkeys
S. Groman1, B. Lee2, R. Rivera1, E. London2, D. Jentsch1,2, 1Psychology, University of
California, Los Angeles, Los Angeles, CA, 2Psychiatry and Biobehavioral Sciences, University
of California, Los Angeles, CA
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BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium XVI Rose Ballroom B
10:00 - 11:00 AM
PRECLINICAL RESEARCH ON STRESS AND ADDICTION
Chairs: John R. Mantsch and Klaus A. Miczek
10:00 The vicious cycle of stress and drug use: Glucocorticoid-dependent plasticity and CRF systems
in cocaine addiction
John R. Mantsch, Marquette University, Milwaukee, WI
10:20 Episodic and continous social stress: Divergent changes in cocaine reward and tegmental BDNF
Klaus A. Miczek, Tufts University, Medford, MA
10:40 Pro-addictive actions of dynorphin opioids
Charles Chavkin, University of Washington, Seattle, WA
Symposium XVII Rose Ballroom B
11:15 AM - 12:15 PM
COCAINE COCKTAILS: THE IMPACT OF CONCURRENT DRUG
USE ON TREATMENT OF COCAINE
Chairs: Joy Schmitz and Alison Oliveto
11:15 Comorbid opioid dependence status and treatment response to medications for cocaine
dependence: The example of disulfiram
Alison Oliveto, UAMS, Llittle Rock, AR
11:35 Challenges in evaluating novel treatments for combined cocaine and alcohol
Kyle M. Kampman, University of Pennsylvania, Philadelphia, PA
11:55 The influence of concurrent marijuana use on treatment of cocaine dependence
Joy Schmitz, University of Texas Medical School-Houston, Houston, TX
BRUNCH WITH CHAMPIONS Poolside Terrace
(Pre-Registrants Only) 12:00 - 1:30 PM
Symposium XVIII Rose Ballroom A
1:30 - 3:30 PM
NICOTINIC CHOLINERGIC MECHANISMS IN DRUG
DEPENDENCE: RECEPTOR SUBTYPES AND LIGANDS
Chairs: William A. Corrigall and David Shurtleff
1:30 Presynaptic nAChR subtypes that modulate dopamine release; possibilities for selective
activation of α6β2*nAChRs
Sharon Grady, University of Colorado, Boulder, Boulder, CO
1:55 The role of accessory subunits in modifying the function of alpha4beta2 receptors
Jon Lindstrom, University of Pennsylvania, Philadelphia, PA
2:20 Modulation of nicotine receptor functional tone by therapeutic agents and endogenous factors
Roger Papke, University of Florida, Gainesville, FL
2:45 The alpha5 nAChR subunit in nicotine dependence and cancer risk
Thorgeir Thorgeirsson, deCode, Reykjavik, Iceland
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3:10 Drug discovery efforts in the nicotine receptor field
Murali Gopalakrishnan, Abbott Laboratories, Abbott Park, IL
Oral Communications 20 Rose Ballroom B
1:30 - 3:30 PM
KEEPING THE FOCUS ON ADHD
Chairs: Scott Kollins and Lisa J. Merlo
1:30 A double-blind, placebo-controlled trial of osmotic-release methylphenidate in initiating and
maintaining abstinence in smokers with attention deficit hyperactivity disorder
T. Winhusen1, E. Somoza1, G. Brigham1, D. Liu2, C. Green3, L. Covey4, I. Croghan5, L. Adler6,
R. Weiss7, J. Leimberger8, D. Lewis1, E. Dorer1, 1Psychiatry, University of Cincinnati,
Cincinnati, OH, 2National Institute on Drug Abuse, Bethesda, MD, 3Kaiser Permanente
Northwest, Portland, OR, 4New York State Psychiatric Institute, New York, NY, 5Mayo Clinic,
Rochester, MN, 6New York University, New York, NY, 7Harvard University, Belmont, MA,
8Cancer Research Institute, Duke University, Durham, NC
1:45 Prospective study of ADHD and risk for drug abuse
K. Winters1,2, G. August1, G. Realmuto1, 1Psychiatry, University of Minnesota,
Minneapolis, MN, 2Treatment Research Institute, Philadelphia, PA
2:00 Prospective examination of the association of stimulant medication history and drug use
outcomes in ADHD youth
G. August, K. Winters, C. Realmuto, Psychiatry, University of Minnesota, Minneapolis, MN
2:15 Adolescent methylphenidate treatment augments later vulnerability to cocaine addiction in rats
with an ADHD phenotype
R. C. Harvey, K. M. Kantak, Psychology, Boston University, Boston, MA
2:30 Contingency management for smoking cessation in adults with and without Attention Deficit
Hyperactivity Disorder
S. Kollins, F. J. McClernon, E. VanVoorhees, J. S. English, M. Hallyburton, A. Holdaway,
Duke University Medical Center, Durham, NC
2:45 Sex effects on nicotine withdrawal in smokers with and without ADHD
E. E. Van Voorhees, S. Kollins, F. J. McClernon, J. E. Rose, Duke University Medical Center,
Durham, NC
3:00 Attitudes of college students toward use and misuse of psychiatric medications
A. M. Stone1, L. J. Merlo2,1, 1Psychiatry, University of Florida, Gainesville, FL, 2Psychiatry,
Washington University, St. Louis, MO
Oral Communications 21 Ponderosa B
1:30 - 3:30 PM
DOUBLE DOWN WITH MOM AND BABY:
DRUGS OF ABUSE IN PREGNANCY
Chairs: Loretta Finnegan and Susan Stine
1:30 Using community-based participatory research techniques to screen for substance abuse in low-
income pregnant women receiving WIC services
L. Keyser-Marcus, M. Welch, R. Singleton, D. Svikis, Psychology, Virginia Commonwealth
University, Richmond, VA
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1:45 Characteristics associated with cocaine use in pregnant opioid-dependent women: Preliminary
results from the Maternal Opioid Treatment, Human Experimental Research study
S. Stine1, A. Arria2, K. O’Grady2, K. Kaltenbach3, G. Fischer4, P. Martin5, S. Heil6, M. Coyle7,
P. Selby8, H. Jones2, 1Psychiatry and Behavioral Neurosciences, Wayne State University
School of Medicine, Detroit, MI, 2Johns Hopkins U, Baltimore, MD, 3Thomas Jefferson U,
Philadelphia, PA, 4Medical U Vienna, Vienna, Austria, 5Vanderbilt U, Nashville, TN, 6U of
Vermont, Burlington, VT, 7Brown U, Providence, RI, 8U of Toronto, Toronto, ON, Canada
2:00 Telling the whole truth and nothing but the truth: Relationship between self-report measures of
drug use and urine/hair assay results in post-partum women
C. Smith1, S. Ondersma2, P. Lam2, V. Conners2, D. Svikis1, 1Psychology, VCU, Richmond, VA,
2Psychiatry, Wayne State, Detroit, MI
2:15 Cigarette smoking and its treatment in pregnant, polysubstance-dependent women: Knowledge,
attitudes and practice of patients and staff
M. Chisolm, E. C. Pfeil, M. Tuten, E. C. Strain, H. E. Jones, Johns Hopkins University School
of Medicine, Baltimore, MD
2:30 Delivery and neonatal outcomes of methadone-maintained pregnant patients with and without a
current mood disorder
M. Tuten1, H. Jones1, K. O’Grady2, H. Fitzsimons1, S. Heil3, M. Chisolm1, 1Johns Hopkins
University, Baltimore, MD, 2University of Maryland, College Park, College Park, MD,
3University of Vermont, Burlington, VT
2:45 Neonatal isolation alters mother-pup interactions
T. A. Kosten1, P. Kehoe2, 1Psychiatry, Baylor College of Medicine, Houston, TX, 2University of
California School of Nursing, Los Angeles, CA
3:00 Smoking cessation and breastfeeding
T. M. Higgins1, S. T. Higgins2, S. H. Heil2, G. J. Badger2, 1Bates College, Lewiston, ME,
2University of Vermont, Burlington, VT
3:15 Abnormal brain metabolite levels in children with prenatal nicotine exposure
L. Chang, C. Cloak, L. Anderson, R. Kitamura, C. Jiang, S. Buchthal, A. Hoo, T. Ernst,
Medicine, Division of Neurology, John A. Burns School of Medicine, University of Hawaii at
Manoa, Honolulu, HI
Oral Communications 22 Bonanza
1:30 - 3:30 PM
METHAMPHETAMINE
Chairs: Leonard L. Howell and Sunmee Wee
1:30 A receptor mechanism for methamphetamine action in dopamine transporter regulation
Z. Xie, G. M. Miller, Neuroscience, New England Primate Research Center of Harvard
Medical School, Southborough, MA
1:45 Increased reward thresholds (“dysphoric”-like state) in rats with extended access to
methamphetamine self-administration
S. Wee1, G. Schulteis2, G. F. Koob1, 1Committee on the Neurobiology of Addictive Disorders,
The Scripps Research Institute, La Jolla, CA, 2Anesthesiology, University of California San
Diego, La Jolla, CA
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2:00 Behavioral inhibition is predicted by self-report measures of drug intoxication and withdrawal
in methamphetamine-dependent people
J. R. Coyle, M. J. Baggott, J. Mendelson, G. P. Galloway, Addiction Pharmacology, California
Pacific Medical Center Research Institute, San Francisco, CA
2:15 Effects of amphetamine derivatives on memory performance and tissue content of monoamine
and amino acid neurotransmitters in mice
K. S. Murnane1, S. A. Perrine2, W. E. Fantegrossi1,3, M. P. Galloway2, L. L. Howell1,4, 1Yerkes
National Primate Research Center, Atlanta, GA, 2Wayne State University School of Medicine,
Detroit, MI, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Emory
University School of Medicine, Atlanta, GA
2:30 Effects of catecholamine reuptake inhibitors and modafinil on methamphetamine self-
administration in rats
J. Jentsch, A. S. James, Psychology, University of California, Los Angeles, CA
2:45 Modafinil improves cognitive performance in methamphetamine abusers: Evidence from human
behavioral and fMRI studies
D. G. Ghahremani1, G. Tabibnia1, J. Monterosso1, R. A. Poldrack1,2, E. D. London1,3,
1Psychiatry and Biobehavioral Science, University of California, Los Angeles, CA,
2Psychology, University of California, Los Angeles, CA, 3Molecular and Medical
Pharmacology, University of California, Los Angeles, CA
3:00 Functional MRI of methamphetamine users using a Go No-Go Task
A. Stenger1, W. Deng1, H. Nakama2, C. Gonzalez3, W. Haning2, G. Fein1, L. Chang1,
1Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI,
2Psychiatry, University of Hawaii John A. Burns School of Medicine, Honolulu, HI,
3Psychology, University of Hawaii, Honolulu, HI
3:15 Neuropsychological test performance in current and abstinent methamphetamine users
H. Nakama1, C. Gonzales3, V. A. Stenger2, L. Chang2, 1Psychiatry, University of Hawaii,
Honolulu, HI, 2Medicine, University of Hawaii, Honolulu, HI, 3Psychology, University of
Hawaii, Honolulu, HI
SWEEPSTAKES DRAWING Rose Ballroom A
3:35 - 4:05 PM
YOU MUST BE SEATED IN ONE OF THE SESSIONS AT 
3:15 PM IN ORDER TO HAVE YOUR BADGE COLLECTED
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Sunday, June 21
PRESIDENTIAL SYMPOSIUM
Opioid Receptors from the Cutting Edge to the Clinic:
Knockouts, Crosstalk and Behavior
Chair: Sharon L. Walsh
Opioid receptors are critical therapeutic targets for medication development relevant to the treat-
ment of drug dependence and pain.  With increased knowledge of opioid receptors as ligand-reg-
ulated protein complexes and their genetic characterization, new approaches for pharmacological
manipulation of opioid complexes have emerged that promise to increase the effectiveness of opi-
oid-receptor-mediated therapeutics.  This symposium will provide a contemporary review of
molecular mechanisms of opioid receptor signaling and mechanics and translate the importance of
these actions to the underlying mechanisms of tolerance, analgesia and drug reward as well as to
the design of efficacious pharmacotherapeutics.  It is increasingly clear that opioid receptors, like
many other signal-transducing receptors that function in the nervous system, are regulated by
membrane trafficking through the endocytic pathway.  Clinically relevant opioid drugs differ sig-
nificantly in their effects on this regulatory mechanism, and there are also cell type-specific differ-
ences in regulated endocytosis that are only beginning to be understood.  Additionally, the impor-
tance of opioid single nucleotide polymorphisms (SNPs) and their potential role in a variety of
drug addiction and pain sensitivity phenotypes will be reviewed in both animal and human mod-
els.  Thus, both in vitro and in vivo studies will explore the molecular and genetic underpinnings
of opioid receptor-mediated events relevant to analgesia, tolerance and drug dependence.
I. How Does Stress Contribute to Addiction Vulnerability?
Studies from Adolescent and Adult Samples
Chairs: Rajita Sinha and Kathleen T. Brady
Prospective evidence indicates that stress and cumulative adversity increases risk of addictive dis-
orders. Gender differences in stress-related mechanisms may further contribute to such risk. While
there is preclinical evidence indicating that stress-related factors alter the responses of the hypo-
thalamic-pituitary-adrenal (HPA) axis and the mesolimbic reward pathways to increase such risk,
evidence from human studies has been rare. This symposium will present new data from humans,
using prospective longitudinal, laboratory-based and brain imaging approaches, to identify how
stress may contribute to addiction vulnerability. Speakers will discuss the types of stress that
increase addiction risk, the specific HPA axis and brain responses predictive of addiction vulnera-
bility, and the contribution of gender, race and developmental stage (adolescent and adult) on these
effects. Data on effects of stress, emotion regulation and race in prediction of addiction risk in
young, low-income women will be presented as well as prospective longitudinal data from a large
cohort of early adolescents to show HPA axis measures are predictive of later use and abuse of
smoking and drinking. Stress-related HPA axis responses and association with substance use
behaviors in prenatally cocaine exposed and non-exposed adolescent girls and boys will be dis-
cussed. Neuroimaging data on stress-related alteration in nucleus accumbens activity that is asso-
ciated with maladaptive behaviors in adults will be presented. Findings will be summarized in the
broader context of translational research on stress and addiction vulnerability and their implica-
tions for addiction prevention.
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II. Virtual Modeling: A New Frontier for Investigating 
Drug-Receptor Interactions
Chair: Christopher K. Surrat
Computer-based molecular modeling of drug receptors and their ligands has been a goal since the
1970s.  The lack of reliable structural information precluded development of useful molecular
models until the 1990s.  Crystallization of the nicotinic acetylcholine receptor and the cloning of
GPCRs and transporter proteins that recognize abused drugs opened the door to 3-D understand-
ing of drug receptors.  This symposium will outline how in silico approaches are elucidating rela-
tionships between small molecule ligands and their opiate, cocaine or nicotine receptors.  The spe-
cific aims are to visualize in 3-D space drug receptors at amino acid residue level of resolution, to
present 3-D representations of small molecule ligands, and to show plausible ligand-receptor dock-
ing scenarios that can be pharmacologically tested.  New sigma receptor pharmacophores useful
for novel ligand design, data that show how salvinorin A binds to a kappa opioid receptor site dis-
tinct from that of classic opiates, and new epibatidine analogs with selectivity for the primary and
secondary substrate pockets of the monoamine transporters will be presented.  Refined molecular
models such as these may serve as virtual screening tools for new addiction management lead com-
pounds, sifting millions of compounds in a structural library to yield a handful of candidates for
preclinical testing.
Monday, June 22
III. Uncontrolled Intersection: Problem Gambling and Drug Abuse
Chairs: Ken Winters and Linda Cottler
The aims of this symposium are to highlight empirical research on the intersection of problem
gambling (PG) and substance use disorders (SUDs). This co-association has several implications
toward enhancing our understanding of addictive disorders in general and SUDs specifically.
Symposium speakers will provide an overview of the various clinical literatures that have exam-
ined the association of PG and drug dependence, with a focus on the clinical similarities of PG and
dependence, evaluate the effects of level of gambling on reductions in crack use at 4 and 12 months
follow-up among a group of females crack users, and summarize the first two waves of data of a
large-scale longitudinal survey that is tracking gambling involvement and other addictive behav-
iors in a community sample of Alberta residents. A discussion of these various studies in light of
their implications for our understanding of addictive disorders will follow.
IV. Drug Withdrawal, Reinforcing Effects, and Vulnerability to Relapse:
New Methods and Insights
Chair: Lance McMahon
Withdrawal that emerges upon abrupt discontinuation of chronic drug use is often considered a
contributing factor to relapse. Moreover, the reinforcing effects of drugs are considered to vary as
a function of current level of dependence and withdrawal. One practical implication of these pro-
posed relationships is that pharmacotherapy leading to attenuation of withdrawal (cf. nicotine)
plays a role in decreasing relapse and improving treatment outcomes. This symposium provides a
critical review of correlations and causal relationships among withdrawal, reinforcing effects of
drugs, and vulnerability to relapse. Evidence from the pre-clinical literature assessing relationships
between drug withdrawal and reinforcing effects of drugs indexed in a variety of behavioral proce-
dures including drug self-administration will be reviewed. Critical issues to be addressed include
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whether reinforcing effects vary as a function of drug withdrawal and whether pharmacologic
attenuation of withdrawal is responsible for changes in self-administration and reinforcing effects
of drugs.  Evidence from the clinical literature assessing relationships between drug withdrawal
and vulnerability to relapse and, in particular, the extent to which pharmacotherapy of withdrawal
is responsible for decreased relapse and improved treatment outcomes will be presented.
V. Special Symposium Honoring the Memory of Billy Martin
Hot Topics in Cannabinoid Research: From Chemistry to the Clinic
Chair: Mary Abood
Billy R. Martin, PhD, was internationally renowned for his research on the biological basis of drug
addiction, especially for his pivotal work on understanding the mechanism of action of cannabi-
noids.  He was an eminent scholar and scientist, a beloved teacher, mentor, inventor, and humani-
tarian.  This symposium is dedicated to his memory and is designed to highlight recent advances
in cannabinoid research, from medicinal chemistry and receptor and enzyme structure and func-
tion to the clinical basis of drug addiction. 
VI. Preclinical Studies of Sex Differences in Response to Cocaine in
Adolescents: Are They Different from Adults?
Chairs: Cora Lee Wetherington and Jill Becker
Over the past couple of decades, there has been a growing preclinical research literature on sex dif-
ferences in response to cocaine, from behavioral studies of the reinforcing, rewarding and stimulant
properties of cocaine to mechanistic studies of neurotransmitter function and the role of gonadal
hormones. Research on whether these sex differences in adults also occur in adolescents has been
largely unaddressed until recently. Thus, this symposium focuses on this emerging research and its
implications. Presentations will include data from adolescent rats demonstrating sex differences in
the acquisition of cocaine self-administration and progressive ratio performance, the role of ovarian
hormones in mediating cocaine's reinforcing effects in females, sex differences in acquisition and
reinstatement of cocaine-seeking behavior in adolescents versus adults, sex differences in the behav-
ioral and neurochemical effects of social and environmental enrichment in adolescent rats, and the
role of gonadal steroids on dopaminergic neurotransmission across adolescence. The discussion will
present a broad conceptual context within which to understand and study the various biological
mechanisms that contribute to the emergence and development of sex differences.
VII. International Research Priorities for Scaling Up Effective
Interventions for Drug Use and Dependence
Chairs: V. Poznyak and Sharon Walsh
This symposium, jointly organized by CPDD and WHO,  aims to facilitate and support a scaling
up of effective interventions for drug use and dependence in different parts of the world. In spite
of the significant disease burden attributable to drug use and dependence worldwide, the coverage
of effective interventions remains low, particularly in lower and middle income countries, and
research evidence used to inform treatment and policy development is mainly generated in indus-
trialized countries. Main findings from the recent work on global estimates of the number of inject-
ing drug users, the proportion living with HIV/AIDS, and priorities for improving quality and
quantity of data will be presented. The major role that intravenous drug use is playing in the HIV
epidemic in the Central and Eastern European region and important areas for translational research
will be discussed. Gaps in the evidence and the main questions for further research in the area of
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pharmacotherapy of opioid dependence formulated in the process of developing the WHO guide-
lines on psychosocially assisted pharmacotherapy of opioid dependence will be addressed. In addi-
tion, future research implications of the main findings from the recent WHO multi-site internation-
al research project on effectiveness of screening and brief interventions for drug use and priorities
for future international research focused on low and middle income countries will be discussed.
The conclusions of the symposium will provide an important contribution to the process of agen-
da setting for international research to reduce the gap between the population needs and coverage
of effective interventions in different parts of the world.
Tuesday, June 23
VIII. This Is Your Brain on Gambling (and Drugs) … Parsing Drug and
Addiction Influences by Contrasting “Behavioral” and Drug Addictions
Chairs: Marc N. Potenza and Robert Rogers
Considerable debate exists regarding whether non-drug disorders should be considered as addic-
tions. DSM-V committees are considering pathological gambling within an addictions framework.
Pathological gambling, unlike drug dependence, is devoid of chronic drug-upon-brain-substrate
effects that may complicate understanding the core cognitive and neural bases of addiction. This
symposium aims to enhance the audience’s understanding of neurocognitive and neural features of
addiction by comparing and contrasting pathological gambling with drug use disorders. Clinical
data about drug-related behaviors of online casino gamblers and how forms of gambling (e.g., slot
machines) may engage reinforcement circuits and neuromodulators implicated in substance misuse
will be presented. fMRI findings will be described from gambling task studies involving individu-
als with substance use disorders with and without pathological gambling, implicating diminished
ventromedial prefrontal cortical activation in individuals with addictions. Neurocognitive and brain
imaging similarities and differences in impulsivity, cue reactivity, and reward/punishment process-
ing in groups of individuals with pathological gambling, nicotine dependence, or alcohol depend-
ence will be reported. Data will be reported from individuals with gambling or substance use prob-
lems in which individuals from both groups demonstrate overlapping impairments but only sub-
stance-dependent subjects demonstrate executive functioning impairment on tasks assessing work-
ing memory, suggesting a specific substance-related influence. Implications for conceptualization
and categorization of addictive disorders and for treatment development will be discussed.
IX. The Acetylcholine System as Therapeutic Target in Drug Dependence:
Molecular Biology, Neurochemistry, Animal and Human Behavioral
Pharmacology
Chairs: Gerald Zernig and Richard De La Garza, II
The acetycholine (ACh) system is involved in the acute and chronic effects produced by several
drugs of abuse and appears to be an important target for medications development for drug depend-
ence. In animal models, activation of muscarinic and nicotinic ACh receptors is necessary for the
acquisition of drug (i.e., cocaine, morphine and remifentanil) seeking, whereas in chronically self-
administering animals, treatment with the acetylcholinesterase inhibitor (AChEI) tacrine, which
increases synaptic availability of ACh, produces the opposite effect, i.e., decreases the reinforcing
effects produced by cocaine in self-administration, an effect that can also be demonstrated in the
conditioned place preference paradigm. In human neuroimaging studies, control- and cocaine-
addicted subjects differ with respect to muscarinic and nicotinic receptor density in limbic areas
and regional cerebral blood flow in the dorsolateral prefrontal cortex, insula, amygdala, midbrain,
and hippocampus following physostigmine and/or scopolamine infusion. In the human behavioral
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laboratory, the AChEI rivastigmine decreases the positive subjective effects produced by adminis-
tration of intravenous methamphetamine. These data serve as the first clinical evidence of the
effectiveness of AChEIs as treatments for stimulant dependence. 
X. Racial and Ethnic Disparities in Substance Abuse and Addiction:
Native Americans and Native Hawaiians
Chairs: Rumi Kato Price and Lula A. Beatty
Health disparities research on substance abuse mostly focuses on racial and ethnic minority popu-
lations. A common misperception is that minorities use drugs more than Caucasians, but epidemi-
ologic data do not support such a perception. Exceptions are Native populations. Large-scale
national surveys suggest Native Americans are at the highest risk for substance use, abuse, and
dependence among all racial groups in the U.S. Native Hawaiians report much higher levels of sub-
stance abuse than Asian subgroups. Although the NIH Roadmap aims to reshape clinical research
to accelerate medical discovery and improve people’s health, wide gaps remain between biomed-
ical research that includes race/ethnicity information and social/behavioral health disparity
research aiming to reduce racial/ethnic disparities in drug abuse and associated consequences. This
mini-symposium organized by the Underrepresented Populations Committee (URPOP) aims to
examine common and unique risk and protective factors that would provide some answers as to
why Native populations are disproportionately afflicted by substance abuse problems, and to inte-
grate neurobiological findings in these populations into efforts to reduce health disparities.
XI. HIV Risk Prevention in the NIDA Clinical Trials Network
Chair: Raul Mandler
The NIDA Clinical Trials Network (CTN) is an invaluable venue for implementing and evaluating
evidence-based interventions for HIV prevention in diverse community drug treatment programs.
This diversity allows for the examination of intervention effects within important subgroups of
treatment programs. In this mini-symposium, we will examine differential effects of two effective
HIV prevention interventions for two major treatment programs types, outpatient psychosocial
(primarily serving cocaine and/or alcohol abusers) and methadone maintenance (primarily serving
heroin dependent patients). Comparison of HIV prevention intervention between these two pro-
gram types has important implications for drug treatment researchers and providers. There is wide-
spread use of both modalities throughout the U.S., and there are considerable structural differences
between these types of programs. In addition, cocaine and alcohol use are more widely associated
with sexual risk behavior than opioid use. Comparative intervention effects across these types of
programs for the CTN Safe Sex for Men and for the CTN Safe Sex for Women protocols will be
presented. Focus will be on identification of any treatment program type differences related to sex-
ual risk behavior prior to the intervention, intervention attendance, and intervention effectiveness.
Implications of these results for future HIV prevention research efforts in drug treatment settings
planned for the CTN will be discussed.
Wednesday, June 24
XII. Regulating Nicotine in Tobacco Products:
State of the Science and Future Policy
Chairs: Dorothy Hatsukami and Jack Henningfield
The authority to reduce the yield of nicotine to non-addicting levels is one of the provisions in the
legislation that is being considered by Congress to restore regulatory oversight of tobacco products
to FDA. However, the scientific basis for determining the feasibility of the “nicotine reduction”
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approach is limited and the resulting population impact is unknown. In the past year, a workgroup
of scientists and tobacco control experts has been meeting to discuss the current science, the sci-
entific gaps and future research needs to bring clarity to whether or not regulating nicotine content
in tobacco products is a feasible policy approach. The focus of this symposium will be to describe
the most up-to-date research in this area and the key recommendations from the workgroup meet-
ings. A regulatory policy framework for examining reduced nicotine cigarettes will be provided.
Research on the impact of gradually reducing the levels of nicotine on smoking behavior, biomark-
ers of exposure and effect, nicotine addiction and cessation, evidence from laboratory behavioral,
brain imaging, and smoking cessation studies that support the usefulness of denicotinized ciga-
rettes as a cessation method will be presented. Animal models for determining nicotine dose
thresholds for the acquisition and extinction of nicotine self-administration will also be discussed.
The political and scientific challenges associated with nicotine regulation will be addressed.
XIII. Risk Management and Post-marketing Surveillance of CNS Drugs
Chair: Robert Balster
An important goal of drug regulation, including labeling and scheduling under the Controlled
Substance Act, is to reduce unintended consequences. Risk management programs (RMP), includ-
ing the congressionally promulgated Risk Evaluation and Mitigation Strategy (REMS) provides
additional layers of control (e.g., restricted marketing, and enhanced education and post-marketing
surveillance). In the late 1990s, the FDA began to require RMPs for drugs with special concerns,
e.g., isotretinoin for acne, thalidomide for leprosy, tramadol approval without scheduling, transmu-
cosal fentanyl, controlled release oxycodone, buprenorphine for opioid dependence, and transder-
mal methylphenidate. Although the concept of risk management is generally supported, the science
base remains weak, thus, impeding effective and appropriate risk management implementation.
Drugs with abuse potential pose special challenges including the goals of reducing abuse and diver-
sion, which become more complicated for novel chemical entities and formulations. The CPDD
convened a conference in October, 2008, to explore the challenges to research and regulation raised
by the increasing application of risk management to CNS drugs with known or suspected abuse
potential. Approximately 100 researchers, regulators, pharmaceutical developers, and research insti-
tution representatives, discussed issues, shared perspectives, and informed the development of rec-
ommendations for research and regulation by an Expert Panel. Commissioned papers were present-
ed by leaders in key areas relevant to the science of risk management. These papers will be updat-
ed and presented in this symposium along with the Expert Panel recommendations. The symposium
has implications for drug development, and prioritization of research and research funding.
XIV. Development of Protein-Based Pharmacotherapies 
for Drug Addiction
Chairs: Thomas R. Kosten and C. Nora Chiang
Currently, there are no FDA-approved medications for treating cocaine and methamphetamine
addiction. Recent advances in biotechnology make it feasible for the development of large protein
molecules as potential pharmacotherapies for drug addiction. Unlike small molecules targeting the
neural pathways and receptors involved in drug addiction, these protein therapies target the drug
itself, providing alternative strategies for medications development. Newly bioengineered drug-
specific metabolizing enzymes have the potential to rapidly eliminate the drug from the body and
thus are promising for treating drug overdose or addiction. New innovations in technology have
facilitated the development of drug-protein conjugate vaccines, which elicit antibodies of high
affinity that are specifically capable of neutralizing the drug in the body and attenuating its phar-
macological effects. This symposium will review the current status and future perspectives of the
use of these proteins for treating drug addiction. 
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Thursday, June 25
XV. From Trials to Practice: The Implications of Inclusion 
and Exclusion Criteria in Clinical Trials of Pharmacotherapies 
to Treat Drug Dependence
Chairs: Howard Chilcoat and Anne Andorn
Clinical trials that test the efficacy of medications to treat drug dependence include numerous
inclusion and exclusion criteria designed to maximize the detection of an efficacy signal as well as
minimizing safety concerns. A negative consequence of these criteria is that the characteristics of
clinical trials participants can be very different from those with drug dependence in the general
population. Consequently, the efficacy of pharmacotherapies to treat drug dependence in individ-
uals who would have been excluded from clinical trials can differ from results obtained in clinical
trials. In addition, restrictive clinical trial criteria can result in difficulties in subject recruitment
and can influence marketability of medications. This symposium will 1) assess empirically the
impact of inclusion/exclusion criteria on generalizability of clinical trial results using data both
from clinical trial and epidemiologic samples; 2) evaluate the utility of widely used
inclusion/exclusion criteria; 3) address the implications of clinical trial results for public health and
their import for research conducted by government, academic institutions, and industry. Contrasts
between clinical trial and population samples and assessment of impact of clinical trial criteria will
be presented for alcohol and nicotine dependence. The utility of clinical trial criteria for legal and
illegal drug dependence and the impact of restrictive criteria on NIDA-sponsored research will be
examined. A discussion will focus on the importance of the findings for research and regulatory
and commercial implications.
XVI. Preclinical Research on Stress and Addiction
Chairs: John R. Mantsch and Klaus A. Miczek
Anecdotal reports as well as epidemiological and basic research findings suggest that stress plays
a role in addiction. However, the mechanisms through which stressful stimuli regulate addiction-
related processes and behaviors are not fully understood. This symposium will highlight current
preclinical research findings investigating the relationship between stress and addiction. In addi-
tion to examining the neurobiological systems that may contribute to acute stressor-induced relapse
(e.g., corticotropin releasing factor, dynorphins/kappa opioid receptors, arginine vasopressin, pep-
tide YY3-36, orexins/hypocretins), the symposium will explore mechanisms through which repeat-
ed stress can predispose individuals to the effects of abused drugs and the processes through which
repeated drug exposure can alter stressor-responsiveness to promote further drug use during peri-
ods of stress.
XVII. Cocaine Cocktails: The Impact of Concurrent Drug Use 
on Treatment of Cocaine Dependence
Chairs: Joy M. Schmitz and Alison Oliveto
Polysubstance use complicates the clinical presentation of cocaine dependence. Understanding
clinical and neurobiological linkages between cocaine and other drugs of abuse are advancing the
development of more targeted treatment approaches.   This symposium will bring together new
ideas toward broadening the scope of cocaine clinical trials by addressing concurrent patterns of
drug use.  Two recently completed clinical trials of pharmacotherapies for dual cocaine/alcohol
dependence will provide evidence of efficacy, while identifying modifiers of outcome, including
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baseline and early drug use, gender, genotype, and medication compliance.  Issues related to phar-
macological approaches for reducing cocaine use in non opioid-dependent and opioid-dependent
individuals will be discussed, using results of several disulfiram clinical trials to highlight differ-
ences in efficacy depending upon co-morbid opioid dependence status.  In view of the fact that
marijuana is the most commonly used illicit substance among cocaine abusers, yet arguably the
least studied in medication development research, outcome data across a series of cocaine clinical
trials will show how response to treatment differs according to level of concurrent cannabis use.   
XVIII. Nicotinic Cholinergic Mechanisms in Drug Dependence:
Receptor Subtypes and Ligands
Chairs: William A. Corrigall and David Shurtleff
This symposium will describe novel aspects of nicotinic cholinergic mechanisms at the receptor
level. For nicotine dependence itself, the association with nicotinic cholinergic receptors (nAChRs)
is obvious, and the alpha4beta2 nAChR subtype has always been considered critical. While it
remains an important subtype in this disorder and other nicotinic mechanisms, recent studies have
shown that accessory subunits in this receptor subtype alter its function markedly, with the sensi-
tivity of (alpha4beta2)2 receptors being highly dependent on the identity of the additional subunit
in the receptor. In addition, it has recently been demonstrated that the alpha5 subunit influences
dependence and disease risk, in that a common variant in the nAChR cluster on human chromo-
some 15q24 is associated with amount smoked, addiction and the prevalence of cancer. Still other
nAChR subtypes are linked to drug dependence because they play a role in dopamine release, a
cardinal feature of dependence, or because they are located within brain regions that have been
linked to dependence mechanisms as the discovery of the relevant disease circuitry has been elab-
orated. With the greater delineation of subtypes of nAChRs and their roles in disease states, includ-
ing dependence and mental health, greater emphasis is being placed on the development of novel
ligands for use as research tools and as the basis for medications, using approaches such as struc-
tural modeling of the extracellular domain of the receptor and genetically modified organisms. 
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Sunday, June 21
I. Interventions for Parents with Substance Use Disorders:
New Findings from Clinical Research
Chair: Nancy Suchman
Accumulating evidence suggests that changes in dopaminergically regulated reward systems
resulting from chronic drug use may contribute to maladaptive parenting (e.g., parental neglect and
compromised sensitivity). In the past few years, as psychosocial and neurobiological implications
of chronic drug use for parenting become increasingly clear, the development of effective treat-
ments for parents has become increasingly paramount. In this workshop, four experts on psychoso-
cial treatment development and evaluation will report preliminary findings from ongoing trials
testing the efficacy of four innovative interventions for substance-using parents. New findings
from three controlled clinical trials testing (1) a contingency-management and relational therapy
program for fathers, (2) a sobriety program for couples, and (3) an attachment-based program for
mothers of infants and toddlers and one pilot study testing the preliminary efficacy of a contin-
gency-management and interaction coaching program for mothers will be reported. Workshop par-
ticipants can expect to develop a better understanding of the following:
• Four conceptually diverse approaches to intervention with substance-using parents
• The potential of each approach to improve parental functioning, psychiatric status, 
substance use, and child psychosocial adjustment
• New strategies for implementing clinical trials with substance-using parents and children
• Implications of trial results for future intervention development and evaluation
II. Fit to Be Tied: Abuse Potential of Anti-epileptics?
Chairs: Edward M. Sellers and Jack E. Henningfield
A few traditional anti-epileptic drugs are scheduled under the Controlled Substances Act (e.g., phe-
nobarbital, benzodiazepines) many others are not. While many older drugs with sedative and other
"abuse-related adverse events" may not have been as carefully evaluated pre-approval for their
abuse liability, there is little evidence for their abuse. This has resulted in an assumption that anti-
epileptic drugs have little or no abuse liability. New anti-epileptics with novel mechanisms of
action may have a variety of clinical adverse events (e.g., euphoria, sedation, drunkenness, dizzi-
ness) suggesting abuse potential. In human abuse liability studies they may produce "liking at the
moment", “high” and other subjective reports which could lead to scheduling. Recent studies with
anti-epileptics raise some regulatory and scientific challenges. For example, levetiracetam in an
initial human abuse liability study produced moderate "high" but no next day “liking” (Feltner et
al, CPDD 2006). The aim of this workshop is to review the medical need for newer anti-epileptics
and the regulatory perspective on such agents; to present and discuss clinical and human abuse lia-
bility data from representative newer anti-epileptics e.g., levetiracetam, lacosamide and retigabine;
to discuss the potential that different factors above and beyond those within the regulatory frame-
work are important from a scientific and public health perspective with anti-epileptics.
III. What’s New at NIDA and NIH: A Peek into the Black Box
Chair: Gerald McLaughlin
This workshop is intended to provide an opportunity for participants to learn about new policies
and procedures at NIH and NIDA that are relevant to them. Topics will include new policies result-
ing from the NIH lengthy examination of the peer review process, changes in the review process
at NIDA and the Center for Scientific Review (CSR), tips on how to write a good grant applica-
tion, and ways to get help on application preparation. Other topics and questions of interest to the
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audience will be addressed. This is very much an interactive, audience-directed activity. Although
we will have a list of topics of interest, as is always the case with these presentations, audience
members may ask about the budget, recent Advisory Council Reports, new research directions at
NIDA, various NIH mechanisms, or any other subject.
IV. Leadership in the Making: Impact and Insights from Leadership
Development Programs for Leaders of Addiction Services
Chairs: Anne Helene Skinstad and Pamela Waters
Leadership training and preparation is critical for the future of addiction service agencies.
Historically, leaders have been promoted from clinical positions to leadership roles, with little
opportunity for leadership education or development. With many changes facing this profession,
such as the “graying” of the workforce, the need for strong leaders has become increasingly impor-
tant. The presenters in this session collectively work to foster new leadership by organizing activ-
ities through which leadership can naturally develop. This workshop showcases leadership devel-
opment efforts both within and outside the ATTC network, with specific focus on gender and cul-
tural differences. 
Monday, June 22
V. 15th Annual Contingency Management Working Group
Chairs: Stacey C. Sigmon and Kelly Dunn
The Annual Meeting of the Contingency Management Working Group represents an opportunity
each year at CPDD for the dissemination and discussion of current research in the area of contin-
gency management interventions for treating drug abuse. Contingency management procedures
have been consistently demonstrated to be efficacious in reducing use of a wide range of drugs
across a variety of populations, and the behavioral approach represents one of the most effective
interventions for the treatment substance abuse. At the 15th Annual Meeting, junior and senior
researchers will present preliminary data from ongoing studies. Participants and topics will be cho-
sen during the spring of 2009 in order to capture the most hot-off-the-press data in contingency
management research and clinical applications for presentation at our annual working group.
VI. Evaluating the Abuse Potential of Novel Compounds 
and Abuse-Resistant Formulations
Chair: Michael A. Nader
Clinical and preclinical research can be designed to evaluate the abuse liability of novel drugs thus
informing the DEA as to the appropriate scheduling of compounds having abuse potential. DEA
seizures show growing evidence for the abuse of new substances that are analogues of Schedule I
drugs.  DEA policy on scheduling substances and various formulations, forensic and epidemiolog-
ical data on these seized compounds will be described, and the need for additional basic science on
the mechanisms leading to abuse and the consequences of drug exposure will be addressed. NIDA
has several avenues that can be explored in order to obtain the necessary data on mechanisms of
abuse liability. Issues related to animal and human research involving assessment of abuse liability
of novel compounds and abuse-resistant formulations will be discussed.  In the end, this workshop
is intended to formulate a viable approach and timeline to work within government and academic
mechanisms to scientifically address the schedule and control issues of emerging drugs of abuse.
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VII. Substance Use Disorders in DSM-V: A Progress Report
Chairs: Thomas J. Crowley and Charles O’Brien
Studies indicating that DSM-IV’s criteria for “Abuse” and “Dependence” do not form separate fac-
tors will be discussed, as will the Workgroup’s consideration of combining the two diagnoses into
one diagnosis, graded, e.g., as mild, moderate, or severe, probably by symptom count. Potential
advantages of, and problems with, this proposal will be addressed. A proposal to include Cannabis
Withdrawal Disorder and “withdrawal” as a criterion for Cannabis Dependence in the DSM-V will
also be reviewed. The implications of this change on diagnostic, clinical, and epidemiological stud-
ies will be discussed. Additional issues related to diagnosis of other withdrawal and dependence
disorders that became apparent during this process will be raised for discussion. A proposal to
establish a category of “Addictive Disorders” in DSM-V will also be considered. Sub-categories
would be “substance use disorders” and “non-substance addictions”, each classified as mild, mod-
erate or severe. “Abuse” and “Dependence” would not be used as they are now. “Dependence”
would return to its original, single meaning: the clearly defined and normal “neuroadaptive”
response to medications. The workshop will further include a discussion of incorporating indica-
tors of heavy drinking patterns as a possible diagnostic criterion for alcohol use disorders for the
DSMV in the US and in other populations. New data will be presented for emergency room
patients in Argentina, Mexico, Poland and the United States showing DSM-IV alcohol use disor-
ders with and without indicators of heavy drinking patterns.
VIII. Four Practical Interventions to Make Outpatient Treatment
Attractive and Accountable –Translational Research in the Real World
Chairs: A. Thomas McLellan and David Festinger
With increasing acceptance that many cases of addiction will require chronic, continuing care, the
ability to provide attractive, effective outpatient treatment becomes particularly important. Because
of NIDA-funded research, there are now more effective treatment components available for outpa-
tient treatment than ever before. But the reality across this country is that very few of these evi-
dence-based components of care are being used. Outpatient treatment looks much as it did in 1970;
and most importantly, the modal treatment episode in most outpatient programs is only 1 – 2 vis-
its, less than 12% remain for even two months. This workshop will describe and discuss the trans-
lational research leading to system implementation of evidence-based treatment interventions to
improve four important aspects of outpatient addiction treatment: Initiation, Transition,
Supervision/Adaptation, Monitoring. Discussion will include describing principles of translation
and human engineering necessary to adapt evidence based clinical practices to suit contemporary
outpatient treatment systems.
NIDA International Research Posters
Chair: Steven W. Gust
This workshop will be similar to the ones conducted previously by the NIDA International
Program, consisting of a poster session presenting drug abuse research being conducted outside of
the United States. The primary goal is to provide a venue for CPDD members to meet, exchange
ideas, and explore areas of mutual scientific interest with potential collaborators from other coun-
tries. Approximately 150 investigators will present research projects from around the globe, and
NIDA divisions, offices, and programs will present posters outlining their international priorities
and activities. This popular NIDA Workshop at CPDD is successful for both NIDA and CPDD; its
success is reflected in substantial increases in participation and positive feedback on evaluation
forms. Forging new collaborations among U.S. and foreign investigators is one of the primary goals
of the NIDA International Program.
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Tuesday, June 23
IX. Career Development: A Perspective from Junior 
and Senior Researchers
Chairs: Gerald McLaughlin, Scott Chen, Jose Ruiz, and Eliane Lazar-Wesley
Creating a career involves a series of decisions, decisions that often are made with limited infor-
mation or assistance. The purpose of this workshop is to provide a forum for thinking more cre-
atively and systematically about one's career decisions by inviting both junior and more senior sci-
entists to reflect on their own career choices and experiences, as well as those of their colleagues,
and encouraging substantial audience participation. Topics will include choosing a mentor; net-
working effectively at a professional meeting; moving to academia, industry or government posi-
tions; handling job interviews. 
X. Mathematical and Simulation Modeling in Biological and
Epidemiological Studies of Drug Addiction
Chairs: Georgiy Bobashev and Boris Gurkin
This is the fourth Modeling Workshop in a series of very successful CPDD workshops that started
in 2006. The purpose of the workshop is to showcase the spectrum of recent modeling approaches
and to discuss their application to solve real-world problems in drug abuse. The workshop aims at
fostering dialogue and collaborations between the substantive and computational scientists work-
ing in both epidemiological and biological areas of substance abuse and addiction. In epidemiolo-
gy, modeling allows scientists to simulate the consequences of various intervention and prevention
scenarios, while in biology modeling allows to describe and simulate complex neurophysiological
processes.
XI. Communicating the Risks of Opioid Analgesics:
How Can We Do Better?
Chairs: Michael Wolf and Meredith Y. Smith
The misuse and abuse of prescription opioid analgesics is a significant public health challenge in
the United States today. Successful efforts to mitigate this problem will depend, ultimately, on
effective communication concerning the optimal use of opioid medications and the associated risks
of overdose, misuse, abuse and diversion. Among the key constituencies to be targeted for such
communication are pain patients, healthcare prescribers, and the general public. To date, many of
the traditional risk communication vehicles have not been consistently successful in reducing risks,
especially those associated with abuse and diversion. New Internet-based tools are increasingly
being employed to communicate risk information associated with opioid analgesic use yet little
data are available concerning the impact of these virtual approaches on patient and provider behav-
ior. The specific aims of this workshop are 1) To identify methods, strategies and tools that can
improve the consistency and effectiveness of communication regarding the benefits and risks asso-
ciated with opioid analgesics, including ways to enhance traditional communication vehicles; 2) To
discuss evaluating the effectiveness of such approaches; and 3) To highlight research that needs to
be conducted in this area.
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XII. Advances in Implementation Science Related 
to Adolescent Substance Abuse Treatment
Chairs: Ashli J. Sheidow and Michael Dennis
Since 2002, The Society of Adolescent Substance Abuse Treatment Effectiveness (SASATE) has
met at CPDD. This year’s SASATE workshop focuses on how recent advances in research are
impacting the dissemination of evidence-based practices. Presentations will include a recently
completed meta-analysis of the effects of adolescent substance abuse treatment to examine the
relationship between measures of the quality with which treatment is implemented and the magni-
tude of effects on substance use that result; NIDA-funded research testing therapist training proto-
cols; Phase IV replication of MET/CBT5 in 36 sites and how the results varied by site, client char-
acteristics, and implementation; a CSAT-funded project to replicate A-CRA in 32 sites and related
NIAAA-funded implementation research. The session ends with a brief business meeting.
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The following organizations have generously supported the work of the 
College on Problems of Drug Dependence during the past year:
Abbott Labs
Acologic, Inc.
Astra Zeneca
Bristol Myers Squibb
CRS Associates
CSAT  (Center for Substance Abuse Treatment)
Endo
Glaxo Smith Kline
Inflexxion
Javelin
Jazz Pharmaceuticals
Johnson & Johnson
NIDA (National Institute on Drug Abuse)
Pfizer Inc.
Pinney Associates, Inc.
Purdue Pharmaceuticals
Reckitt Benckiser Pharmaceuticals, Inc.
SAMHSA  (Western Consultants)
Sanofi-Aventis, US
Shire US Inc.
Society for Research on Nicotine and Tobacco
